# **T** Phoenix

# Solvency and Financial Condition Report 2021

Standard Life International dac, part of the Phoenix Group For the year ended 31 December 2021

# Contents

| Summary                             | <u>ා</u> |
|-------------------------------------|----------|
| Directors' responsibility statement | 3        |
| Business and performance            | 6        |
| A.1 Business                        | 7        |
| A.2 Underwriting performance        | 10       |
| A.3 Investment performance          | 12       |
| A.4 Performance of other activities | 12       |
| A.5 Any other information           | 13       |
|                                     |          |
| System of governance                | 14       |
| B.1 General information             | 15       |
| B.2 Fit and proper requirements     | 24       |
| B.3 Risk management system          | 25       |
| B.4 Internal control system         | 27       |
| B.5 Internal audit function         | 29       |
| B.6 Actuarial function              | 30       |
| B.7 Outsourcing                     | 30       |
| B.8 Any other information           | 30       |
|                                     |          |
| Risk profile                        | 31       |
| C.1 Underwriting risk               | 33       |
| C.2 Market risk                     | 35       |
| C.3 Credit risk                     | 36       |
| C.4 Liquidity risk                  | 39       |
| C.5 Operational risk                | 40       |
| C. 6. Other meterial risks          | 10       |

C.6 Other material risks42C.7 Any other Information43

| Valuation fo | r solvency purposes                         | 46     |
|--------------|---|--------|
| D.1 Assets a | and liabilities                             | 48     |
| D.2 Technic  | cal provisions                              | 52     |
| D.3 Other li | abilities                                   | 64     |
| D.4 Alterna  | tive methods for valuation                  | 64     |
| D.5 Any oth  | er information                              | 64     |
|              |   |        |
| Capital man  | agement                                     | 65     |
| E.1 Own fu   | nds   | 66     |
| E.2 Solvenc  | cy capital requirement                      |        |
| <u> </u>     | num capital requirement                     | 7C     |
| E.3 Use of t | he duration-based equity risk sub-module    |        |
| in the c     | alculation of the solvency capital requirem | ent 72 |
| E.4 Differer | nces between the standard formula           |        |
| and any      | r Internal Model used                       | 72     |
| E.5 Non-co   | mpliance with the minimum capital           |        |
| require      | ment and non-compliance with                |        |
| the solv     | ency capital requirement                    | 72     |
| E.6 Any oth  | er information                              | 72     |
|              |   |        |
|              | nd additional information                   | 73     |
| Appendix 1-  | - Quantitative reporting templates          |        |
|              | (31 December 2021)                          |        |
| SE.02.01.16  | Balance sheet                               | 74     |
| S.05.01.01   | Premiums, claims and expenses               |        |
|              | by line of business                         | 76     |
| S.05.02.01   | Premiums, claims and                        |        |
|              | expenses by country                         | 77     |
| S.12.01.01   | Life and health technical provisions        | 78     |
| S.22.01.01   | Impact of long term guarantees              |        |
|              | and transitional measures                   | 80     |
| S.23.01.01   | Own funds                                   | 8      |
| S.25.01.01   | Solvency capital requirement –              |        |
|              | using the standard formula                  | 82     |
| S.28.01.01   | Minimum capital requirement                 |        |
|              | for life or non-life insurance              | 83     |
| Appendix 2   | -Glossary                                   | 84     |

# Directors' responsibility statement

#### Introduction and background

This document sets out a Solvency and Financial Condition Report ('SFCR') for Standard Life International DAC ('SLIDAC' or 'the Company') for the year ended 31 December 2021, to satisfy the requirements of Solvency II. The SFCR and the accompanying Quantitative Reporting Templates ('QRTs') provide detailed information of the Company's business and performance, governance, risk profile and capital position.

The purpose of the report is to assist policyholders and other stakeholders to understand the capital position of the Company under Solvency II as at 31 December 2021. In 2016, the Solvency II regulatory regime came into force for insurers across the European Union ('EU'). Under Solvency II, every insurer is required to identify its key risks and hold sufficient capital to withstand adverse outcomes from those risks. The capital required to withstand these outcomes is the Solvency Capital Requirement ('SCR'). The SCR is calibrated so that the likelihood of a loss exceeding the SCR is less than 0.5% over one year. This ensures that capital is sufficient to withstand broadly a '1 in 200 year event'. The capital resources available to meet the requirements are called Own Funds.

The main purpose of holding capital is to provide security to policyholders and other customers. The Company considers itself to be strongly capitalised under Solvency II, as Own Funds are significantly higher than the SCR, as set out in the Capital Management section of this Summary. As at 31 December 2021 the Company's Solvency II surplus over the SCR is €298,466k, with a ratio of eligible own funds to SCR of 173%.

Please note that, due to the nature of the information displayed in tables throughout this report, there may be rounding differences in some cases.

#### Section A - Business and performance

The Company is a private company limited by shares, incorporated, registered and domiciled in Ireland. The Company's main activities consist of the provision of life assurance and pension products in the UK, Ireland, Austria and Germany, with the business written in Ireland and Germany. The Company is authorised and regulated by the Central Bank of Ireland ('CBI').

The Company's immediate parent is Phoenix Group Holdings plc ('PGH'), a company incorporated and resident in the United Kingdom. A simplified PGH Group structure chart is presented in section A.1.2.1.

The performance of the Company, as set out in section A, is described using results as presented in the IFRS financial statements. The operating profit measure is stated after adjustments to exclude the impact of short-term economic variances and items considered to occur outside the normal course of business.

Operating profit of  $\leq 45$ m (2020:  $\leq$ (11)m) was positively impacted by a reduction in reserves arising from the alignment of SLIDAC's reserving methodology with Phoenix Group. Further details on the components and the key drivers of the operating result are included in section A.2.

In 2021, the Company posted a profit before tax of €52.7m (2020: €(18.6)m).

#### Section B - System of governance

The Company has an established system of governance, which includes the Enterprise Risk Management ('ERM') framework of policies, controls and practices by which it meets all the requirements of sound, risk-based management. The Company operates under its ERM framework in line with the Phoenix Group harmonised framework.

The system of governance was reviewed in 2021. A number of changes were made as detailed in Section B.1.4 to ensure the continuing effectiveness of the system of governance and ERM framework.

This, along with the review by the Chief Risk Officer of the overall effectiveness of our system of governance and risk and control framework, leads to the conclusion that the system of governance is adequate given the nature, scale and complexity of the risks inherent in the Company.

#### Section C - Risk profile

The Company operates a standardised Risk Management Framework ('RMF'), for the identification and assessment of the risks it may be exposed to, and the amount of capital that should be held in relation to those exposures. The capital assessment has been carried out on a Standard Formula basis since the introduction of the Solvency II regulatory regime on 1 January 2016. Therefore, the Solvency II position of the Company and the results presented in this SFCR are based on the Standard Formula.

The Company has recently received approval from the Central Bank of Ireland to use a Partial Internal Model (PIM) to calculate its solvency position. The next Solvency and Financial Condition Report will present results using that model. The high level impact of this change in model is described in section C.7.4. The risk profile of the Company has remained broadly in line with 2020. The main changes to the risk exposure in 2021 were:

- Credit rating of Standard Life Assurance Limited ('SLAL') was upgraded to AA- in July 2021. This reduced the amount of credit risk capital in the Solvency Capital Requirement relating to the reinsured with profits liabilities.
- The allocation of business costs has been reviewed. This resulted in a shift away from acquisition expenses towards maintenance expenses, which increased the total expense included in future modelled cash flows.
- The update of underwriting assumptions across a variety of products to reflect the results of experience analysis.
- Large increases in the value of equities have increased the value of unit-linked assets, and the equity risk capital charge has increased as current equity values are higher than the average over the last three years.
- The asset fund backing the annuity liabilities had revisions to its investment mandate, reducing the proportion of corporate bonds and increasing the proportion of sovereign and supranational bonds, which reduces the overall spread risk.

The chart below shows the composition of the Company's undiversified Solvency Capital Requirement ('SCR') as at 31 December 2021. The largest component of the undiversified SCR is lapse risk, which is the risk of adverse movements in either surrender rates or persistency rates on policies, leading to losses of future income. Lapse risk falls within the Underwriting Risk category in the table below.

The definitions of the risk categories are provided in section C with further details on the SCR set out in section E.2.1.

# Risk profile Underwriting risk 38% Market risk 36% Credit risk 13% Operational risk 13%

#### Section D - Valuation for solvency purposes

For the purposes of Solvency II reporting, the Company applies the Solvency II valuation rules to value its assets, technical provisions and other liabilities. The principle that underlies the valuation methodology for Solvency II purposes is to recognise assets and liabilities at an amount for which they could be exchanged, transferred or settled by knowledgeable and willing third parties in an arm's length transaction.

The excess of assets over liabilities measured on a Solvency II basis for the Company is set out in the table below:

|                                   | 2021<br>€'000 | 2020<br>€'000 |
|-----------------------------------|---------------|---------------|
| Excess of assets over liabilities | 708,393       | 589,650       |

The Tier 2 ancillary own funds of €55 million are included in the above figures for both years. This represents a commitment from SLIDAC's parent company, PGH.

Section D provides further information on the description of the bases, methods and main assumptions used in the valuation of assets, technical provisions and other liabilities, including explanations of the material differences between IFRS and Solvency II.

#### Section E - Capital management

The capital positions for the Company at 31 December 2021 and 31 December 2020 are presented in the table below:

|                              | 2021      | 2020      |
|------------------------------|-----------|-----------|
| Solvency II capital position | €'000     | €'000     |
| Eligible Own funds           | 708,393   | 589,650   |
| SCR                          | (409,927) | (446,634) |
| Solvency II capital surplus  | 298,466   | 143,015   |
| Solvency cover               | 173%      | 132%      |

The Company held Own Funds in excess of both the SCR and Minimum Capital Requirement ('MCR') throughout the reporting period and therefore, fully complied with the capital requirements.

#### Quality of Own Funds

Eligible Own Funds represent the available capital to support the SCR.

Of the Company's Eligible Own Funds, 92% are unrestricted Tier 1, and are principally comprised of ordinary share capital, share premium account related to ordinary share capital, surplus funds and the reconciliation reserve. The remaining 8% (€55,000k) are Tier 2 Ancillary Own Funds which will become Tier 1 if called upon. The Company has sufficient Tier 1 own funds to cover its capital requirements. Following receipt of approval from the CBI, on 18 December 2020 the Company executed an ancillary own funds transaction within the meaning of the Solvency II Directive (2009/138/EC). The Tier 2 Own Funds are ancillary own-funds and represent a €55 million commitment from SLIDAC's parent company, PGH. The commitment allows SLIDAC to call Fixed Rate Reset Perpetual Restricted Tier 1 Write-Down Notes (of €55 million) from PGH, during the term of the agreement without any encumbrance. PGH's obligations under the commitment expire on 17 December 2025.

As at 31 December 2021, the Company's Solvency II surplus over the SCR is €298,466k, with a ratio of Eligible Own Funds to SCR of 173%. The increase in the Solvency II surplus from €143,015k at the end of 2020 reflects the economic impacts over the course of the year along with SLAL's credit rating upgrade. Further details of material drivers of change are provided in E.1.4.2.

Further details regarding the Company's capital position are set out in Section E.1.

#### Sensitivities and scenario analysis

As part of the Company's internal risk management processes, the Solvency II surplus is tested against a number of financial scenarios. The results of that stress testing on the Company's surplus are provided below and demonstrate the resilience of the Solvency II surplus.

|   | Solvency II<br>Surplus<br>(€'000) |
|---|-----------------------------------|
| Base: 31 December 2021  | 298,466                           |
| Following a 20% fall in equity markets                                      | 303,254                           |
| Following a 15% fall in property values                                     | 298,478                           |
| Following a 60bps interest rates rise                                       | 343,314                           |
| Following a 80bps interest rates fall                                       | 230,461                           |
| Following credit spread widening (equivalent to average widening of 120bps) | 290,643                           |
| Following 6% decrease in annuitant mortality rates                          | 289,742                           |
| Following 10% increase in assurance mortality rates                         | 299,027                           |
| Following a 10% increase in lapse rates                                     | 295,777                           |
| Following a 10% decrease in lapse rates                                     | 297,665                           |

#### **Future developments**

The Company has recently received approval from the Central Bank of Ireland to use a Partial Internal Model (PIM) to calculate its solvency position. The next Solvency and Financial Condition Report will present results using that model.

#### Directors' responsibility statement

Approval by the Board of Directors of the Solvency and Financial Condition Report

Financial period ended 31 December 2021.

We acknowledge our responsibility for preparing the Solvency and Financial Condition Report in all material respects in accordance with the CBI rules and the Solvency II regulations.

The Directors are satisfied that:

- a) throughout the financial year to 31 December 2021, the Company has complied in all material respects with the requirements of the CBI rules, including Solvency II regulations as applicable to the Company; and
- b) it is reasonable to believe that in respect of the period from 31 December 2021 to the date of publication of the Solvency and Financial Condition Report, the Company has continued to comply, and will continue so to comply in future.

For and on behalf of the Board of Directors

Naval Kapoor Chief Financial Officer 31 March 2022

# Business and performance

| In th | his section                     |    |
|-------|---------------------------------|----|
| A.1   | Business                        | 7  |
| A.2   | Underwriting performance        | 1C |
| A.3   | Investment performance          | 12 |
| A.4   | Performance of other activities | 12 |
| A.5   | Any other information           | 13 |

#### A.1 Business

#### A.1.1 Information regarding the Company

SLIDAC was established in Ireland in 2005 (originally registered as Standard Life International Limited). Standard Life International Limited converted to a Designated Activity Company in April 2016, under the Companies Act, 2014. The Company is an insurance undertaking and its main activities consist of the provision of life assurance and pension products in the UK, Ireland and Germany. As at 31 December 2021, the Company was a wholly-owned subsidiary of PGH.

The Company is incorporated in Ireland under the Irish Companies Act, 2014.

The Company is authorised by the CBI to transact insurance business in Ireland and cross-border life assurance business in the EU under the European Union (Insurance and Reinsurance) Regulations 2015 (S.I. 485 of 2015).

The Company submitted a Part 4A application to the Prudential Regulation Authority ('PRA') and has been accepted into the Temporary Permissions Regime ('TPR') to support the ongoing provision of the International Bond (offshore) to our existing customers resident in the UK and to continue to offer this product to new customers in the UK market.

With regard to the conduct of business requirements, the Company operates within the CBI's Consumer Protection Framework. Products sold into the UK are overseen by the Financial Conduct Authority's ('FCA') in respect of Conduct of Business rules. For business in Germany and Austria, conduct is supervised by Bundesanstalt für Finanzdienstleistungsaufsicht ('BaFin') and the Finanzmarktaufsicht ('FMA').

The Company's supervisor is the Central Bank of Ireland, North Wall Quay, Spencer Dock, Dublin, Ireland.

The CBI applies group supervision under Solvency II to Standard Life International dac at the level of PGH.

The Company's external auditor is Ernst & Young Ireland, Harcourt Centre, 2 Harcourt Street, Saint Kevin's, Dublin 2.

#### A.1 Business continued

#### A.1.2 Company and Group structure

A.1.2.1 Legal Structure of the Group


A simplified Phoenix Group structure chart as at 31 December 2021 is provided below, and shows the Company's position within the legal structure of the Phoenix Group. All shareholdings are 100% unless shown otherwise. N.B. a complete Group structure can be found in the Group's SFCR.

Subsequent analysis of financial information in this section relates to the Company only.

#### Phoenix Group Structure Chart – Summary 31 December 2021

ST December 2021

# Shareholdings are 100% unless shown otherwise Classification: Public



Branches

#### A.1 Business continued

#### A.1.2.2 Governance and Organisation

Prior to 31 August 2018, the Company was a wholly-owned subsidiary of Standard Life Assurance Limited ('SLAL'), which in turn was a subsidiary of Standard Life Aberdeen plc ('SLA') and the management of the Company was carried out in a manner consistent with the policies of SLA in relation to strategy, governance and risk management.

Following the acquisition of SLAL (and the Company as its wholly owned subsidiary) by PGH on 31 August 2018, the Company transitioned to a new governance framework.

On 21 February 2019, SLAL sold all of the shares it held in SLIDAC to PGH. As a result of this, PGH is the 100% shareholder of the Company.

Further information on the governance structure is provided in Section B.

#### A.1.3 Material lines of business and geographical areas

A.1.3.1 Material Lines of Business

There are four Solvency II lines of business which are based on the characteristics of the different products administered. The table below shows the material Lines of Business ('LoB') for the Company:

|  | SLIDAC       |
|--|--------------|
| Insurance with-profit participation    | $\checkmark$ |
| Index-linked and unit-linked insurance | $\checkmark$ |
| Health insurance                       | -            |
| Other life insurance                   | $\checkmark$ |

#### A.1.3.1.1 Insurance with-profit participation

The insurance with-profit participation LoB is comprised of conventional with-profit products and unitised with-profit products.

A with-profit, or participating, policy is one where the policyholder participates in the profits of the fund. An insurer aims to distribute part of its profit to the with-profit policyholders in the form of bonuses. The value of such distributions is based on, among other things, the performance of the underlying pool of assets. Policy pay-outs are generally subject to a minimum guarantee and are 'smoothed' to lessen the impact of changes in the underlying value of the assets in the short term.

All with-profit policies are entitled to potential incremental bonuses throughout the life of the policy as well as a terminal, or final, bonus. The terminal bonus represents the policyholder's final share of the assets of the fund.

#### A.1.3.1.2 Index-linked and unit-linked insurance

The value of unit-linked products is linked directly to the performance of the underlying assets. The policyholder typically bears all of the investment risk with unit-linked products. The benefits attributable to the policyholder are determined by reference to the investment performance of a specified pool of assets.

Customers do not legally own the underlying assets or the units themselves; they own a contract (the policy) with a right to a benefit. The value of that benefit is determined by reference to the price of their chosen fund.

The unit-linked funds retroceded back to SLIDAC under the reinsurance arrangement are included within this LoB.

#### A.1.3.1.3 Health insurance

Health insurance business is not material in the context of the Company's overall insurance business.

#### A.1.3.1.4 Other life insurance

Other life insurance includes all remaining underwritten business and includes protection policies and annuity business.

The majority of the business included in this line of business is annuity business. Annuities generally provide a specified income stream over the life of the policyholder.

#### A.1 Business continued

#### A.1.3.2 Geographical Areas

The Company is headquartered in Ireland and sells life assurance and pension products to customers in the United Kingdom, Ireland, Germany and Austria. Irish and UK policies are serviced by the Irish office and German and Austrian policies are serviced by the SLIDAC German branch.

#### A.1.4 Significant business and other events over the reporting period

The existence of COVID-19 created volatility in the financial markets. Whilst many potential operational impacts of COVID-19 were effectively mitigated through the contingency plans that have been put in place by SLIDAC's management and the worst of the pandemic is hopefully behind us, there remains some potential for future disruption of our business operations and the wider economy.

To date, there has been minimal disruption to the Company's operations, with the measures taken to reinforce the Company's resilience ensuring it has continued to provide services to policyholders throughout these uncertain times whilst safeguarding its financial strength.

On 31 January 2020 the UK left the European Union. In order to future-proof against this the Company had previously obtained regulatory approval in March 2019 to act as a base from which to serve all European customers, thus preserving the continuity of existing operations in Ireland, Germany and Austria, including the ability to continue to write new business following the UK's withdrawal from the EU.

In addition, the Company has been accepted into Temporary Permissions Regime ("TPR") with effect from 31 December 2020, following submission of a Part 4A application to the Prudential Regulatory Authority ("PRA"). This has ensured continuing provision of the International Bond (offshore) to its existing customer's resident in the UK along with new customers in the UK market.

On 23 February 2021, PGH announced that it had entered into a new agreement with Standard Life Aberdeen plc ("SLA plc") which simplifies the arrangements of their Strategic Partnership, enabling the Phoenix Group to control its own distribution, marketing and brands, and focusing the Strategic Partnership on using SLA plc's asset management services in support of the Phoenix Group's growth strategy. Under the terms of the transaction, the Phoenix Group will sell certain UK products to SLA plc, and acquire ownership of the Standard Life brand. SLA plc has since been rebranded "abrdn".

On 11 March 2022, approval was received from the Central Bank of Ireland to bring the Company onto a partial internal Solvency II model effective 30 June 2022.

The Company is transferring all fund-accounting services from its existing provider Citibank to HSBC. A partial migration of policyholder and shareholder assets from Citi to HSBC completed successfully on 31 August 2021, with remaining assets to be transferred during 2022.

#### A.1.5 Significant events after the reporting period

The political situation in Ukraine has created uncertainty in the economic environment. The Company is monitoring the situation closely.

#### A.2 Underwriting performance

The Company commenced writing life assurance business in 2006. Total net earned premiums on insurance contracts for the year ended 31 December 2021 were €994m (2020: €609m). The Company reported a profit after tax for the year of €37m (2020: €(23)m).

The key performance indicators for the year are set out below:

- Assets under management increased to €34.5bn (2020: €30.8bn) of which €16.3bn (2020: €16.2bn) relates to an intra-group reinsurance arrangement with SLAL;
- Net inflows of €998m (2020: €257m) were a result of gross inflows of funds received from customers of €2,220m (2020: €1,280m) and gross outflows of funds withdrawn of €1,222m (2020: €1,023m);
- Operating profit of €45m (2020: €(11)m) was positively impacted by a reduction in reserves arising from the alignment of SLIDAC's reserving methodology with Phoenix Group;
- The Company's shareholder liquidity position of €568m (2020: €507m) remains robust. Shareholder liquidity continues to be invested in collective investment schemes;
- At 31 December 2021, the Company had available capital resources of €708m (2020: €590m) as measured on a Solvency II ("SII") basis, and its SCR was €410m (2020: €447m). The solvency coverage ratio as at 31 December 2021 was 173% (2020: 132%). Phoenix Group Holdings' credit rating was upgraded by Fitch on 2 July 2021. The Insurer Financial Strength Rating for the Group's principal operating life subsidiaries, including Standard Life Assurance Limited (SLAL), has increased to AA- (very strong) from A+ (strong). The upgraded rating significantly reduced the Company's counterparty default risk under the standard formula resulting in a material increase in the solvency coverage ratio in the year.

#### A.2 Underwriting performance continued

The financial highlights for the year are set out below:

- Gross written premiums increased by €375m in 2021 to €1,773m (2020: €1,398m) driven by strong sales in the UK International bond market;
- Net investment income for the year was €1,567m, compared to €713m in 2020;
- In 2021, the Company posted a profit before tax of €52.7m (2020: €(18.6)m);
- Shareholders' equity increased to €606m (2020: €570m).

The Company will continue to strive for profitable growth by offering products in the Ireland, Germany, Austria and the UK designed to meet customer needs in line with market developments. The objective is to generate satisfactory returns for the shareholders whilst meeting the reasonable expectations of policyholders under its statutory, financial and regulatory obligations.

#### A.2.1 Operating profit

A summary of the Company's performance during the year ended 31 December 2021 is presented below and in sections A.3 and A.4. The information below is presented on an operating profit basis and reconciled to the IFRS result in the financial statements.

|   | Section<br>Reference | 2021<br>€'000 | 2020<br>€′000 |
|---|----------------------|---------------|---------------|
| Operating profit/(loss)   | A.2.1                | 45,012        | (10,759)      |
| Adjusted for the following items:                                 |                      |               |               |
| Total investment return variances and economic assumption changes | A.4                  | (3,338)       | (11,394)      |
| Other non-operating items   | A.4                  | (340)         | (905)         |
| IFRS profit/(loss) before tax attributable to owners              |                      | 41,335        | (23,058)      |
| Tax (charge)/credit   |                      | (15,466)      | (4,141)       |
| Less: tax attributable to policyholders' returns                  |                      | 11,399        | 4,507         |
| Tax credit attributable to owners                                 |                      | (4,067)       | 366           |
| IFRS profit/(loss) for the year attributable to owners            |                      | 37,268        | (22,692)      |

Operating profit is used as a performance measure of the underwriting activities of the Company and is considered an appropriate measure of the underlying performance of the Company as it excludes the impact of short-term economic volatility and other one-off items which, due to their size or nature, are not indicative of long-term operating performance.

Operating profit includes the effects of variances in experience for non-economic items, such as mortality and expenses, and the effect of changes in non-economic assumptions. It also incorporates the impacts of significant management actions where such actions are consistent with the Company's core operating activities (for example, actuarial modelling enhancements and data reviews). Operating profit excludes investment return variances and economic assumption changes, non-operating items considered to fall outside of the course of the Company's normal operations and shareholder tax.

The operating profit in 2021 of  $\in$  45.0m is a considerable improvement on the loss experienced in 2020 ( $\in$  (10.8)m). This was driven by a reduction in reserves arising from the alignment of SLIDAC's reserving methodology with Phoenix Group.

#### A.2.2 Analysis of operating profit

The operating profit of the Company split by geographical area is as follows:

|                             | Ireland<br>€′000 | Germany<br>& Austria<br>€'000 | UK<br>€'000         |
|-----------------------------|------------------|-------------------------------|---------------------|
| Operating Income            | 44,195           | 73,487                        | 27,436              |
| Operating Expenses          | (41,300)         | (38,778)                      | (15,214)            |
| Operating profit before tax | 2,896            | 34,709                        | 12,223 <sup>1</sup> |

1 The operating profit result in the UK excludes corporate costs associated with the management of shareholder assets of €4.8m

The Ireland operating profit before tax is partly due to favourable annuity reserve movements, while the Germany and UK results are driven by a reduction in reserves arising from the alignment of SLIDAC's reserving methodology with Phoenix Group.

The Company's fee based business is made up of products that generate revenue primarily from asset management charges ('AMCs'), premium based charges and transactional charges. AMCs are earned on products such as individual pensions and investment bonds, and are calculated as a percentage fee based on the assets held. Investment risk on these products rests principally with the customer, with the shareholder's major indirect exposure to rising or falling markets coming from higher or lower AMCs. Fee business includes unit-linked business predominantly.

The Company's spread/risk business mainly comprises of products that provide a guaranteed level of income for customers in return for an investment. The 'spread' primarily relates to the difference between the guaranteed amount paid to customers and the actual return on related assets over the period of the contract. Spread business consists of annuities and risk based business consists of protection products.

#### A.2 Underwriting performance continued

The split of operating profit by line of business is shown below. Each line has experienced an operating profit, with unit-linked showing the benefit of the reduction in reserves.

|                                     | Unit-linked                | Other life | With-profit   | Health    |
|-------------------------------------|----------------------------|------------|---------------|-----------|
|                                     | insurance                  | insurance  | participation | insurance |
|                                     | €′000                      | €'000      | €'000         | €'000     |
| Operating profit before tax (€′000) | <b>47,109</b> <sup>1</sup> | 255        | 2,463         | -         |

1 The operating profit result through unit-linked excludes corporate costs associated with the management of shareholder assets of €4.8m

#### A.3 Investment performance

The Company uses investment return as a measure of investment performance. The following table shows the Company's investment return by asset class, for the year ended 31 December 2021 and the prior year:

|  | 2021   | 2020   |
|--|--------|--------|
|  | €′000  | €'000  |
| nvestment income   |        |        |
| Interest income on loans and deposits at amortised cost  | 36     | 82     |
| Other interest income on instruments at amortised cost   | 0      | 3,046  |
| Interest income on financial assets designated at fair value through profit or loss on initial recognition | 5,032  | 9,727  |
| Dividend income  | 56,399 | 61,486 |
| Rental income  | 2,082  | 1,931  |
| Foreign exchange gains on instruments at amortised cost  | 933    | (2,689 |
|  | 64,482 | 73,583 |

#### Fair value gains/(losses) on items at fair value through profit or loss

| Net investment income               | 1,567,002 | 712,747 |
|-------------------------------------|-----------|---------|
|                                     | 1,502,520 | 639,164 |
| Investment property                 | 1,700     | (2,632) |
| Investment in subsidiaries          | 97,141    | (5,763) |
| Designated upon initial recognition | 1,442,084 | 615,499 |
| Held for trading – derivatives      | (38,405)  | 32,060  |
| Financial assets and liabilities:   |           |         |

#### A.3.1 Investment income and expenses

Net investment return in the year was a gain of €1,567m (2020: €713m).

#### A.4 Performance of other activities

Other material income and expenses which are not included within operating profit are outlined below:

|   | 2021<br>€′000 | 2020<br>€'000 |
|---|---------------|---------------|
| Other income and expense items                                    |               |               |
| Total investment return variances and economic assumption changes | (3,338)       | (11,394)      |
| Other non-operating items   | (340)         | (905)         |
| Total other income and expenses                                   | (3,677)       | (12,299)      |

In 2021 there was €3.7m in non-operating expense items made up of investment return variances and economic assumption changes, and other non-operating items. The other non-operating items of €0.3m relates to one-off project and restructuring expenses.

#### A.4.1 Analysis of investment return variances and economic assumption changes

In 2021 the Company had €3.3m in non-operating investment return variances and economic assumption changes. These arise due to differences in the IFRS reporting basis compared to the hedged Solvency II position, after allowance for risk capital.

The investment performance measure used by the Company is investment return variances and economic assumption changes. These represent the impact of short term volatility. Further details are set out below.

Short term fluctuations are calculated based on expected returns on investments backing equity holder funds, with consistent allowance for the corresponding expected movements in equity holder liabilities. Impacts arising from the difference between the expected return and actual return on investments, and the corresponding impact on equity holder liabilities except where they are directly related to a significant management action, are excluded from operating profit and are presented within investment return variances and economic assumption changes as a component of profit before tax.

#### A.5 Any other information

The Company continues its preparations for the introduction of the new insurance accounting standard, IFRS 17, which will change the way the Company measures its insurance contracts and investment contracts with discretionary participation features ("DPF"), impacting profit emergence patterns and adding complexity to valuation processes, data requirements, assumption setting and reporting.

There is no further material information to be disclosed regarding business and performance.

# System of governance

| In th | his section                 |    |
|-------|-----------------------------|----|
| B.1   | General information         | 15 |
| B.2   | Fit and proper requirements | 24 |
| B.3   | Risk management system      | 25 |
| B.4   | Internal control system     | 27 |
| B.5   | Internal audit function     | 29 |
| B.6   | Actuarial function          | 30 |
| B.7   | Outsourcing                 | 30 |
| B.8   | Any other information       | 30 |
|       |                             |    |

#### B.1 General information on the system of governance

This section provides information on the system of governance in place for the Company. Any material changes that have taken place over the reporting period are also included. Details on the structure of the Board and committees are provided, with a description of their main roles and responsibilities, as well as a description of the main accountabilities and responsibilities of all key functions.

#### **B.1.1 Overview**

The Company has an established system of governance, which includes the ERM framework of policies, controls and practices by which it meets all the requirements of sound, risk-based management. The Company has enhanced its ERM framework in line with the Phoenix Group harmonised framework. This document reflects that position.

Following the sale of the Company's previous parent company, SLAL, to PGH on 31 August 2018, work has been undertaken to harmonise risk management frameworks across SLAL, SLIDAC and the Phoenix Group.

For SLIDAC, this involved assessing the appropriateness of the Group policies and the risk and control standards within them, before adopting or adapting them into the SLIDAC equivalents. Generally, the work carried out showed that the Group's policy framework was fit for purpose, with some strengthening of controls put in place to make it more appropriate to SLIDAC's business and risk profile. In this way, the Company is able to maintain standalone policies while aligning to those of the rest of the Phoenix Group.

The existing system of governance comprises:

- Governance framework how we manage our business including the role of the Board and its committees.
- Organisational and operational structure how we structure our business and define roles, responsibilities and reporting lines to ensure that appropriate spans of control operate throughout the organisation.
- Risk management system a risk-based approach to managing our business. It includes the methods and processes we use to manage risks consistently. We refer to our risk management system as the ERM framework.
- Internal control system contains a range of processes, captured within the Company's policies, to manage risks at the highest level, how we assess impact and likelihood of risks and how we determine the effectiveness of our key controls.

The effectiveness of the system of governance and ERM framework is reviewed each year and updated where necessary.

The Company has a clearly defined system of governance and ERM framework as at 31 December 2021. In addition to the established Board, there also exists a Nomination Committee, an Audit Committee, a Remuneration Committee, a Risk Committee and a Model Governance Committee. At a management level, the Company has an established European Senior Leadership Team ('ESLT'), with the following subcommittees:

- Enterprise Risk Management Committee;
- Country Leadership Teams (one for Ireland and one for Germany & Austria);
- Investment and Credit Committee;
- Partial Internal Model Committee;
- Operational & Conduct Risk Committees (one for Ireland and one for Germany & Austria);
- Reinsurance Business Committee;
- Product Oversight Governance Committee;
- Customer Incident Management Committee (for Ireland);
- Regulatory Change Forum (for Ireland); and
- Product Pricing and Profitability Committee.

All of the above are key components in the Company's role as the European hub for the Phoenix Group. A graphical representation of this and the inherent decision making structure can be seen in the following section.

#### B.1 General information on the system of governance continued

#### B.1.2 System of governance


The governance framework provides a structure to support compliance with the Company's regulatory and Corporate Governance Requirements obligations. The Company's governance framework is approved by the Board, kept under regular review and documented in the Board Charter. The Company Secretary reviews the Board Charter and the Terms of Reference for each Board Committee annually, taking into account developments in regulatory guidance and corporate governance best practice, and recommends any changes to the Board, for its approval.

The framework consists of the following key elements which are discussed further in this section:

- · Decision making structure;
- The Function of the Company Board;
- The Role of Non-Executive and Executive Directors;
- Board committees; .
- · The Executive and Executive committees;
- · Scheme of Delegation;
- . Code of conduct;
- . Prudent Person Principle;
- Fitness and Probity regime; and
- Remuneration

#### Company governance structure chart

The diagram below provides an illustration of the Company's governance structure as at 31 December 2021.



- respective committees derive their authority from the ESLT they also
- both feedback information upwards to the respective board committees.

16

Joint SLAL & SLIDAC Management Committee

#### B.1 General information on the system of governance continued

The function of the Company Board SLIDAC is an insurance company and is operated in accordance with its Board Charter.

The Board's role is to organise and direct the business of SLIDAC in a manner designed to further the best interests of the Company, having regard to the interests of its shareholders and other stakeholders, while complying with its legal, regulatory and fiduciary duties and corporate governance requirements, including those duties and requirements set out under the Companies Act 2014 (as amended), the Company's Constitution and Articles of Association, Board Charter and the Corporate Governance Requirements 2015. As a high impact firm, there are additional obligations placed on the Company by the Corporate Governance Requirements for Insurance Undertakings 2015 with respect to, amongst other things, the frequency of Board meetings. The Board shall meet as often as is appropriate to fulfil its responsibilities effectively and prudently. The Board shall meet at least six times per calendar year and at least three times in every six month period.

The Board Charter identifies matters that are specifically reserved for decision by the Board. In order to achieve Board approval, a majority of Directors must concur. In some cases, unanimous approval by the Directors is required.

The Company's Board must refer certain matters to the SLAL Board and the PGH Board, including certain matters relating to corporate structure, capital, transactions, communications, and governance and these are also outlined in the Company's Board Charter.

The Board of Directors has overall responsibility for the approval of the ERM framework, including the Risk Strategy, the Risk Appetite Framework, the Risk Registers and all related quantitative risk limits, and review of its implementation including monitoring management actions in respect of any breaches, and the implementation of any Board recommendations arising as a result of any breaches as well as managing the Company's internal control framework. The framework is designed to manage, rather than eliminate, risk and can only provide reasonable, not absolute, assurance against material misstatement or loss.

The Board consists of the following roles:

- Three independent Non-Executive Directors;
- One Group Non-Executive Director; and
- Three Executive Directors

The Chairperson of SLIDAC is currently one of the independent Non-Executive Directors. Board composition and the skills and competencies of the Board are kept under regular review and assessed at least annually as part of the Board effectiveness review.

The Board is collectively responsible for:

- · determining the Company's objectives and strategy;
- ensuring that the necessary financial and human resources, including succession plans at Board and executive level, are in place to allow the Company to achieve its objectives;
- ensuring the Company has a Remuneration Policy that is in line with the risk strategies of the Company;
- ensuring the Company has an adequate and effective internal control framework, that includes well-functioning risk management, compliance, actuarial and internal audit functions as well as appropriate financial reporting and accounting frameworks;
- determining the amounts, types and distribution of internal capital and own funds adequate to cover the Company's risks;
- ensuring that robust and transparent corporate and management structures with effective communication and reporting channels are in place to allow the Company to achieve its objectives;
- · determining policies applicable to the Company, including approving Company policies and adopting Group policies;
- determining and overseeing the strategy for the on-going management of material risks and establishing and maintaining a framework of internal controls that enables the financial and operational risks of the Company to be assessed and managed;
- monitoring progress by the Company towards the achievement of its objectives and compliance by the Company with approved plans and policies;
- reporting to relevant stakeholders on the Company's activities;
- · appointing Board committees to meet the Company's requirements and relevant corporate governance standards;
- delegating clearly defined authorities to the Chairperson, the Chief Executive, Board committees and otherwise as the Board will determine from time to time; and
- · formally reviewing its own effectiveness as well as the effectiveness of its Committees.

#### B.1 General information on the system of governance continued

The role of Non-Executive and Executive Directors

The role of the Non-Executive Directors is to participate fully in the work of the Board including advising, supporting and challenging management as appropriate. Their roles and responsibilities are set out in the Board Charter.

Executive Directors' duties are to manage the day-to-day business of the Company with the other members of the Executive team, within the parameters set out by the Board and in the Board Charter. They also have separate responsibilities as members of the Board. Their roles and responsibilities are set out in the Board Charter.

Executive and Non-Executive Directors have the same statutory responsibilities.

#### **Board Committees**

The Board is supported in the oversight of the System of Governance – including the ERM Framework, the Own Risk and Solvency Assessment ('ORSA') process and the system of internal controls – by the Audit Committee, the Risk Committee, the Nomination Committee, the Remuneration Committee and the Model Governance Committee. Further details regarding each of these committees are set out in the table below.

| Committee       | Role, duties and responsibilities   |  |
|-----------------|---|--|
| Audit Committee | The role of the Audit Committee is to consider and to make appropriate recommendations to the Board on:   |  |
|                 | <ul> <li>Financial reporting documentation including: draft financial statements (including significant reporting issues and judgments), interim and preliminary results' announcements, any announcements relating to financial performance, financial returns to regulators and any significant financial information contained in any document for Board approval;</li> <li>The Company's Solvency II capital position and related messaging, as disclosed in the Annual Report and Financial Statements, the Regular Supervisory Report ('RSR'), annual SFCR and the year-end Quantitative Reporting Templates ('QRTs');</li> <li>The Company's internal and external audit arrangements, including the independence of the external audit firm; and</li> <li>The Company's internal controls over financial and regulatory reporting, money laundering and financial crime.</li> </ul>   |  |
|                 | The Audit Committee meets at least four times a year to coincide with the Company's financial reporting cycle.<br>Members of the Committee are appointed by the Board. The Committee shall be made up of at least three members<br>and all members of the Committee shall be Non-Executive Directors with the majority being independent Non-<br>Executive Directors.   |  |
| Risk            | The role of the Risk Committee is to provide oversight and challenge of, and advice to, the Board on:   |  |
| Committee       | <ul> <li>The Company's material risk exposures, current risk strategy and future risk strategy and their impact on capital;</li> <li>The structure, implementation and maintenance of the Company's ERM Framework and its suitability to react to forward-looking issues and the changing nature of risks;</li> <li>The Company's Risk Management Function, Risk Appetite Framework ('RAF'), and changes to both the RAF and the quantitative risk limits;</li> <li>The due diligence on risk issues and aspects of major transactions, investments, strategic proposals, major product developments and other corporate transactions, ensuring the potential consequences of any such transactions are appropriately considered;</li> <li>Regulatory Compliance and Regulatory Reporting matters;</li> <li>Material actuarial matters affecting the Company;</li> <li>The annual review of the appropriateness to the Company of Group policies and review any proposed new or amended Group policies and determine whether they should be recommended to the Board for adoption by SLIDAC; and</li> <li>The Company's ORSA including steering how the assessment is to be performed and challenging the results.</li> </ul> |  |

#### B.1 General information on the system of governance continued

| Committee                 | Role, duties and responsibilities  |
|---------------------------|--|
| Nomination                | The role of the Committee is to:   |
| Nomination<br>Committee   | <ul> <li>Review/consider and/or make recommendations to the Board with regard to: <ul> <li>The structure, size, diversity and composition of the Board;</li> <li>The short, medium and long-term contingency and succession planning for the Board, in particular the Board Chairperson, and approve the succession plans for Pre-Approval Controlled Function (PCF) holders;</li> <li>The appointment and removal of the Board Chairperson, the Deputy Board Chairperson (if appointed), the Non-Executive Directors, the Executive Directors and the Chief Executive Officer (CEO);</li> <li>The appointment of members and chairpersons to Committees of the Board;</li> <li>The continued appointment of any Non-Executive Director at the conclusion of his or her specified term of office on the Board, haing given due regard to their performance and ability to continue to contribute to the Board in light of the knowledge, skills and experience required; and</li> <li>Make recommendations to the Board with regard to the Board.</li> </ul> </li> <li>Keep under review the Board's policy on diversity (in all its forms) and any measurable objectives that the Board has set for implementing the policy, and progress on achieving the objectives;</li> <li>In considering appointments prepare a comprehensive job description, taking into account for Board appointments, the existing skills and expertise and diversity of the Board and involvement outside Board meeting;</li> <li>Ensure that on appointments prepare a comprehensive ibo description, taking into account for Board appointments out clearly what is expected of them in terms of time commitment, service on committees of the Board and involvement outside Board meeting;</li> <li>Approve and review the implementation of processes for identifying the training needs of Directors; and processes for selecting, inducting and training Directors;</li> <li>Approve outside appointments of the Board Chairperson and make recommendations to the Board with regard to the authorisation of any actual or potential confli</li></ul> |
| Remuneration<br>Committee | <ul> <li>The role of the Committee is to:</li> <li>Ensure compliance with the Company Remuneration Policy;</li> <li>Review the ongoing appropriateness and relevance of the Group Remuneration Framework, in particular in the context of changing business strategy and risk environment;</li> <li>Review on an annual basis the remuneration, of the Company's executive directors and members of senior management, against local benchmarks and the Group Remuneration Framework and the Company Remuneration Policy and liaise with the Group Remuneration Committee on an arm's length basis as part of the annual Group remuneration-setting process;</li> <li>Provide any feedback to the Group Remuneration Committee in respect of the performance of executive directors and/or members of senior management as part of the annual Group remuneration-setting process;</li> <li>Liaise with the Group Remuneration Committee on an arm's length basis in terms of providing advice on specific risk adjustments to be applied to performance objectives set in the context of incentive packages – in the event of any difference of view appropriate risk adjustments should be decided by the Committee Chairperson and the Non-Executive Directors;</li> <li>Be aware of and advise, where appropriate, on any major changes in employee benefit structures throughout the Group; and</li> <li>Be exclusively responsible for establishing the selection criteria, selecting, appointing and setting the terms of engagement for any remuneration consultants who advise the Committee and considering any other connection that they may have with the Company;</li> </ul>  |

#### B.1 General information on the system of governance continued

| Committee                                     | Role, duties and responsibilities  |
|---|--|
| Committee<br>Model<br>Governance<br>Committee | <ul> <li>The role of the Committee is to:</li> <li>Review and recommend on the strategic direction of the PIM;</li> <li>Review and recommend on the on-going appropriateness of the design and operation of the PIM, including when appropriate, summary information produced under the PIM Triggers Process, and oversee that the PIM continues to appropriately reflect the risk profile;</li> <li>Review and recommend the Model Governance Policy to the Board Risk Committee and the underlying Model Change Policy at least annually;</li> <li>Review the reasonableness of the PIM including accepted limitations, as well as areas that require improvement and the status of efforts to improve previously identified weaknesses;</li> </ul>                      |
|   | <ul> <li>Oversee that an appropriate PIM change prioritisation and planning process is in operation and provide challenge, as necessary, and that the materiality and proportionality framework is operated in relation to the PIM;</li> <li>Ensure that the governance requirements set out in the Validation Framework (underlying the Model Governance Policy) are met;</li> <li>Provide oversight and challenge on the effectiveness and independence of Independent Validation and Assurance, and the Risk Department's oversight of the PIM and ensure that the PIM is an integral part of the Risk Management Framework;</li> <li>Ensure that there are adequate independent review procedures in place around the PIM design, operation and validation:</li> </ul> |
|   | <ul> <li>Provide oversight of the Company's assessment of the extent to which the PIM complies with the Solvency II Directive;</li> <li>Report to the Board on the oversight exercised by the Committee, including as appropriate, key findings and opinions over the PIM, taking into account Validation, Independent Validation, and Independent Assurance; and</li> <li>Support of its oversight of the PIM, review the outputs of the PIM, to the extent that this informs its governance over the Reasonableness of the PIM and in support of oversight of compliance with the Use Test Minimum Control Standards within the Model Governance Policy.</li> </ul>  |
|   | The Model Governance Committee is required to meet at least twice a year at appropriate times in the reporting cycle or more frequently, as circumstances require. The Committee shall comprise two Non-Executive Directors who sit on the SLIDAC Board, the SLIDAC Chief Risk Officer, the SLIDAC Head of Actuarial Function, the SLIDAC Chief Financial Officer and the SLIDAC Chief Operating Officer. The Board can also appoint any additional members it deems appropriate. Members of the Committee shall have been determined by the Board to have recent and relevant financial experience.   |

#### B.1 General information on the system of governance continued

#### **Executive and Executive Committees**

**Chief Executive Officer** 

The role of the CEO is to manage the day-to-day business of the Company subject to Matters Reserved for the Board and the matters assigned by the Board to the Board Committees. The CEO assists the Board in carrying out its role by providing advice and recommendations consistent with the agreed strategic direction and operational, financial and regulatory good practice.

#### **European Senior Leadership Team**

The ESLT is installed to manage the business of SLIDAC on a day-to-day basis according to the delegated authorities of and with the SLIDAC CEO. The ESLT's key responsibilities are:

- Supporting and implementing strategies of the SLIDAC business as approved by the Board as appropriate;
- Approving for submission to the Board detailed business plans for the SLIDAC business, including business priorities, sales targets, product and customer propositions and budgets in accordance with the agreed International business plan and priorities;
- Monitoring business results against agreed plans;
- Reviewing and monitoring Strategic Risks;
- Ensuring the following key operating principles are followed:
- Operate a sustainable life assurance company consistent with the criteria of the SLIDAC Business and the Group;
- Provide competitive, relevant products and a superior level of service to customers;
- Maintain the good standing reputation, image and integrity of the SLIDAC business;
- Retain the confidence and support of the Group Executive; and
- Manage all risks in line with approved appetite and reduce level of unrewarded risk.
- Ensuring the operation of an effective internal control framework; and
- · Reviewing key outputs from the SLIDAC Enterprise Risk Management Committee and taking appropriate actions.

#### **Executive Committees**

In addition to the ESLT, there are ten other Management committees which are to oversee the operations of SLIDAC, namely the:

- ERMC It derives its authority from the Board, which is delegated to the CEO, and ultimately reports to the CEO. The scope of the ERMC covers SLIDAC's International Bond business in the UK, its Irish Domestic business and its German Branch (including Austrian business). The ERMC considers and has responsibility for all strategic, financial, operational and regulatory risks and conflicts of interest arising from the current and proposed activities of SLIDAC's business. The Committee considers conduct risk and receives and relies on reporting from the Operational & Conduct Risk Committees in that regard;
- Country Leadership Teams They exist in both Ireland and Germany and have responsibility for the day-to-day delivery of local level reporting
  and inputs required by the ESLT. The Teams derive their authority from and ultimately report to the CEO, with a direct reporting line to the ESLT;
- Investment and Credit Committee The overarching responsibility of the Committee is to support the SLIDAC ESLT in delivering effective
  management of credit and investment risks. Individual members of the Committee are accountable for the provision of appropriate input;
- Partial Internal Model (PIM) Committee The role of which is to support the European Senior Leadership Team in reviewing all aspects of the Partial Internal Model. The Committee provides assurance to the Model Governance Committee (and to the SLIDAC Board, if the Model Governance Committee deem appropriate) on the ongoing Appropriateness and Reasonableness of the Partial Internal Model;
- Operational & Conduct Risk Committees They are established in both Ireland and Germany. The Committees are sub Committees of the SLIDAC ERMC. The scope of the Committees covers operational and conduct risks concerning the Irish and the German & Austrian businesses. Compliance and Financial Crime matters are in scope as well. All significant risk and control issues are reported via the risk dashboard/ Views on Risk and Compliance Report to the SLIDAC ERMC (one for Ireland and one for Germany & Austria);
- Reinsurance Business Committee It exists in the context of the intra-group reinsurance arrangements between SLAL and SLIDAC, to provide a mechanism through which both parties may communicate with each other and obtain and consider information in relation to the reinsured business, to facilitate the running of the operational processes associated with the reinsurance and to oversee significant claims and the acceptability of pricing of new business;
- Product Oversight Governance Committee It is responsible for maintaining oversight of Product Governance for all SLIDAC Propositions
  in order to prevent and mitigate customer detriment and embed the delivery of fair outcomes for all customers. The aim is to ensure that
  the interests of our customers are taken into consideration throughout the life cycle of products, including the process of designing and
  manufacturing the product, bringing it to the market, monitoring the product once it has been distributed and exiting the product if applicable;
- Customer Incident Management Committee The purpose of the Committee is to identify and oversee improvements to customer experience
  and outcomes, in line with customer strategies and propositions and to fully understand, make decisions and challenge actions in relation to the
  management of conduct and customer risk across the SLIDAC Irish & UK businesses in line with established risk appetites;
- Regulatory Change Forum (for Ireland) The purpose of the Forum is to oversee that all regulatory change impacting the SLIDAC business is
   actively assessed and appropriately implemented; and.
- The Product Pricing and Profitability Committee (PPPC) is a management committee whose purpose is to be responsible for the pricing
  of SLIDAC products in all markets; actively consider where profitability targets are conflicting with market competitiveness for new business
  and recommend remedial action where appropriate; provide commercial review and challenge to the development of new products or
  amendments to existing products; and be responsible for the monitoring of appropriate MI in relation to new business pricing and profitability of
  existing business.

### B.1 General information on the system of governance continued

#### Scheme of Delegation

The SLIDAC Scheme of Delegation sets out the flow and principles of delegation from the SLIDAC Board to its Committees, Executive Directors and members of senior management. The SLIDAC Board can delegate, where appropriate, all or part of its authority to an individual Director or to a Board Committee or other individuals competent to carry out that task.

The Delegated authorities document outlines the appropriate authority levels that have been assigned to senior representatives across the business to apply to settlement transactions carried out on behalf of the Company.

Delegated authority is an important control that allows the business to operate in a controlled but efficient and effective manner by giving individuals clear accountability for specific activities.

#### Code of Conduct

Good governance within the Company is predicated on the ethical behaviour of the organisation's staff. In recognition of this, the Company has developed, adopted and communicated a Code of Conduct which provides guidance on the high standards of ethical behaviour expected from staff to fulfil the Company's aim of becoming the trusted home for the financial future of customers.

#### **Prudent Person Principle**

The Prudent Person Principle is a set of qualitative requirements used to govern investment decisions and asset allocations. In particular, it sets out the expectation that insurers will exercise prudence in relation to the acquisition and holding of assets and places responsibility on the insurer to decide whether the nature of any investment is appropriate and to be able to show that it has systems and controls to hold and manage any such investments.

The Company's policies state the standards that business units must comply with in managing the key risks that threaten the achievement of our strategy and business objectives. A range of these standards are directly relevant to the requirements of the Prudent Person Principle and are primarily contained in the following policies:

- Market Risk Management policy
- Credit Risk Management policy
- Insurance Risk Management policy
- Capital Management policy
- · Liquidity and Funding Policy

Policy compliance reporting on our internal risk management system, called GCM, demonstrates whether the Company has been compliant with the relevant policy standards and, as a consequence, with the requirements of the Prudent Person Principle. Further details on Prudent Person Principle compliance can be found in Section C, Risk Profile.

#### Fitness and Probity regime

Under the CBI's Fitness and Probity regime, only individuals who are deemed to be fit and proper can carry out Controlled Functions. Pre-Approval Controlled Functions are a subset of Controlled Functions which require approval from the CBI prior to the candidate being appointed to the role.

#### Remuneration

The Company's Remuneration Policy is fully aligned to the strategic aims of the Company and to Phoenix Group's Remuneration Policy. Its aim is to attract and retain talent at all levels focused and capable of delivering business objectives whilst considering the interests of shareholders and other stakeholders, balanced with the affordability to make these payments.

The SLIDAC Board is responsible for ensuring that these principles are applied and that individuals are not rewarded for taking on undue risks. The Remuneration Committee of the Board supports it in achieving these objectives.

The independent Non-Executive Directors on the SLIDAC Board have consulted with the Head of HR (Europe) and the Group Remuneration Committee and are satisfied that the bonus structure for the Executive Directors of SLIDAC is not excessive and that it does not drive inappropriate risk taking.

Fixed and variable elements of remuneration: employee remuneration is composed principally of fixed and variable elements of reward as follows:

(a) Fixed reward:

- Fixed remuneration: salary (and cash allowances, if appropriate)
- Benefits (including pension)
- (b) Variable reward: bonus, including the Phoenix Group Deferred Bonus Share Scheme where awards in excess of a predefined limit for senior employees are delivered in shares with a three year vesting period. Senior employees may also be awarded a long-term incentive award

#### B.1 General information on the system of governance continued

Appropriate ratios of fixed to variable remuneration will be set so as to ensure that fixed and variable components of total remuneration are appropriately balanced; and the fixed component is a sufficiently high proportion of total remuneration to allow the Company to operate a fully flexible policy on variable remuneration components including paying no variable remuneration component. Bonus awards are contingent upon the company meeting various business targets set at the start of each year. The targets were based on financial and customer measures in 2021.

Executive Directors and non-independent Non-Executive Directors are members of Phoenix pension schemes. The schemes are defined contribution and operated through Standard Life Asset and Employment Services Limited. Independent Non-Executive Directors have no supplementary pension or early retirement scheme with SLIDAC.

There were no material transactions during the reporting period with shareholders, persons exercising significant influence, or members of the Board.

All employee share plans: employee share ownership was promoted through two initiatives:

- The Phoenix Share Incentive Plan
- The Phoenix Irish and German Sharesave Plans

#### B.1.3 Overview of organisational and operational structure

The Company has an established and well-defined organisational and operational structure with clearly defined roles, responsibilities and reporting lines to ensure that appropriate spans of control operate throughout the organisation, in relation to its business activities and risk management.

Each business within PGH, including SLIDAC, maintains a list of all of its decision-making committees. Each committee operates under its own terms of reference, which sets out its authority, purpose, scope and quorum details. The purpose of a quorum rule is to give decisions made by a committee enough authority to allow binding action to be conducted.

The Company's governance functions include Risk and Compliance, Internal Audit and Actuarial who have responsibility for monitoring, reviewing, challenging and reporting on the status of the Company's risks on an ongoing basis. Fit and proper checks are carried out on applicable staff from key functions to ensure that they possess the competency, expertise and integrity necessary for the performance of their duties.

#### Three lines of defence

The Company operates a "three lines of defence" model of risk management, with clearly defined roles and responsibilities for individuals and committees:

- First line: Day-to-day risk management is delegated from the Board to the Chief Executive Officer and, through a system of delegated authorities, with specified limits, to business managers. The role of business managers in the first line is to establish, own and operate the key elements of the risk control processes.
- Second line: The role of the second line is performed by the SLIDAC Risk and Compliance Function. The second line are responsible for providing effective advice and challenge to the business stakeholders in the first line, providing oversight of risk management activities and ensuring that risks are being identified, assessed, controlled, monitored and reported appropriately. The second line also undertakes independent assurance reviews, as set out in the annual plan which is approved by the Board Risk Committee. The overall second line Mission and Mandate have been set out at the ERMC and Board Risk Committee.
- Third line: The role of the third line is performed by Internal Audit that provides independent verification of the adequacy and effectiveness of governance, risk management and internal controls.

#### B.1.4 Changes to the System of Governance and ERM framework during 2021

Key changes to the System of Governance and ERM framework during 2021 have been:

- The Company has entered the UK's Temporary Permissions Regime ("TPR") as a cross-border services provider which means that it: (i) does not yet have an establishment in the UK; (ii) is deemed authorised in the UK; and (iii) can continue to sell the International Bond from Ireland to UK customers;
- The role of the Model Governance Committee is to monitor the strategic direction and overall governance of the Partial Internal Model used by the Company and provide assurance to the Board on the on-going Appropriateness and Reasonableness of the Partial Internal Model;
- The establishment of a new management committee; the Partial Internal Model (PIM) Committee whose purpose is to support the European Senior Leadership Team in reviewing all aspects of the Partial Internal Model;
- The Company submitted an application to the Central Bank of Ireland to implement a Partial Internal Model (approved 11 March 2022); and
- The establishment of a new management committee; the Product Pricing and Profitability Committee.

#### B.2 Fit and proper requirements

SLIDAC carries out due diligence and 'fit and proper' checks before appointing people to Controlled Function (CF) and Pre-Approval Controlled Function (PCF) roles. PCFs include new Directors (including non-executive Directors), Executives and other roles specified by the CBI. The checks are fully documented and include an assessment of whether the person is 'fit' based on professional and formal qualifications, knowledge and relevant experience for the responsibilities of the role; and 'proper' based on honesty, financial soundness, character and criminal record.

Each year a Competency and Capability review is conducted to ensure that individuals carrying out PCF and CF roles are fit to carry out the role and individuals are asked to review the Fitness and Probity Standards and re-certify that they comply with those Standards.

Effectiveness reviews of the SLIDAC Board, the Audit Committee, the Risk Committee, the Remuneration Committee and the Nomination Committee were undertaken in November 2021. Directors also completed self-assessment questionnaires, with actions agreed from the reviews.

SLIDAC's employees are subject to the Performance Management Process which takes into consideration whether there are any material issues identified that will materially impact the competence and capability of employees to carry out their role.

#### B.3 Risk management system

The Company's risk management system is part of the wider system of governance and includes the ERM framework and the ORSA.

#### B.3.1 Enterprise risk management framework

A key part of the Company's system of governance is the ERM framework. The ERM framework includes the methods and processes used to manage risks, and identify and seize commercial opportunities related to the achievement of our objectives, protecting and enhancing value. It enables a risk based approach to managing the business and incorporates the five elements listed below and integrates concepts of strategic planning, operational management and internal control. The framework has been developed and embedded in the business over a number of years.



#### B.3 Risk management system continued

All of the ERM components (listed below) are interconnected and work together to provide the Company with a holistic framework encouraging proactive and pre-emptive risk management across the business

- Risk culture: the way we think and act as individuals and as a business. It encompasses our attitudes, capabilities and behaviours towards risk. Our culture drives how we identify, understand, openly discuss and act on current and future risks.
- Risk control processes: the practices by which we manage financial and non-financial risks within the Company. They are used to identify, assess, control and monitor risk.
- Strategic risk management: this forms an integral part of the strategic planning process and is directly linked to our corporate objectives. It supports the development of long-term value by ensuring well informed risk-reward decisions are taken in pursuit of our business plan, and that capital is distributed to the areas where most value can be created from the risks taken.
- Risk and capital models: the models that we use to measure our risk exposures and capital position and the work that we do to test and understand the sensitivity of these positions.
- Emerging risks: the aim of emerging risk management is to identify risks before they materialise to help us anticipate future threats. This gives us time to engage with the risk, understand it and respond accordingly. Our screening process informs stress testing and capital adequacy requirements.

Work to harmonise the Standard Life and PGH ERM frameworks has continued across SLIDAC in 2021.

#### B.3.2 Own risk and solvency assessment

The ORSA is a set of processes that underpin our ERM framework. These processes identify, assess, control and monitor the risks which inform our capital requirements. A core principle of the Company's ORSA is that it is not a single annual exercise but the combination of inter-linked risk management processes happening continuously throughout the year.

The purpose of the ORSA is to inform and develop:

- Our understanding of the current and potential risks to the business over the product lifecycles. This includes both financial and non-financial risks including environmental, social and governance risks and their potential to affect both the long and short-term value of the business;
- Our appetite for these risks and how we manage them;
- Our own assessment of current solvency and capital requirements with respect to the risks; and
- A forward-looking assessment of the risk and solvency needs of the business over a multi-year time horizon in light of the business plans.

#### B.3 Risk management system continued

The Company's ORSA processes play a key role in supporting decision making and strategy developments at boards and risk committees. These processes run concurrently, operate continuously throughout the year and underlie the identification, assessment, control and monitoring of risks.

An ORSA Report is reviewed and approved by the Board at least annually or in the event that the ORSA triggers are met, for example when there has been a material change in risk appetites or a material change to risk exposures.

The Company's solvency needs are assessed using the Standard Formula at each reporting period and projected into the future as part of the business planning cycle. The appropriateness of the Standard Formula is reviewed at least annually to ensure that the risk profile is properly captured. After the Company submitted an application for a PIM, differences between the two methods were assessed in the 2021 ORSA.

The risk management system interacts with our capital management activities by ensuring that well-informed risk-reward decisions are taken in pursuit of our business plan objectives, allowing capital to be delivered to areas where most value can be created from the risks taken. Our consistent application of effective and pre-emptive risk management across our business protects our short-term value while encouraging the development of long-term value. Oversight of risk within the business is delivered through the ORSA processes.

The ORSA process is summarized in the diagram below.

#### Annual ORSA Report

Full forward-looking assessment of risks and capital position

# Stress &

### **Scenario** Testing

Stress & Scenario Testing programme provides insight into principal risks across a continuum of plausible stress environments

#### Risk Management & Monitoring

Risk policies manage the risks in line with appetite. Risk reporting provides ongoing oversight of risk exposures

#### Delivery of the strategy & business plan exposes

business plan

Strategy &

& business plan exposes business to risk

#### Risk Exposure & Appetite

Board expresses appetite to risk it is willing to accept in pursuit of strategic and business plan objectives

## Risk Capital Assessment

Capital requirements reflect the risk profile of the business

#### **B.4 Internal control system**

Our internal control system contains a range of processes which are captured under our Conduct and Operational Risk framework as part of the risk control process element of the ERM framework.

#### B.4.1 Conduct and operational risk framework

A key feature of the ERM framework is the Risk Universe, upon which the Risk Policy framework is based. The Risk Policy framework incorporates key risks and Minimum Control Standards relating to each policy and key risk. The ERM framework also features a holistic Risk and Control Self-Assessment approach and Incident and Breach Management procedures. Tracking of actions plans and key risk indicators also forms part of the framework. The Conduct and Operational Risk framework comprises the following processes outlined below:

- Business risk profiles;
- Risk policy framework;
- Risk assessment including risk registers;
- Risk and Control self-assessment;
- Incident and breach management;
- Action plan management; and
- Key risk indicators.

#### **Business Risk Profiles**

A Business Risk Profile ('BRP') is a Line 1 report for a particular risk category which provides an overview of how well that risk is managed. BRPs contain a risk definition, qualitative and quantitative assessments of risks, details of key controls, key risk indicators and any relevant internal or external loss data. They also contain details of the top-down and bottom-up emerging risks and action plans to improve risk mitigation.

BRPs exist for each material Level 2 or Level 3 risk category and each BRP has an identifiable Risk Owner in Line 1. The Risk Owner is responsible for ensuring that the BRP is completed and they are supported in this by Risk Champions within their area. Risk Owners update most BRPs on a quarterly basis.

#### **Risk policy framework**

The policy framework helps the Company to achieve the high level business objectives by providing a structure to help articulate how the code of conduct, governing principles and all of the policies and procedures fit together to make sure that the business and employees operate within approved limits and standards, as defined by the Board.

The fair treatment of customers is integral to all of our business activities and of fundamental importance. As such, policies are implemented with their specific impact on the customer in mind. This framework provides a structured process for developing and implementing policies consistently across the business.

#### Risk assessment including risk registers

Risk assessment is the process whereby operational risks which might adversely affect the Company's ability to meet its stated business objectives are identified, assessed and managed in order to minimise any adverse impact. Conducting the risk assessment process increases the likelihood of meeting our business objectives and plans because we have identified up-front what can go wrong and have taken actions to prevent this.

It is mandatory for all business units to establish, own and operate risk assessment processes. The recording, ongoing monitoring and management of the risks identified through these processes is enabled through the use of 'risk registers' which are held on the GCM system.

The registers detail a range of information captured through the risk assessment process including: a description of the risk; details of the likely causes and impacts; an assessment of the risk in impact and likelihood terms; details of the responses to the risk; and, details of the 'owner' for each risk. Responsibility for implementing a risk assessment process including appropriate responses, and the creation and ongoing management of a risk register rests with business unit leaders and managers. They will be supported in this by their business unit risk team.

#### **Risk and Control Self-Assessment**

Risk and Control Self-Assessment ('RCSA') is a self-assessment tool, its purpose being to ensure that the risks that exist in key processes and the primary controls within them are documented and subject to regular assessment by business owners. The assessments include:

- the inherent likelihood and impact of key risks;
- the likelihood and impact of those risks following actions taken and controls put in place to mitigate against them;
- a review of the adequacy of the design of the suite of controls;
- an assessment of the actual performance of those controls;
- evidence to support control performance; and
- an overall control effectiveness conclusion.

#### B.4 Internal control system continued

The results of the RCSA certification process feed into the BRPs and provide senior management with assurance over the awareness of risks, and the effectiveness and quality of the control environment operated across the key business processes.

RCSA results may also lead to designing new procedures or changing existing procedures in order to reduce the probability of control failures.

#### Incident and Breach Management

An incident is a risk that has materialised as a result of a deficiency in our system of internal control or an external event and a breach is an incident that has gone beyond the appetites set for risks. Since they can have a significant impact on the Company's reputation and performance, we aim to identify and understand these quickly to ensure that an appropriate response is taken. The GCM system is used to log any incidents and breaches that occur and ensure action plans are put in place for corrective action.

#### **Action Plan Management**

Action plan management is an important aspect of the conduct and operational risk control framework. Its purpose is to:

- · Ensure that control improvement work is identified, what is required is clearly expressed, ownership is clear and target dates are set;
- · Demonstrate active management of the control environment;
- Prioritise control improvement work; and
- · Provide progress on work to allow source owners to determine the impact of outstanding issues

#### **Key Risk Indicators**

Our key risk indicators ('KRIs') aim to identify potential issues before they materialise and are used as a monitoring tool to provide a snapshot of the current business exposure to specific risks.

KRIs are a blend of control indicators and other management information that is focused on a particular risk. The key differential of a KRI is that the metric has a direct correlation to an increase or decrease in probability, impact or exposure to a specific risk.

KRIs assist both business management and risk management functions by providing a tool to:

- · Monitor risks by measuring trends or performance of KRIs;
- · Provide an early warning to enable proactive rectifying action and help to minimise exposure to losses;
- · Promote a proactive risk culture by providing a trigger for management action; and
- Bring objectivity to the risk process

All the outputs from our conduct and operational risk control framework flow through to the other stages of the ERM framework, such as the risks being reflected in our risk and capital models.

#### B.4.2 Risk and Compliance function

The Risk and Compliance function is a second line of defence function and is embedded into our strategic and operational decision making. The function promotes informed decision-making and controlled risk-taking that improves customer outcomes and delivers long-term value for shareholders.

The Risk and Compliance function achieves this by:

- · Providing guidance, advice, challenge, independent review and assurance of key activities;
- · Developing Regulatory relationships that help deliver the business strategy;
- Ensuring that Compliance activities are undertaken; and
- · Designing and implementing a risk management framework that supports the execution of business strategy.

The Risk and Compliance function is led by the Chief Risk Officer, who has dual reporting lines to the SLIDAC Chief Executive Officer and the Group Life Company Chief Risk Officer. The SLIDAC Chief Risk Officer also has access to the chairperson of the Risk Committee and regularly attends Board Risk Committee meetings. The function covers all elements of the Risk Universe.

Support is also provided by Group functions.

#### B.4 Internal control system continued

#### B.4.3 Regulatory compliance

The Company's Regulatory Compliance policy requires the business to provide assurance that they are complying with the relevant regulations.

The Regulatory Compliance policy sets out the standards the business must adhere to in complying with the relevant regulations. These standards are in place to prevent non-compliance. The Chief Risk Officer is the policy implementation manager for this policy and is also responsible for the annual review of the standards and benchmarks for this policy.

The assessment of the adequacy of the measures adopted to prevent non-compliance is a continuous process and follows an annual cycle starting and ending at annual policy review. The assessment includes:

- Board review and approval of the policy standards (with benchmarks approved by the Chief Risk Officer) to apply in the following year;
- A quarterly self-assessment of compliance with the Board approved policy. Where this highlights areas of non-compliance, action plans are set up to ensure compliance (along with appropriate timescales);
- A review of the above assessment by the policy implementation manager. This review will consider the evidence provided to show compliance, the action plans and other information already reported in the GCM system;
- A review of the policy standards and benchmarks by the policy implementation manager. This review takes into account the cases of noncompliance (or near misses) reported over the year and the adequacy of the current standards and benchmarks in reducing the numbers and controlling the impact of these cases; and
- · Board review and approval of the revised policy standards resulting from the above review

#### **B.5 Internal Audit function**

Internal Audit activities for the Company are provided by Standard Life International Internal Audit ('SLIIA') function. The primary role of SLIIA is to support the Board and Executive Management to protect the assets, reputation and sustainability of the organisation. This is achieved by assessing whether all significant risks are identified and appropriately reported, assessing whether they are adequately controlled and challenging Executive Management to improve the effectiveness of governance, risk management and internal controls.

SLIIA operates in compliance with the International Standards for the Professional Practice of Internal Auditing, the Internal Audit Code of Ethics and the Guidance on Effective Internal Audit in the Financial Services Sector and guidance provided by the European Confederation of Institutes of Internal Audit ('ECIIA').

#### B.5.1 Roles and responsibilities of Internal Audit

The SLIIA scope is unrestricted and there are no aspects of the organisation which SLIIA is prohibited from reviewing. Key business risk areas and industry themes identified both internally and externally, are prioritised to receive more extensive coverage, regular ongoing review and opinion formation.

The function has a number of responsibilities, including producing, delivering and reporting on the annual Internal Audit plan.

#### **B.5.2 Reporting**

SLIIA attend, and issue reports to the Company's Board Audit Committee ('SLIBAC') and any other governing bodies and Board committees as appropriate.

SLIIA's reporting to the SLIBAC will include significant control weaknesses, root-cause and relevant 'lesson learned' analysis, themes and a view on the adequacy of management's remediation plans. Bi-annually, SLIIA will provide an opinion on the strength of the design and operation of the Risk Management/Internal Control Framework (and adherence to the risk appetite framework across the business).

#### B.5.3 Independence and objectivity of the Internal Audit function

In order to maintain its independence and objectivity from the activities it reviews, SLIIA ensures the following:

- The Company's Head of Internal Audit ('SLIHIA') reports functionally to the Company's Board (through the SLIBAC Chair) and administratively
  to the Phoenix Group Head of Internal Audit ('PGHIA'). The SLIBAC Chair is the final approval point for recommendations made by the PGHIA
  regarding the performance objectives, appraisal, appointment or removal of the SLIHIA as well as the overall compensation package of the
  SLIHIA which is further ratified by the Group Audit Committee.
- The remuneration of the SLIHIA is structured in a manner such that it avoids conflicts of interest, does not impair independence and objectivity and is not directly or exclusively linked to the short term performance of the organisation.
- The SLIHIA ensures that Internal Audit remains free from anything that impacts its ability to carry out its responsibilities in an unbiased manner.
  Internal Audit has the right to attend and observe all or part of executive management meetings and any other key management decision-
- making forums. It also has sufficient and timely access to all Board and Executive management information and a right of access to all of the organisation's records, necessary to discharge its responsibilities.
- Effective Risk Management, Compliance and other assurance functions are an essential part of the Company's corporate governance structure. SLIIA is independent of these functions and is neither responsible for, nor part of, them. In evaluating the effectiveness of internal controls and risk management processes, in no circumstances does SLIIA rely exclusively on the work of these other assurance providers. SLIIA exercises informed judgement as to when to leverage the work of other assurance providers and always examine for itself an appropriate sample of the activities under review, after a thorough evaluation of the effectiveness of other assurance providers' work in relation to the applicable area.

#### **B.6 Actuarial function**

The actuarial function has the following responsibilities:

- Technical provisions: co-ordinate calculation of technical provisions; ensure the appropriateness of the methodologies and underlying models used as well as assumptions made in the calculation of the technical provisions; inform the Board of the adequacy of calculation; provide opinion on the adequacy of technical provisions;
- Underwriting: prepare an opinion on overall underwriting policy;
- Reinsurance: prepare an opinion on adequacy of reinsurance arrangements;
- With Profits: prepare an opinion on the compliance of the technical provisions with the principles in the With Profits Operating Principles ('WPOPs') document; and
- Risk management: contribute to an effective risk management system; provide an opinion to the Board on the range of risks and adequacy of the scenarios considered as part of the ORSA.

In addition to the above which are required by the Solvency II Directive delegated acts and guidelines, the Actuarial function also performs the following functions:

- Assumptions and methodology: assess whether the methodologies used in the calculation of the technical provisions and SCR are appropriate for the business. Review and propose changes to methodologies, having regard to the available data;
- IFRS actuarial liabilities: recommend to the Board methodology and assumptions for the calculations of IFRS actuarial liabilities;
- Investment Oversight: oversight and management of investment decisions relating to SL Intl's shareholder funds and funds backing annuities, and oversight of investment decisions affecting SL Intl's With Profit customers;
- · Capital and liquidity management: monitor and manage capital and liquidity; and
- With-Profits and Reinsurance Management: monitor management of the with profits funds and compliance with relevant regulations. Oversee the adequacy and effectiveness of reinsurance arrangements.

In addition to the requirements of Solvency II, the Actuarial Function is subject to the requirements of the CBI's Domestic Actuarial Regime.

#### **B.7 Outsourcing**

The Company's Sourcing and Procurement Policy and Supplier Management Governance Process set the standards that the Company must comply with for outsourcing arrangements.

The Company expressly retains responsibility for meeting all relevant regulatory and legal requirements by the outsource providers and includes the requirement for the implementation of appropriately robust governance structures. The Sourcing and Procurement Framework also highlights that customer outcomes must be considered at the outset and throughout the lifecycle of any outsourcing arrangement.

For each outsourced arrangement with the Company, an Executive Sponsor, Accountable Authority and Supplier Relationship Manager are appointed. Outsourced control functions (as per CBI fitness and probity definitions) are required to satisfy the fitness and probity requirements. In addition to these, the Supplier Governance Manager, the Chief Risk Officer, Chief Operating Officer and local level Operational & Conduct Risk Committees ('OCRC') have specific roles in relation to the approval and subsequent governance of outsourcing arrangements. The OCRC is responsible for reviewing all proposed outsourcing arrangements that are identified by the Chief Risk Officer (or nominated deputy) as potentially having a material impact on the risk profile and annually reviews the complete master list of outsourcing arrangements across the Company.

The Company uses a number of outsourcing partners to operate and deliver core systems, capabilities and processes. Most arrangements are to other companies within the Phoenix Group and are located in the UK. We also have arrangements with companies based in Ireland and Germany.

#### **B.8 Any other information**

The Company continues to exercise oversight in relation to its outsourcing arrangements, in line with Governance rules, and review its overall operation of organisational governance through the COVID-19 crisis.

Please note information on the Company's approach to Responsible Investment can be found on the following webpage (and the German version below):

#### https://www.standardlife.ie/news/responsible-investment

https://www.standardlife.de/ueber-uns/nachhaltigkeit

# Section C

# **Risk profile**

# In this sectionC.1Underwriting risk33C.2Market risk35C.3Credit risk36C.4Liquidity risk39C.5Operational risk40C.6Other material risks42C.7Any other information43

# Section C – Risk profile continued

#### **Risk profile**

Section B.3 sets out the risk management system including information on how the Risk Management Framework ('RMF') is implemented and integrated into the organisational structure and decision-making processes of the Company.

This section provides information on the risk profile of the Company, including for each category of risk, a description of the risks, a description of the measures used to assess these risks, material risk exposures, concentrations and risk mitigation techniques. Sensitivity analysis for each category of risk is also provided.

The Company's principal risks and uncertainties are described in Note 37 of the 2021 Annual Financial Statements. These are:

| Risk                                 | Description  | More detail included in section    |
|--------------------------------------|--|------------------------------------|
| Demographic and<br>Expense Risk      | DemographicThe risk that arises from the inherent uncertainties as to the<br>occurrence, amount and timing of future cash flows due<br>to demographic experience differing from that expected.<br>This class of risk includes risks that meet the definition of<br>  | C.1 Underwriting risk              |
| Financial Market<br>and Credit Risks | Market<br>The risk that arises from the Company's exposure to market<br>movements which could result in the value of income, or<br>the value of financial assets and liabilities, or the cash flows<br>relating to these, fluctuating by differing amounts.<br>Credit<br>The risk of exposure to loss if a counterparty fails to perform<br>its financial obligations, including failure to perform those<br>obligations in a timely manner. | C.2 Market risk<br>C.3 Credit risk |
| Liquidity Risk                       | The risk that the Company is unable to realise investments<br>and other assets in order to settle its financial obligations<br>when they fall due, or can do so only at excessive cost.  | C.4 Liquidity risk                 |
| Operational Risk                     | The risk of adverse consequences for the Company's<br>business resulting from inadequate or failed internal<br>processes, people or systems, or from external events. This<br>includes conduct risk as defined below.  | C.5 Operational risk               |
| Conduct Risk                         | The risk that through our behaviours, strategies, decisions<br>and actions the Company delivers unfair outcomes to our<br>customers/clients and/or poor market conduct.  | C.6 Other material risks           |
| Strategic Risk                       | Risks which threaten the achievement of the strategy through poor strategic decision-making, implementation or response to changing circumstances.   | C.6 Other material risks           |

The risks above are covered in this section, which follows a prescribed format and order. Sections C.1 to C.6 provide information on specific material risks to which the Company is exposed. Section C.7 covers information which applies across these material risks.

Capital held in respect of these risks is described in Section E. Please see Quantitative Reporting Template S.25.01.01 to see the split of the SCR by risk category.

# Section C – Risk profile continued

#### Risk profile continued

The table below shows the composition of the actual Company undiversified SCR, calculated in accordance with the Standard Formula:

| Risk profile                        | Section<br>reference | SLIDAC SCR<br>31 December 2021 | SLIDAC SCR<br>31 December 2020 |
|-------------------------------------|----------------------|--------------------------------|--------------------------------|
| Underwriting risk                   | C.1                  | 38%                            | 34%                            |
| Market risk (including credit risk) | C.2&C.3              | 49%                            | 54%                            |
| Liquidity risk                      | C.4                  | 0%                             | 0%                             |
| Operational risk                    | C.5                  | 13%                            | 12%                            |
| Other risks                         | C.6                  | 0%                             | 0%                             |
| Total                               |                      | 100%                           | 100%                           |

There is very little movement in the above table versus 2020 for the overall risk groups. Credit risk has been included within the Market Risk category for the purposes of the summary table above, with Credit Risk making up 13% of the undiversified SCR in 2021 versus 27% in 2020. The reduction in Credit Risk is due to the upgrade of the credit rating of SLAL, the main reinsurance counterparty, to AA- in July 2021.

The Market Risk category now also includes Concentration Risk which makes up less than 1% of the overall Market Risk module. The Company does not hold SCR for liquidity or other risks, as explained further in Section C.4.1 and C.6.1.

The key factors affecting the movement of each risk category are set out in their respective sections below.

More details regarding the SCR are set out in section E.2.

#### C.1 Underwriting risk

#### C.1.1 Risk exposure

Underwriting risk refers to the risk that the frequency or severity of insured events may be worse than expected and includes expense risk. Contracts underwritten by the Company include the following material sources of underwriting risk:

| Risk Source      | Description   |
|------------------|---|
| Lapse Risk       | Adverse movement in either surrender rates or persistency rates on policies, leading to losses. This includes the risk of greater than expected policyholder option exercise rates giving rise to increased claims costs. |
| Mortality Risk   | Higher than expected number of deaths experienced on life and protection products or greater than expected increase in mortality rates.   |
| Longevity Risk   | Lower than expected number of deaths experienced on annuity products or greater than expected improvements in annuitant mortality.  |
| Catastrophe Risk | Once-off catastrophic event causing a sharp spike in mortality rates.   |
| Expense Risk     | Unexpected timing or value of expenses incurred.  |

The table below shows the split of the undiversified SCR in respect of underwriting risk.

| Components of Underwriting Risk | 31 December 2021 | 31 December 2020 |  |
|---------------------------------|------------------|------------------|--|
| Lapse Risk                      | 24%              | 22%              |  |
| Mortality Risk                  | 1%               | 0%               |  |
| Longevity Risk                  | 3%               | 4%               |  |
| Catastrophe Risk                | 0%               | 0%               |  |
| Expense Risk                    | 9%               | 7%               |  |
| Total Underwriting Risk         | 38%              | 34%              |  |

During the year ended 31 December 2021, the key changes to the Company's exposure to underwriting risk include:

- The allocation of business costs has been reviewed. This resulted in a shift away from acquisition expenses towards maintenance expenses, which increased the total expense included in future modelled cash flows.
- The update of underwriting assumptions across a variety of products to reflect the results of experience analysis.

The ongoing consequences of the Coronavirus pandemic on health and longevity are not yet known, but may eventually have an effect on the Company's exposure to mortality and longevity risk.

# Section C - Risk profile continued

#### C.1 Underwriting risk continued

#### C.1.2 Risk measurement

The Company uses several methods to assess and monitor underwriting risk exposures both for individual types of risks insured and the overall risks. These methods include the Solvency II Standard Formula, experience analyses, external data comparisons, sensitivity analyses, scenario analyses and stress testing.

The risk capital requirement for underwriting risk is assessed using the Standard Formula model, which is calibrated to withstand a stress event to a 99.5% confidence level over a one-year period.

As at 31 December 2021, underwriting risk represented 38% of the Company's total undiversified SCR as shown in the table at the beginning of Section C.

#### C.1.3 Risk concentration

The Company is not exposed to any material concentration of underwriting risk. For all underwriting risks described above, the Company's exposure is spread across a diversified portfolio of products. No individual policyholder contract size is large enough to represent a material concentration as a proportion of the Company's total risk exposure.

#### C.1.4 Risk mitigation

Reinsurance is used within the Company primarily to reduce risk exposures arising on With-Profits policies. The reinsurance arrangements (including those with SLAL) covering these policies reduce the Company's underwriting risk exposure in respect of these policies. There are also some rider benefits on this reinsured book that are reinsured with external parties. If the external agreements were to default, the liability would be captured by the SLAL reinsurance treaty. There is also a small amount of reinsurance on the retained German business, where some rider benefits on policies are reinsured to third parties.

For business retained within SLIDAC, underwriting risks are managed through the use of appropriate and active pricing and regular monitoring of experience. We also have a risk appetite framework which limits the amount of exposure we have to individual risks.

The Company actively monitors its actual experience on longevity and persistency, along with other underwriting risks. This gives timely identification of any significant divergence from long-term trends, which can enable the underlying causes to be identified and appropriate actions implemented.

#### C.1.5 Sensitivity analysis

As part of the Company's internal risk management processes, the impact of a number of underwriting risk scenarios on the SCR is monitored. These sensitivities incorporate some modelling approximations and results are indicative. The results of such stress testing on the Company's SCR are provided below.

|   | SCR     | SCR       |
|---|---------|-----------|
|   | (€'000) | Ratio (%) |
| Base: 31 December 2021                              | 409,927 | 173%      |
| Following 6% decrease in annuitant mortality rates  | 410,810 | 171%      |
| Following 10% increase in assurance mortality rates | 406,749 | 174%      |
| Following a 10% increase in lapse rates             | 396,459 | 175%      |
| Following a 10% decrease in lapse rates             | 426,554 | 170%      |

As can be seen from the results, the Company is reasonably resilient to such scenarios.

# Section C - Risk profile continued

#### C.2 Market risk

#### C.2.1 Risk exposure

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market influences. The Company is exposed to the following material sources of market risk:

| Risk Source        | Description   |
|--------------------|---|
| Equity Risk        | The risk of reduction in earnings and/or value, from unfavourable movements in equity asset values. In this context, equity assets should be taken to include shares, equity derivatives and equity collectives (OEICs, unit trusts, investment trusts).                      |
| Property Risk      | The risk of adverse property market movements which could result in a financial loss.   |
| Interest Rate Risk | The risk that the fair value of future cash flows of a financial instrument will fluctuate relative to the respective liability due to the impact of changes in market interest rates and the associated guarantees on certain insurance contracts.                           |
| Spread Risk        | The risk of reduction in earnings and/or value, from unfavourable movements in the spread between corporate bond yields and swap rates used to discount insurance liabilities.  |
| Currency Risk      | The risk of reduction in earnings and/or asset and liability values, arising solely as a consequence of changes to currency exchange rates. This risk category also covers the risk of a change in swap rates in one currency, relative to the swap rate in another currency. |
| Concentration Risk | The risk that holdings in single assets or groups of associated assets magnify the market risk due to the concentrated nature of the exposure, due to a lack of diversification.  |

The table below shows the split of the undiversified SCR in respect of market risk for the Company.

| Components of Market Risk | 31 December 2021 | 31 December 2020 |
|---------------------------|------------------|------------------|
| Equity Risk               | 23%              | 13%              |
| Property Risk             | 0%               | 0%               |
| Interest Rate Risk        | 1%               | 1%               |
| Spread Risk               | 4%               | 7%               |
| Currency Risk             | 7%               | 5%               |
| Concentration Risk        | 1%               | 0%               |
| Total Market Risk         | 36%              | 27%              |

During the year ended 31 December 2021, the following are the key changes to the Company's exposure to market risk:

- Large increases in the value of equities have increased the value of unit-linked liabilities, and the equity risk capital charge has increased as current equity values are higher than the average over the last three years.
- The asset fund backing the annuity liabilities had revisions to its investment mandate, reducing the proportion of corporate bonds and increasing the proportion of sovereign and supranational bonds, which reduces the overall spread risk.

#### C.2.2 Risk measurement

The Company uses several methods to assess and monitor market risk exposures both for individual market risk categories and for the aggregate exposure to all market risks. These methods include monitoring of asset portfolio composition, interest rate mismatch metrics, strategic asset allocation, and hedge effectiveness. In addition, risk is measured using the Standard formula, sensitivity analyses, scenario analyses and stress testing.

The risk capital requirement for market risk is assessed using the Standard Formula model, which is calibrated to withstand a stress event to a 99.5% confidence level over a one-year period.

As at 31 December 2021, market risk represented 36% of the Company's total undiversified SCR.

#### C.2.3 Risk concentration

Market risk concentrations are minimised by offering a wide range of investment options to the Company's customers. The Company also has a risk appetite framework which limits the amount of exposure it has to individual risks.

# Section C - Risk profile continued

#### C.2 Market risk continued

#### C.2.4 Risk mitigation

A number of financial risk mitigation techniques are used throughout the Company including:

| <b>Risk Mitigation Technique</b> | Description  |  |  |
|----------------------------------|--|--|--|
| Diversification                  | Where possible investments are diversified across class, industries and counterparties.  |  |  |
| Cashflow Matching                | In the case of the immediate annuity portfolios assets with similar cash flows to the liabilities are selected to minimise the risk of reinvesting cash flows at adverse prices.   |  |  |
| Hedging                          | Hedging programmes are in place within the with profits funds of the Company to reduce the exposure to equity risk on future policyholder charges, and to manage market risk (in particular equity and interest rate risk). To mitigate exposure to interest rate risk, assets with similar sensitivity to interest rate risk as the corresponding liabilities are selected where possible. Foreign Exchange forward contracts are used to mitigate currency risk on charges on the unit-linked funds. |  |  |

#### C.2.5 Sensitivity analysis

As part of the Company's internal risk management processes, the impact of a number of market risk scenarios on the SCR is monitored. These sensitivities incorporate some modelling approximations and results are indicative. The results of such stress testing on the Company's SCR are provided below.

|   | SCR     | SCR       |
|---|---------|-----------|
|   | (€'000) | Ratio (%) |
| Base: 31 December 2021                  | 409,927 | 173%      |
| Following a 20% fall in equity markets  | 356,786 | 185%      |
| Following a 15% fall in property values | 408,198 | 173%      |
| Following a 60bps interest rates rise   | 393,443 | 187%      |
| Following a 80bps interest rates fall   | 426,582 | 154%      |

The Company's biggest exposure is to a fall in interest rates, which increases the value of the with profit liabilities reinsured to SLAL. This has an impact on counterparty default and operational risk in the SCR, and increases the risk margin under the standard formula. This risk was most strongly experienced in 2019 and 2020 when interest rates dropped to historic lows.

Section C.7.4 describes how the Partial Internal Model will reduce the sensitivity of the solvency ratio to market risks, particularly interest rate risk.

#### C.3 Credit risk

#### C.3.1 Risk exposure

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge its obligation. These obligations can relate to both on and off balance sheet assets and liabilities. The Company is exposed to the following material sources of credit risk:

| Risk Source   | Description   |  |
|---|---|--|
| <b>Spread Risk</b> The risk of reduction in earnings and/or value, from unfavourable movements in the spread between or yields and swap rates used to discount insurance liabilities. |   |  |
| Investment<br>counterparty risk   | The risk of reduction in earnings and/or value, arising from counterparty defaults on invest-ments such as bonds, derivatives and cash deposits.  |  |
| Reinsurance<br>counterparty risk  | The risk of reduction in earnings and/or value, arising from the failure of a reinsurance counterparty to meet its contractual obligations by way of default or delayed claim settlements |  |

During the year ended 31 December 2021 there were no key changes to the Company's credit risk exposures; the following remain the key exposures to credit risk:

- SLAL's credit rating was upgraded to AA- in July 2021. This reduced the amount of credit risk capital in the Solvency Capital Requirement relating to the reinsured with profits liabilities.
- Corporate bond assets held to back the annuity liabilities; and
- The currency hedges in place, initially implemented in September 2019, and which are currently refreshed on a rolling three-month basis.

### C.3 Credit risk continued

The Partial Internal Model that the Company has applied for will replace the Counterparty Default Risk model.

The Counterparty Default Risk module is a similar model to the Standard Formula, but is able to capture more of the specific features of the reinsurance arrangements that the Company has put in place with SLAL for the with-profits business. This includes modelling that the Company would have recourse to more of the assets in the fund than can be included in the Standard Formula calculation. This means that the value of funds that would be lost if SLAL were to default on the reinsurance is smaller using the Partial Internal Model assessment, and in turn the capital requirement is somewhat lower, and much less sensitive to factors like the level of interest rates (due to guarantees in the with-profits liabilities) or the credit rating of SLAL.

### C.3.2 Risk measurement

Several methods are used to assess and monitor credit exposures. These methods include monitoring of asset portfolio composition and single name counterparty monitoring. In addition, risk is measured using the Standard Formula, sensitivity analyses, scenario analyses and stress testing.

The risk capital requirement for credit risk is assessed using the Standard Formula, which is calibrated to withstand a stress event to a 99.5% confidence level over a one-year period.

### C.3.3 Risk concentration

Concentration of credit risk exists where the Company has significant exposure to an individual counterparty or a group of counterparties with similar economic characteristics that would cause their ability to meet contractual obligations to be similarly affected by changes in economic and other conditions. Counterparty credit risk is monitored by the counterparty limits contained within the investment guidelines and investment management agreements.

An indication of the Company's exposure to credit risk can be illustrated using the credit rating of the counterparty that issued bonds that we hold or that we have a reinsurance arrangement with. The table below provides information regarding the aggregate credit exposure split by credit rating, for direct holdings (other than assets held for unit-linked contracts) in government and corporate bonds and reinsurance counterparties.

| Rating      | Market Value<br>€'000 | Percentage of Total<br>% |
|-------------|-----------------------|--------------------------|
| AAA         | 150,709               | 4%                       |
| AA          | 2,707,534             | 78%                      |
| A           | 506,075               | 15%                      |
| BBB         | 50,397                | 1%                       |
| BB          | -                     | 0%                       |
| B and below | 54,407                | 2%                       |
| Non-rated   |                       | 0%                       |
| Total       | 3,469,122             | 100%                     |

### C.3 Credit risk continued

As at 31 December 2021, the largest credit counterparty exposures to a single name counterparty in the Company's asset portfolio were:

| Top 10 single name credit exposures | €'000     |
|-------------------------------------|-----------|
| SLAL <sup>1</sup>                   | 2,514,259 |
| European Investment Bank            | 55,830    |
| Standard Chartered Bank             | 34,843    |
| China Construction Bank Corp        | 30,171    |
| BPCE                                | 28,291    |
| Qatar National Bank QPSC            | 27,821    |
| Sumitomo Mitsui Trust Bank Ltd      | 26,080    |
| BGB                                 | 20,207    |
| BARCLAYS BANK PLC                   | 20,187    |
| FRENCH DISCOUNT T-BILL              | 17,892    |

1 The exposure to SLAL shown here is the expected recoverable, adjusted for collateral, risk-mitigating effects and a market risk adjustment.

The Company is exposed to concentration risk in respect of reinsurance ceded to SLAL, although this is largely mitigated by collateral arrangements with the reinsurers and concentration limits in respect of individual reinsurance counterparties.

### C.3.4 Risk mitigation

The Company manages its exposure to credit risk, including concentration risk in-line with its Credit Risk Policy. This helps to mitigate the Company's credit risk by ensuring that appropriate processes, controls and governance is in place to monitor, report and manage all aspects of credit risk (including concentration risk).

The large exposure that the Company has to SLAL through the internal reinsurance arrangements is mitigated by two security arrangements that were entered into at the same time as the reinsurance arrangement. A 'fixed charge' provides the Company with a charge over specified assets in SLAL and acts as collateral for the majority of the reinsurance asset with SLAL. The remaining 'uncollateralised' reinsurance asset is secured with a floating charge that the Company has over the remainder of the assets of SLAL.

The ongoing effectiveness of credit risk mitigation is monitored on a regular basis by the Investment and Credit Risk Committee.

### C.3.5 Sensitivity analysis

As part of the Company's internal risk management processes, the impact of a credit risk scenario on the SCR is monitored. This sensitivity incorporates some modelling approximations and results are indicative. The result of such stress testing on the Company's SCR is provided below.

|   | SCR     | SCR       |
|---|---------|-----------|
|   | (€'000) | Ratio (%) |
| Base: 31 December 2021  | 409,927 | 173%      |
| Following credit spread widening (equivalent to 50% of the standard formula stress) | 408,821 | 171%      |

### C.4 Liquidity risk

### C.4.1 Risk exposure

Liquidity risk is defined as the failure of the Company to maintain adequate levels of financial resources to enable it to meet its obligations as they fall due. The Company has exposure to liquidity risk as a result of normal business activities, specifically the risk arising from an inability to meet short-term cash flow requirements.

The Company does not hold risk capital against liquidity risk. Liquidity risk is managed by holding an appropriate proportion of the assets in liquid form, with the proportion determined based on periodic investigations into liquidity requirements, which include consideration of cash flows in normal conditions, as well as investigation of scenarios where cash flows differ markedly from those expected (primarily due to significant changes in policyholder behaviour).

### C.4.2 Risk measurement

Liquidity risk is measured by comparing the level of liquid assets with the amount required to maintain the normal monthly level of cash flows over the business planning period, with allowance made for any expected non-recurring cashflows.

### C.4.3 Risk concentration

Liquidity risk for SLIDAC arises primarily from the following key sources:

- Operational risk events
- Mass lapse events
- Longevity risk on annuity business
- · Asset defaults (beyond best estimate) on assets exposed to credit risk which support the Company's annuity liabilities
- Very short-term pre-funding of large investments or switches
- Changes in the amount of collateral posted to track the movement in the value of foreign exchange forward contracts

The Company is not exposed to material concentrations of liquidity risk due to holding sufficient liquidity to cover fluctuations in cash outflows arising from these areas.

### C.4.4 Risk mitigation

For annuity and unit-linked business, liquidity risk is primarily managed by holding a range of diversified instruments which are assessed against estimated cash flow and funding requirements.

For annuity contracts, assets are held which are specifically chosen with the intention of matching the expected timing of annuity payments. The Company actively manages and monitors the performance of these assets against liability benchmarks and liquidity risk is minimised through the process of planned asset and liability matching.

For non-participating unit-linked contracts, a core portfolio of assets is maintained and invested in accordance with the mandates of the relevant unit-linked funds. Policyholder behaviour and the trading position of asset classes are actively monitored. The unit price and value of any associated contracts would reflect the proceeds of any sales of assets.

The Company undertakes regular assessments of its cash flow requirements under normal conditions, as well as considering scenarios where cash flows differ markedly from those expected (primarily due to extreme policyholder behaviour). In addition, the Company performs periodic reviews of its liquidity risks and performs stress testing on these risks to define minimum liquid asset requirements. These liquid asset requirements are monitored against available liquidity and tangible assets across various time horizons, with the outcomes reported through regular management information. This mitigates the risk that the Company does not have appropriate liquidity under severe stress conditions

The Company is required to monitor, assess, manage and control liquidity risk in accordance with the relevant principles within the Company's risk policy framework. Oversight is provided both at a Phoenix Group level and within the Company. In addition, the Company benefits from membership of a larger group to the extent that, centrally, the Phoenix Group:

- · Coordinates strategic planning and funding requirements;
- Monitors, assesses and oversees the investment of assets within the Phoenix Group;
- Monitors and manages risk, capital requirements, and available capital on a group-wide basis; and
- Maintains a committed £1.25bn (currently undrawn) Revolving Credit Facility.

The Company adopted its own risk policy framework in 2018 and in 2020 did a full refresh of its policies in line with the harmonisation of the risk management frameworks across the entities in the Phoenix Group; the risk policies approved by the Board are at least as stringent as the PGH risk policies. All of the policies are reviewed and re-approved on an annual basis. Each entity in the Group, including the Company, is responsible for the definition and management of its contingency funding plan. Liquidity risk is managed by each entity in consultation with the relevant PGH functions.

As a result of the policies and processes established with the objective of managing exposure to liquidity risk, the Company expects to be able to manage liquidity risk on an ongoing basis.

### C.4 Liquidity risk continued

### C.4.5 Expected profits in future premiums

Own Funds are used to cover the SCR (see more details in section E.1). The value of liabilities, included within Own Funds, takes into account expected future premium payments even if the policyholder is not contractually committed to making the payments. This methodology for valuing liabilities therefore implicitly allows for any Expected Profits In Future Premiums ('EPIFP') which reduces the liability value and increases Own Funds.

As at 31 December 2021, the Company's EPIFP (Gross of Reinsurance) is shown below. This is comprised of future profits arising across all lines of business.

|                                      | 31 December 2021<br>(€'000) | 31 December 2020<br>(€'000) |
|--------------------------------------|-----------------------------|-----------------------------|
| EPIFP (gross of tax and reinsurance) | 492,726                     | 596,944                     |

### C.5 Operational risk

### C.5.1 Risk exposure



Operational risk is defined as the risk of loss or adverse consequences for the business resulting from inadequate or failed internal processes, people or systems, or from external events. The Company has developed a 'Risk Universe', illustrated in the diagram above, which classifies the various risk exposures under categories in three levels of detail. Conduct risk is an overarching risk that spans all of the categories, but operational risk most closely reflects the different sources of conduct risk.

The key material operational and conduct risks that the Company is exposed to are captured within the following categories:

- Financial control and reporting the risk of financial failure, reputation loss, loss of earnings and/or value arising from the inappropriate recording, reporting and disclosure of financial information.
- Data protection/Information Security the risk of financial or reputational loss that can result from failing to ensure confidentiality of information, failing to protect the integrity of information and/or, failing to secure and maintain availability of information.

### C.5 Operational risk continued

- Regulatory compliance the risk of having the 'licence to operate' withdrawn by a regulator, or having conditions applied (retrospectively or
  prospectively) that adversely impact the economic value of the firm. This includes reductions in earnings and/or value through either financial or
  reputational loss.
- Legal the risk of financial or reputational loss that can result from lack of awareness or misunderstanding of, ambiguity in, or reckless indifference to, the way law and regulation apply to the business, its relationships, processes, products and services.
- Financial crime and anti-bribery the risk to the organisation or customer from fraud, money laundering, terrorist financing, corruption and bribery or international sanctions violations.
- Information technology the risk of reductions in earnings and/or value through financial, operational or reputational loss associated with inappropriate use of Information Technology, including failing to manage service availability or to design appropriate services.
- Human resources the risk of reduction in earnings and/or value, through financial or reputational loss from inappropriate staff behaviour, industrial action or Health & Safety issues. Loss can also be incurred through failure to recruit, retain, train, reward or incentivise appropriately skilled staff to achieve objectives and/or through failure to take appropriate action as a result of staff under performance.
- Business continuity the risk of reductions in earnings and/or value, through financial or reputation loss resulting from a failure to plan for the continuity of operations associated with a systems failure, loss of premises, equipment or people.
- Change the risk of reputational damage, loss of investor confidence and/or financial loss arising from the impact of a significant change initiative, or a number of change initiatives running at the same time, creating an adverse effect on business conditions and/or customer. This includes changes to processes, the development and implementation of new IT systems and/or delivery channels, the development of new products and the failure of change initiatives and/or new strategies to meet the required business case. This also includes the cost of inherent delays or failure to deliver benefits.
- Sourcing and procurement the risk of reductions in earnings and/or value through financial or reputation loss associated with outsourced partners, third party suppliers, or managing material internal suppliers to provide the service required by the business (either through their own organisational failure, or simply substandard performance).
- Operational risk and control framework this captures the additional operational risk the Company would be exposed to due to an ineffective risk management framework, from inadequacies or failures. This may be at any level, from the policies and objectives, to resources, processes and activities carried out.

Risk control processes are the practices by which we manage financial and non-financial risks within our business. They are used to identify, assess, control and monitor risk.

We use a control framework which comprises: minimum control standards, Risk and Control Self-Assessment, key risk indicators, breach and incident recording and action plan management. The process is supported by the GCM system.

During the year ended 31 December 2021, the key changes to the Company's exposure to operational risk included:

- the coronavirus pandemic caused the Company to continue to operate with the vast majority of staff remote working, with only essential staff required to be present in our offices (mail scanning, IT infrastructure maintenance, etc.). This has changed the nature and relative sizes of exposures of the risk categories but the types of operational risks faced remain the same;
- the end of the UK's withdrawal period from the European Union has removed the UK from the single market. This changes the ways that SLIDAC can operate across borders, both in terms of servicing customers but also in how shared services across the Group are arranged and
- across the financial services industry, we have seen increases in the frequency of cyber attacks, and the Group continues to invest in systems, processes and people to maintain our data security.

### C.5.2 Risk measurement

The Company uses the Standard Formula calculation for operational risk to contribute to the SCR. This calculation is based on the level of with-profits technical provisions held at the valuation date, and the level of expenses incurred on maintaining unit-linked business over the previous 12 months.

The capital held in respect of the Company's operational risk on the Standard Formula basis was €81,894k at 31 December 2021 and represented 13% of the Company's total undiversified SCR as shown in the table at the beginning of section C.

For the assessment of own solvency needs under the ERM framework, we perform a more detailed analysis of operational risks and how they arise. This is a comprehensive assessment of the risks which are faced by the Company, and is able to reflect the controls and processes in place to mitigate against them. Each operational risk or risk category within the Risk Universe (in section C.5.1) is assessed at workshops involving risk owners and subject matter experts from the business, and representative scenarios for each risk/category are proposed to be included in the capital calculation. These scenarios are designed to be extreme but plausible, and the likelihood of the event arising and the impact on the business are calibrated to determine a capital requirement for each. The correlations and interactions between different types of operational risk are assessed at separate workshops, and an aggregation model is used to determine the overall capital requirement for operational risk for the Company.

### C.5 Operational risk continued

The risk capital requirement for operational risk is assessed using the same model that PGH and SLAL have developed for use in the harmonised Group for their Internal Model, which is calibrated to withstand a stress event to a 99.5% confidence level over a one-year period. This is also the Operational Risk model that is included in the Partial Internal Model. This model defines the operational risk categories and loss distribution functions used to quantify capital requirements. As there is limited historical data on extreme operational losses, operational risks are assessed using ground-up scenario analysis. Stochastic models are used to determine the amount of capital for low probability, high impact events.

Compared to the Standard Formula, which uses a simple factor-based calculation to determine the capital requirement, based on past expenses for unit-linked business and the size of the with-profits premiums and liabilities, the Partial Internal Model Operational Risk assessment is much more tailored to the Company. It will also be more responsive to improvements in processes and controls, which can then be reflected in reductions to the capital requirements.

### C.5.3 Risk concentration

Within the Company, operational risks are not significantly concentrated into any of the categories listed above. The largest exposures lie within the financial control & reporting, financial crime, data protection and regulatory compliance categories. The Company carries out the majority of its operations in offices in Dublin, Edinburgh, Frankfurt and Wythall. Each of these premises has regularly-tested business continuity plans and off-site secondary locations where operations can continue in case an incident makes the primary premises unavailable. With the majority of staff currently working from home, the availability of premises generally is not an issue; however, IT infrastructure is still based in these offices and so service availability is still a key focus and subject to testing.

### C.5.4 Risk mitigation

Our aim is to minimise our exposure to operational risk by use of our control framework as described in Section B. However, there is an acceptance that in order to achieve our business strategy we will be exposed to a certain amount of operational risk. A number of insurance policies are used to reduce operational risk exposures in practice. The key policies are Crime, Cyber Crime, Professional Indemnity, Premises and Business Interruption and Employer's Liability Cover for all employees.

There is however minimal allowance made for this within the assessment of own solvency needs due to the expected length of time for recoveries exceeding the one-year forward-looking period. The methodology for this is under review across the Group and more allowance may be made for these recoveries in future.

### C.6 Other material risks

A business-wide review of risks is performed to determine a list of risks which should be assessed. This assessment considers:

- Reputational risk, including conduct risk, the risk of a downgrade to SLAL's or PGH's external credit rating and impacts on underwriting risks such as persistency and expenses.
- Strategic risk, including impacts on underwriting risks such as persistency, expenses and new business levels.

The approach taken to the assessment is a qualitative analysis of each of the risks in turn appropriate to the nature, scale and complexity of these exposures. The assessment described here concludes that there are no other material risks that the Company is exposed to. As a consequence:

- There is currently no requirement to hold additional capital in respect of these risks.
- Other risks are not considered when investing assets according to the Prudent Person Principle.
- No material other risks were identified through the sensitivity, scenario and stress tests described in section C.7.2.

Customer risk is the risk arising from the failure to have a customer centric culture, including failure to meet reasonable customer expectations, failure to design and/or manage products/propositions appropriately, or inappropriate (unclear, unfair or misleading) financial promotions, sales practices and/or distribution agreements resulting in poor customer outcomes. The types of scenarios leading to these outcomes are included in the assessment of operational risk, and so there is no requirement to hold additional capital in respect of these risks.

### C.7 Any other information

### C.7.1 Prudent Person Principle

The Prudent Person Principle ('PPP') is a set of requirements which governs the investments that an insurer is allowed to make. For example, insurers may only invest in assets and instruments whose risks they can properly identify, measure, monitor, manage, control and report, and appropriately take into account in the assessment of their overall solvency needs. To avoid repetition, we describe the PPP compliance of all asset classes together rather than individually.

The Company's investment risk management framework ensures that assets that are backing technical provisions are invested in accordance with the requirements of the PPP, as set out in Article 132 of the Solvency II Directive.

The investment risk management framework is underpinned by the policy framework, which includes Market Risk, Insurance Risk, Credit Risk, Liquidity & Funding, and Capital Management Policies and requires that the risks associated with investments are identified, assessed, controlled and monitored.

Decisions on significant investment matters (including the types of asset that can be invested in) are the responsibility of the SLIDAC Board. Any new proposals follow robust governance and review processes to ensure that proper consideration of the risks, benefits, costs and other implications has been given.

The Company's shareholder and policyholder assets, other than those relating to unit-linked policies are invested in External Fund options. These assets must be managed in accordance with requirements that are set by the Company with reference to the nature, term and other relevant characteristics of the liabilities that they back, along with considerations of the risk characteristics of the assets. Compliance with these requirements is monitored on an ongoing basis and reviewed at least annually to ensure the ongoing appropriateness of existing asset allocations and constraints. Compliance with regulatory requirements such as the CBI's and FCA's Conduct of Business rules is also monitored.

There is a Group-wide Conflicts of Interest Policy and localised controls are in place to ensure that where conflicts arise they are managed appropriately with the best interests of customers in mind.

The Company manages assets on behalf of with-profits and unit-linked customers as well as assets backing non-profit business and shareholder assets. Further detail of the PPP compliance for these types of business is given in the sections below.

### With-profits business

Within the Company's with-profits business, the Company manages investments with the objective of balancing the level of risk taken to deliver growth over the long term and the need to meet all contractual obligations to policyholders.

The with-profits assets are managed in a collection of funds and are invested according to the currency, term and nature of the underlying liabilities. These investments include some assets backing non-profit business that was written prior to SLAL's demutualisation and is owned by the Heritage With-Profit Fund. For all of these assets, the Company seeks to ensure the security, quality and liquidity of the portfolio of assets as a whole by predominantly investing in liquid securities that are listed or traded on regulated exchanges. Concentrations of assets are avoided by adhering to limits set by, for example, asset type, geography and counterparty.

The Company aims to make with-profits investment decisions in the best interests of all its with-profits customers. It is the role of the With-Profits Actuary to advise the SLIDAC Board on its use of discretion for the with-profits funds and on the reasonable expectations and fair treatment of policyholders in the SLAL with-profits funds. The With-Profits Actuary is supported in this aim by the SLAL With-Profits Committee, which provides independent advice to the Company's Board in relation to matters affecting the fair treatment of policyholders within the with-profits funds.

### Shareholder funds

Shareholder funds are directly exposed to investment profits and losses. The most significant funds are the assets backing annuities and the liquidity fund. These funds are primarily invested in fixed interest investments and cash, with the objective of optimising the risk-adjusted return and ensuring the diversification of credit risk exposures. Derivative instruments may be used to hedge against market risk exposures, for example the risk of adverse currency exchange rate movements.

The investment strategy is operated within constraints set within the qualitative and quantitative requirements of the risk policies that relate to managing investments: Credit Risk, Market Risk, Liquidity Risk and Capital Management. The investment constraints set may vary from time to time, but are designed to ensure that adequate levels of diversification and liquidity are maintained. Examples of the types of constraints include limits on permitted asset types and exposures to individual companies, market sectors and credit ratings.

This investment approach ensures the security, quality, liquidity and profitability of the portfolio as a whole.

The Investment and Credit Risk Committee has a key role in ensuring that shareholder investment strategy and investment performance are fully aligned to expectations and are within risk appetite.

### C.7 Any other information continued

### Unit-linked

Within the Company's unit-linked business we offer a wide range of funds which offer customers a choice of investment risk, asset classes and investment styles. These funds comprise both the Company's own funds (internal funds) and EFL. Our internal funds are managed by Aberdeen Standard Investments ('ASI').

There is a fund mandate for each of the Company's internal funds which details key aspects of how the fund is to be managed by ASI, including the objective of the fund, its benchmark, and the assets that the fund is permitted to invest in, including any restrictions.

We operate an extensive governance framework covering all of our unit-linked funds (internal and external) to ensure that our unit-linked fund range is developed and managed appropriately on an ongoing basis. As part of this, all unit-linked funds are reviewed regularly to ensure that expectations set with customers remain aligned to how the funds are being managed by the investment manager. The effectiveness of the operation of this framework is regularly reported to the SLIDAC Board.

To ensure the quality, security and liquidity of our funds, we predominantly invest in liquid securities that are listed or traded on regulated exchanges, or in daily priced funds that are authorised or recognised by the financial regulators in the markets where we operate. Discretionary Investment Managers must only invest policyholder assets in permitted links according to the service level agreements in place between them and the Company. During significant market events, we ensure our funds are priced appropriately and we may take other action as required to protect all customers in the fund. For example, we may place a fund into deferral in response to liquidity concerns until an appropriate level of liquidity is reached.

### C.7.2 Sensitivity analysis

As part of the Company's Risk Management Framework ('RMF'), stress and scenario tests are used extensively to support the assessment of risk and provide an analysis of their financial impact.

The Solvency II surplus is quite sensitive to market risks, in particular to interest rate movements, and there is a moderate sensitivity to credit risk.

The table below shows the effect of a change on key assumptions, with all other variables held constant on the Company's Solvency II Solvency Capital Requirement. Some modelling approximations have been used in the calculation of these results.

|   | SCR     | SCR       |
|---|---------|-----------|
|   | (€'000) | Ratio (%) |
| Base: 31 December 2021  | 409,927 | 173%      |
| Following a 20% fall in equity markets  | 356,786 | 185%      |
| Following a 15% fall in property values   | 408,198 | 173%      |
| Following a 60bps interest rates rise   | 393,443 | 187%      |
| Following a 80bps interest rates fall   | 426,582 | 154%      |
| Following credit spread widening (equivalent to 50% of the standard formula stress) | 408,821 | 171%      |
| Following 6% decrease in annuitant mortality rates                                  | 410,810 | 171%      |
| Following 10% increase in assurance mortality rates                                 | 406,749 | 174%      |
| Following a 10% increase in lapse rates   | 396,459 | 175%      |
| Following a 10% decrease in lapse rates   | 426,554 | 170%      |

### C.7 Any other information continued

### C.7.3 COVID-19 impacts

The emergence of the COVID-19 pandemic in early 2020 has created volatility in the financial markets and heightened operational risks. However, in 2021, rises in equity markets and in interest rates have meant that the Company's exposures to market risks are similar to the prepandemic levels.

No material impacts are anticipated from mortality, morbidity or longevity risks.

In terms of operational risks, the Company's operational resilience has been tested, but Business Continuity planning and capabilities have enabled it to continue to service customers and fulfil regulatory obligations in a controlled way.

The Company has continued to monitor the situation closely, invoking its Business Continuity plans and assessing impacts on technical provisions and solvency capital on a regular basis.

The Company's liquidity position remains healthy with a strong excess above target buffers

### C.7.4 Partial Internal Model application

The Company has received approval from the Central Bank of Ireland to use a Partial Internal Model (PIM) to calculate its Solvency Capital Requirement. The PIM will replace the Counterparty Default Risk and Operational Risk modules of the Standard Formula with a bespoke model which the Company believes provides a more appropriate measure of its exposure to those risks.

Comparisons between the Standard Formula and Partial Internal Model for Operational Risk and Counterparty Default Risk have been provided in sections C.3.1 and C.5.2.

# Valuation for solvency Purposes

| In th | nis section                       |    |
|-------|-----------------------------------|----|
| D.1   | Assets and liabilities            | 48 |
| D.2   | Technical provisions              | 52 |
| D.3   | Other liabilities                 | 64 |
| D.4   | Alternative methods for valuation | 64 |
| D.5   | Any other information             | 64 |

This section covers the valuation of assets (section D.1), technical provisions (section D.2) and other liabilities (section D.3) for the Company's Solvency II balance sheet. The valuation is determined in line with regulations, and is consistent with the Phoenix Group. The Balance Sheet SE.02.01.16 is included in Appendix 1.

In accordance with Solvency II valuation regulations and unless expressly stated below, the Company has valued its assets and other liabilities at fair value. In order to establish the fair value of assets and other liabilities, the following principles have been applied:

- Assets have been valued at the amounts for which they could be exchanged between knowledgeable willing parties in an arm's length transaction.
- Other liabilities have been valued at the amounts for which they could be transferred or settled between knowledgeable willing parties in an arm's length transaction.

Section D.1.2 provides separately for each of the material classes of assets and liabilities (excluding technical provisions which are covered in section D.2), a description of the bases, methods and main assumptions used in their valuation for solvency purposes. An explanation of differences to the IFRS financial statements is also provided. All classes of assets and liabilities presented are consistent to the SE.02.01.16 Balance Sheet QRT. The Solvency II value of the assets and liabilities are set out together with a 'Statutory accounts value' column.

The recognition and valuation methods used for the completion of the 'Statutory accounts value' column are used by companies in their statutory financial statements in accordance with IFRS. Reclassification of line items has taken place, to align disclosures with the Solvency II presentation format and for ease of comparison between the two sets of numbers. This means that the 'Statutory accounts value' column may not directly agree to line items on the financial statements of the Company.

Some of the Company's assets and liabilities are determined using alternative valuation methods which use non-observable market inputs and follow accepted market practice. Further details are included in section D.4.1.

### D.1 Assets and liabilities

### D.1.1 Overview

This section covers the valuation of assets and liabilities on the Company's Solvency II balance sheet.

The table below sets out the Solvency II balance sheet and the 'Statutory accounts value' columns for the Company.

|   | Note | Solvency<br>II Value<br>€'000 | Statutory<br>Accounts Value<br>€'000 | Difference<br>€′000 |
|---|------|-------------------------------|--------------------------------------|---------------------|
| Balance Sheet as at 31 December 2021  |      |                               |                                      |                     |
| Deferred acquisition costs  | 1    | _                             | 222,324                              | (222,324)           |
| Intangible assets   | 2    | _                             | 3,280                                | (3,280)             |
| Deferred tax assets   | 3    | _                             | 2,466                                | (2,466)             |
| Property, plant and equipment held for own use                                  | 4    | 664                           | 664                                  |                     |
| Investments (other than assets held for index-linked and unit-linked contracts) | 5    |                               |                                      |                     |
| Holdings in related undertakings, including participations                      |      | _                             | _                                    |                     |
| Bonds   |      | 367,817                       | 367,817                              | -                   |
| Collective Investment Undertakings  |      | 540,001                       | 540,001                              | -                   |
| Derivatives   |      | 1,067                         | 1,067                                | -                   |
| Deposits other than cash equivalents  |      | _                             | _                                    | -                   |
| Assets held for index-linked and unit-linked contracts                          | 6    | 17,748,013                    | 17,748,013                           | _                   |
| Loans and mortgages   | 7    | 41,191                        | 41,191                               | -                   |
| Reinsurance recoverables  | 8    | 17,133,667                    | 18,683,033                           | (1,549,366)         |
| Insurance and intermediaries receivables  | 9    | 5,228                         | 5,228                                | _                   |
| Reinsurance receivables   | 9    | 91,926                        | 91,926                               | -                   |
| Receivables (trade, not insurance)  | 10   | 60,887                        | 64,002                               | (3,114)             |
| Cash and cash equivalents   | 11   | 34,148                        | 34,148                               | _                   |
| Total Assets  |      | 36,024,609                    | 37,805,159                           | (1,780,550)         |
| Technical provisions (BEL plus risk margin)                                     | 12   | 35,048,422                    | 36,735,767                           | (1,687,345)         |
| Provisions other than technical provisions                                      | 13   | 3,670                         | 3,670                                | _                   |
| Deferred tax liabilities  | 3    | 1,678                         | 779                                  | 898                 |
| Derivatives   | 14   | 13,580                        | 13,580                               | _                   |
| Debts owed to credit institutions   | 15   | 2,343                         | 2,343                                | _                   |
| Insurance and intermediaries payables   | 16   | 159,990                       | 159,990                              | _                   |
| Reinsurance payables  | 16   | 8                             | 88,037                               | (88,028)            |
| Payables (trade, not insurance)   | 17   | 141,526                       | 141,526                              | _                   |
| Any other liabilities not elsewhere shown                                       | 18   |                               | 53,618                               | (53,618)            |
| Total Liabilities   |      | 35,371,216                    | 37,199,309                           | (1,828,092)         |
| Excess of Assets over Liabilities   |      | 653,393                       | 605,850                              | 47,542              |
|   |      |                               |                                      |                     |

### D.1 Assets and liabilities continued

The table above reflects reallocation adjustments which have been applied to assets and liabilities in the Company's IFRS statutory accounts at 31 December 2021. These adjustments relate to the following:

- Presentation adjustments (excluding unit/index-linked) move other balances from the balance sheet line items used in the IFRS statement of financial position to the appropriate balance sheet line items used in the Solvency II balance sheet.
- Presentation adjustments (unit/index-linked) move unit-linked fund balances from the relevant balance sheet line items used in the IFRS statement of financial position into the 'Assets held for index-linked and unit-linked contracts' line in the Solvency II balance sheet.

### D.1.2 Asset and liability valuation bases, methods and main assumptions

The Company's Solvency II valuation principles (including the bases, methods and main assumptions) for each asset and liability class are set out below. Unless otherwise stated (i.e. where there are differences to the 'Statutory accounts value' column) the valuation methods for IFRS are consistent with the valuation methods of the regulations. Further details on the IFRS valuation principles are set out in the Notes to the IFRS financial statements in the SLIDAC Annual Reports and Accounts for the year ended 31 December 2021. There have been no significant changes to the valuation principles set out below during the year. Details regarding the valuation of technical provisions are covered separately in section D.2.

| Note | Balance Sheet Item            | Valuation Principles   |
|------|-------------------------------|--|
| 1    | Deferred acquisition<br>costs | In the Company's IFRS statutory accounts, some costs incurred in issuing certain contracts are deferred<br>and amortised as Deferred Acquisition Costs ('DAC'). For Solvency II DAC are valued at zero unless they<br>can be sold separately and it can be demonstrated that there is value for the same or similar assets (i.e.<br>that a value has been derived from quoted prices in active markets). None of the deferred acquisition<br>costs in the Company have been assessed as meeting these criteria.  |
| 2    | Intangible assets             | For Solvency II intangible assets are valued at zero unless the intangible assets can be sold separately and it can be demonstrated that there is value for the same or similar assets (i.e. that a value has been derived from quoted prices in active markets). None of the Company's intangible assets have been assessed as meeting these criteria and therefore these are valued at zero. Furthermore, any related deferred tax is written off. For IFRS, intangible assets are measured on the balance sheet at cost less accumulated amortisation and any impairment loss recognised to date. The Company has recognised as intangible assets software which has been developed internally and other purchased technology which is used in managing and executing its business. |
| 3    | Deferred tax assets           | Deferred tax is determined on temporary differences between the fair value of assets and liabilities on the Solvency II balance sheet and their tax base at the valuation date. Differences in the value of deferred tax balances between the Solvency II and IFRS balance sheets arise as a consequence of differences in the carrying values of the underlying assets and liabilities.   |
|      |                               | Further details on the origin of the deferred tax assets are provided in section D.1.3.  |

### D.1 Assets and liabilities continued

| Note | Balance Sheet Item                                   | Valuation Principles   |
|------|--|--|
| 4    | Property, plant and<br>equipment held for<br>own use | <b>Property held for own use</b><br>In line with IFRS, owner-occupied property is stated at the revalued amount, being its fair value at the<br>date of the revaluation less any subsequent accumulated depreciation and impairment.   |
|      |  | Plant and equipment held for own use<br>In the Company's IFRS statutory accounts, plant and equipment is initially recognised at cost and<br>subsequently measured at cost less depreciation. Depreciation is charged to the income statement over<br>two to 15 years depending on the length of time the Company expects to derive benefit from the asset.<br>Where property, plant and equipment relates to a right-of-use lease asset, the right-of-use asset is initially<br>measured at cost and subsequently depreciated using the straight-line method from commencement<br>date to the end of the lease term.  |
|      |  | There is no valuation difference between the Solvency II balance sheet and the IFRS statutory accounts<br>in property, plant and equipment held for own use.   |
| 5    | Investments (other than assets held for              | In line with IFRS, the value of investments (other than assets held for index-linked and unit-linked contracts) are determined using a fair value methodology as follows:  |
|      | index-linked and unit-<br>linked contracts)          | <ul> <li>For financial instruments traded in active markets (such as exchange traded securities and derivatives), fair value is based on quoted market prices at the period end provided by recognised pricing services. Market depth and bid-ask spreads are used to corroborate whether an active market exists for an instrument;</li> <li>Where quoted market prices are not available, quoted market prices for similar assets or liabilities are used to determine the fair value;</li> <li>Where either of the above are not possible, alternative valuation methods are used to determine fair value. Where discounted cash flow techniques are used, future cash flows are based on contractual cash flows using current market conditions and market-calibrated discount rates and interest rate assumptions for similar instruments; and</li> <li>Certain financial instruments are determined by valuation techniques using non-observable market inputs based on a combination of independent third party evidence and internally developed models. Further details are included in section D.4.1.</li> </ul> |
|      |  | Holdings in related undertakings, including participations comprise Collective Investment<br>Undertakings where the Company holds a greater than 20% interest (where the interest is less than 20%<br>it is included within 'Collective Investment Undertakings' line). Any investments in Collective Investment<br>Undertakings related to unit-linked contracts are included as Assets held for index-linked and unit-linked<br>contracts.   |
|      |  | In both the Company's IFRS statutory accounts and the Solvency II balance sheet, <b>Government bonds</b> are valued using quoted market prices provided by recognised pricing sources. For <b>corporate bonds</b> listed on a recognised stock exchange, quoted market prices are used. For other corporate bonds, these instruments are valued using pricing data received from external pricing providers or in some cases using broker quotes where observable market data is unavailable. For a small number of investment vehicles and debt securities, standard valuation models (based on a discounted cash flow approach) are used, as by their nature and complexity, they have no external market. Inputs into such models are based on observable market data where applicable.   |
|      |  | In both the Company's IFRS statutory accounts and the Solvency II balance sheet, interests in pooled investment funds, including holdings in property collective investment schemes (referred to as <b>Collective Investments Undertakings</b> under Solvency II) are held at fair value. The Company receives valuations from investment managers of the underlying funds, based on quoted market prices. Where quoted prices are not available they are estimated using pricing models or discounted cash flow techniques. Where pricing models are used, inputs are based on market-related data at the period end.   |
|      |  | In both the Company's IFRS statutory accounts and the Solvency II balance sheet, <b>derivative assets</b> are<br>held at fair value. The fair value of OTC assets is estimated using pricing models, with inputs based on<br>market-related data at the period end. The fair value of exchange traded securities is based on quoted<br>market prices at the period end provided by recognised pricing services. <b>Deposits other than cash and</b><br><b>cash equivalents</b> comprise short-term deposits that cannot be used to make payments before a specific<br>maturity date or without any penalty.  |

### D.1 Assets and liabilities continued

| Note | Balance Sheet Item  | Valuation Principles  |
|------|---|---|
| 6    | Assets held for index-<br>linked and unit-linked<br>contracts                 | Assets held for unit-linked funds are measured based on the fair value of the underlying assets and liabilities (other than technical provisions) held within such funds. Under IFRS, assets and liabilities of unit-linked contracts are separately reported on a line-by-line basis. Under Solvency II, all assets and liabilities backing unit-linked contracts are reported on a single line in Assets held for index-linked and unit-linked contracts.   |
| 7    | Loans and mortgages   | Assets categorised as Loans and mortgages in the Solvency II balance sheet include loans to individuals<br>and loans on policies. In the Company's IFRS statutory accounts, loans to individuals are initially measured<br>at fair value and are subsequently measured at amortised cost, using the effective interest rate method,<br>less any impairment losses. The IFRS accounting values do not differ materially from the fair values and<br>hence there is no valuation difference between the Solvency II balance sheet and the IFRS statutory<br>accounts. |
| 8    | Reinsurance<br>recoverables   | The value of reinsurance recoverables is dependent on the expected claims and benefits arising under<br>the related reinsured policies. To the extent that the Solvency II valuation of the related technical<br>provisions differs to the valuation under IFRS, the valuation of the related reinsurance recoverable will<br>also be impacted. Further details on the calculation approach for Solvency II reinsurance recoverables<br>are included in section D.2.8.  |
| 9    | Insurance and<br>intermediaries<br>receivables,<br>Reinsurance<br>receivables | Given their short-term nature, the carrying amount per the IFRS financial statements is considered to represent the fair value for these assets under Solvency II.  |
| 10   | Receivables (trade, not insurance)  | No value is ascribed for certain prepayments under Solvency II, where they cannot be sold separately to a third party.  |
| 11   | Cash and cash   | In contrast under IFRS, prepayments are recognised as an asset at amount paid less expenses incurred.<br>Cash and cash equivalents comprise of cash balances that are usable for all forms of payments without  |
| 12   | equivalents<br>Technical provisions   | penalty or restriction.<br>Details regarding the valuation of technical provisions are covered in section D.2.  |
| 13   | (BEL plus risk margin)<br>Provisions other than<br>technical provisions       | Consistent with IFRS, under Solvency II, a provision is recognised when the Company has a present legal or constructive obligation, as a result of a past event, which is likely to result in an outflow of resources and where a reliable estimate of the amount of the obligation can be made. If the effect is material, the provision is determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessment of the time value of money and, where appropriate, the risks specific to the liability.             |
| 14   | Derivatives   | In the Company's IFRS statutory accounts and under Solvency II, the fair values of OTC derivative<br>liabilities are estimated using pricing models, with inputs based on market-related data at the period end.<br>The fair value of exchange-traded securities is based on quoted market prices at the period end provided<br>by recognised pricing services.   |
| 15   | Debts owed to credit institutions   | Debts owed to credit institutions consist of the bank overdraft liabilities. These are short term in nature and are valued at fair value, i.e. amounts payable on the balance sheet date.   |
| 16   | Insurance and<br>intermediaries<br>payables, Reinsurance<br>payables          | These are short term in nature and are valued at amortised cost. This approximates the fair value valuation basis under Solvency II for these liabilities. The IFRS amount includes a €74m negative reinsurance asset   |
| 17   | Payables (trade, not insurance)   | In the Company's IFRS statutory accounts, trade payables are recorded at amortised cost. This approximates the fair value valuation basis under Solvency II for these liabilities. Accordingly, there are no valuation differences between the IFRS statutory accounts and the Solvency II balance sheet.   |
| 18   | Any other liabilities<br>not elsewhere shown                                  | This balance sheet caption relates to deferred income balances. In the Company's IFRS statutory accounts, front-end fees on certain service contracts, including investment management service contracts, are deferred as a liability and amortised. In accordance with the Solvency II valuation rules, nil value has been allocated to deferred income balances.  |

### D.1 Assets and liabilities continued

### D.1.3 Analysis of deferred tax

Deferred tax on the Solvency II balance sheet is recognised by reference to expected future taxable profits and valued based on the differences between the carrying value in the balance sheet and its tax base. Under Solvency II, the Deferred Tax Liability exceeds the Deferred Tax Asset, leading to a net liability position at 31 December 2021.

From a Statutory Accounts perspective at 31 December 2021, the SLIDAC Deferred Tax Asset ('DTA') is made up of €2,466k of DTA on historic losses within SLIDAC.

A comparison of the Solvency II and IFRS Deferred Tax is shown in the table below.

|               |  | Solvency II –   |  |  |
|---------------|--|---|--|--|
| Solvency II - | Solvency II –  | Ireland   |  | Statutory  |
|               | ,  | ,   | ,  | Accounts   |
| (€'000)       | (€'000)  | (€'000)   | (€'000)  | (€'000)  |
| 80,491        | 158,055  |   | 238,546  | 19,149   |
|               |  |   |  |  |
| 10,061        | 50,578   |   | 60,639   |  |
| 10,061        | 14,007   |   | 24,958   | 2,466  |
|               |  |   |  |  |
| (156,421)     |  |   | (156,421)  |  |
| (593)         |  |   | (593)  |  |
| 209,814       | 250,317  |   | 460,131  |  |
| 88,976        | (52,252)   |   | 36,724   |  |
| (54,167)      | (154,293)  |   | (208,460)  |  |
| 87,608        | 43,773   |   | 131,382  |  |
|               |  |   |  |  |
| 10,951        | 14,007   |   | 24,958   |  |
|               |  |   |  | 11,597   |
|               |  | 788   | 788  | 779  |
| 10,951        | 14,007   | 788   | 25,747   | 12,376   |
| 890           |  | 788   | 1,678  | 9,911  |
|               | Ireland<br>(€'000)<br>80,491<br>10,061<br>(156,421)<br>(156,421)<br>(593)<br>209,814<br>88,976<br>(54,167)<br>87,608<br>10,951<br>10,951 | Ireland<br>(€'000)         Germany<br>(€'000)           80,491         158,055           10,061         50,578           10,061         14,007           (156,421)         (593)           209,814         250,317           88,976         (52,252)           (54,167)         (154,293)           87,608         43,773           10,951         14,007 | Solvency II –<br>Ireland<br>(€'000)         Solvency II –<br>Germany<br>(€'000)         Ireland<br>Policyholder<br>(€'000)           80,491         158,055           10,061         50,578           10,061         14,007           (156,421)         (593)           209,814         250,317           88,976         (52,252)           (54,167)         (154,293)           87,608         43,773           10,951         14,007           788           10,951         14,007 | Solvency II-<br>Ireland<br>(€'000)         Solvency II-<br>Germany<br>(€'000)         Ireland<br>Policyholder<br>(€'000)         Total Solvency II<br>(€'000)           80,491         158,055         238,546           10,061         50,578         60,639           10,061         14,007         24,958           (156,421)         (156,421)           (593)         (593)           209,814         250,317           460,131         88,976           (54,167)         (154,293)           10,951         14,007           788         788           10,951         14,007 |

### **D.2 Technical provisions**

This section provides separately for each line of business ('LoB') the value of technical provisions, including the amount of the Best Estimate Liability ('BEL'), Technical Provisions ('TPs') as a Whole and the risk margin, as well as a description of the bases, methods and main assumptions used in the valuation of technical provisions.

This section also includes a quantitative and qualitative explanation of material differences between the bases, methods and main assumptions used by the Company for the valuation of technical provision for solvency purposes and those used for their valuation in IFRS.

### D.2.1 Introduction

The valuation of technical provisions is performed in line with the Solvency II Directive, and the more detailed provisions of Chapter III of the Delegated Acts.

This approach values liabilities at the amount to be paid if the Company's insurance obligations were immediately transferred to another insurance undertaking, making use of and consistent with information provided by the financial markets and generally available data on underwriting risks (market consistency).

The value of technical provisions is determined as the sum of technical provisions calculated as a whole, a best estimate liability, and a risk margin. Technical provisions calculated as a whole are the full value of the policyholder unit-linked investment funds, as these are made up of assets which have a reliable observable market value.

The best estimate liability is a probability weighted average of future cash flows, taking account of the time value of money, using an appropriate risk free interest rate term structure. The calculation is based upon realistic assumptions, using appropriate actuarial and statistical methods and taking account of all future cash inflows and outflows required to settle the insurance obligations.

The risk margin is the additional amount required to ensure that the value of the technical provisions is equivalent to the amount that another insurance undertaking would be expected to require in order to take-over and meet the insurance obligations.

The best estimate and the risk margin are calculated separately.

### D.2 Technical provisions continued

The Company does not apply the transitional measure on technical provisions as described in the Solvency II Directive. This allows for a deduction from technical provisions which reduces to zero over the transitional period of 16 years. The transitional risk free interest rate term structure referred to in Article 308c of the Solvency II Directive is not applied by the Company.

The valuation approach is summarised in subsequent sections.

The only simplified method used to calculate technical provisions is the risk driver approach to calculating the Risk Margin as set out in Section D.2.11.

As part of Phoenix Group Harmonisation, in Q2 2021 SLIDAC migrated from RAFM to MG-Alfa as the software application used in the valuation of liabilities. MG-Alfa is a widely used liability software application, supported by Milliman. The migration was a Group wide project which resulted in transfer of SLIDAC and SLAL businesses to the MG-Alfa model that is currently used by the 'heritage' Phoenix Life companies.

### D.2.2 Technical provisions by line of business

This section provides technical provisions split by Solvency II LoB as at 31 December 2021 including the amount of BEL and TPs as a whole, and the risk margin.

For the purpose of Solvency II reporting, lines of business are as follows:

- Insurance with profit participation includes all conventional and unitised with profits business
- Index-linked and unit-linked insurance unit linked business, including the present value of future profits
- Health insurance including permanent health insurance and income protection
- · Other life insurance immediate and deferred annuities, protection, other non-with profits business

At 31 December 2021, the contribution to technical provisions from each LoB was as follows:

| Technical provisions by Line of Business | Insurance<br>with-profit<br>participation<br>€′000 | Index-linked<br>and unit linked<br>insurance<br>€'000 | Health<br>insurance<br>€′000 | Other Life<br>insurance<br>€'000 | Total technical<br>provisions<br>€'000 |
|--|--|---|------------------------------|----------------------------------|--|
| Best Estimate Liabilities                | 15,641,347   | (384,530)   | 174,797                      | 759,202                          | 16,190,817                             |
| Risk margin                              | 134,179  | 58,136  | 1,436                        | 14,709                           | 208,460                                |
| Technical Provisions as a whole          | -  | 18,649,145  | _                            | _                                | 18,649,145                             |
| Gross technical provisions               | 15,775,526   | 18,322,751  | 176,234                      | 773,912                          | 35,048,422                             |

Within each of these groups, the valuation of cash flows is determined at policy level, except that similar policies are grouped together when appropriate for the purposes of the stochastic modelling of with-profits liabilities. The Technical Provisions as a Whole for Index-linked and unit-linked insurance business includes the BEL in respect of the EFL arrangement between SLAL and SLIDAC.

The Company writes business in the UK, Ireland and Germany, with cash flows denominated in Sterling for UK (converted to Euro) and Euro for Ireland and Germany.

### D.2 Technical provisions continued

The table below outlines separately for each LoB, the material differences between the bases, methods and main assumptions used for Solvency II and those used for IFRS.

| Technical provisions – IFRS to Solvency II reconciliation | Note | Insurance<br>with-profit<br>participation<br>€'000 | Index-linked<br>and unit-linked<br>insurance<br>€'000 | Health insurance<br>€'000 | Other Life<br>insurance<br>€'000 | Total<br>technical<br>provisions<br>€'000 |
|---|------|--|---|---------------------------|----------------------------------|---|
| Statutory accounts value technical provisions             |      |  |   |                           |                                  |   |
| – gross   |      | 16,610,093   | 18,670,620  | 172,474                   | 1,190,557                        | 36,643,744                                |
| Statutory accounts value reinsurance                      |      | (16,610,093)                                       | (900,644)   | (171,465)                 | (820,466)                        | (18,502,668)                              |
| Statutory accounts value technical provisions             |      |  |   |                           |                                  |   |
| - net   |      | _  | 17,769,976  | 1,009                     | 370,090                          | 18,141,075                                |
| Change to discount curve                                  | 1    | _  | 7,536   | 20                        | 703                              | 8,259                                     |
| Change in restriction for negative sterling               |      |  |   |                           |                                  |   |
| reserves  | 2    | _  | (389,914)   | _                         | _                                | (389,914)                                 |
| Demographic margin  | 3    | _  | (11,785)  | _                         | (9,502)                          | (21,287)                                  |
| Other   | 4    | -  | -   | _                         | (31,816)                         | (31,816)                                  |
| Solvency II Best Estimate Liabilities – net               |      | 0  | 17,375,817  | 1,029                     | 329,475                          | 17,706,321                                |
| Add Risk Margin   | 5    | 134,179  | 58,136  | 1,436                     | 14,709                           | 208,460                                   |
| Solvency II technical provisions – net                    |      | 134,179  | 17,433,953  | 2,465                     | 344,184                          | 17,914,781                                |
| Solvency II reinsurance                                   |      | 15,641,347   | 888,798   | 173,768                   | 429,727                          | 17,133,641                                |
| Solvency II technical provisions – gross                  |      | 15,775,526   | 18,322,751  | 176,234                   | 773,912                          | 35,048,422                                |

An explanation of the material changes between the IFRS valuation for technical provisions and that used for Solvency II is included below:

| Note | ltem   | Description   |
|------|--|---|
| 1    | Change to discount<br>curve                                | Liabilities are valued using a discount rate derived from the EIOPA swap curve less a credit risk<br>adjustment of 10bps under Solvency II. A volatility adjustment is also applied to the curve for euro<br>denominated lines of business. For IFRS they are valued using a discount rate from the EIOPA swap curve<br>plus an illiquidity adjustment of 10bps.  |
| 2    | Change in restriction<br>for negative sterling<br>reserves | The term 'sterling reserves' represents reserves set aside to cover future cash flow obligations on unit-linked policies, over and above the value of units held. For Solvency II, unit-linked present value of in-force business ('PVIF') are allowed as a reduction to technical provisions. For IFRS, sterling reserves are grouped at cohort level (cohorts are defined by reference to homogenous product groups and by year of policy commencement). Negative reserves are disallowed at a cohort level and thus are set to zero at this level. This effectively includes removing sterling reserves calculated under IFRS and adding PVIF. |
| 3    | Demographic margin   | A margin for demographic risk is included within the IFRS technical provisions. This item is based on a percentage of undiversified demographic risk capital, relating to mortality, longevity, persistency and expenses. Solvency II does not require this margin to be held over and above best estimate.   |
| 4    | Other  | The 'other' line contains the profit margin which is an asset under SII, and the counterparty default adjustment on the reinsurance arrangements the Company has with SLAL and external reassurers (for PHI in payment in respect of Unit Linked business).   |
| 5    | Risk Margin  | Risk margin is included in the SII technical provisions to allow for market consistent valuation.   |

### D.2 Technical provisions continued

D.2.3 Bases, methodology and main assumptions used for best estimate liability

The Company's Solvency II technical provisions comprise the following three components, depending on the line of business:

- TP's as a whole
- BEL
- Risk margin

The valuation approach for the BEL is summarised in subsequent sections.

### D.2.3.1 Best Estimate Liability

The best estimate is a probability weighted average of future cash flows, taking account of the time value of money, using an appropriate risk free interest rate term structure. The calculation is based upon realistic assumptions, using appropriate actuarial and statistical methods and taking account of all future cash inflows and outflows required to settle the insurance obligations.

BEL is calculated gross, without deduction for amounts recoverable on reinsurance contracts. Reinsurance recoverables are valued separately, recognised as a reinsurance asset and calculated in the same manner as the BEL (see section D.2.8 for further details).

All assumptions are updated to reflect current economic conditions and demographic experience. Material changes in the relevant assumptions made in the calculation of technical provisions are covered in section D.2.5.

The following section details the methodology and key assumptions used to calculate the BEL.

### D.2.3.2 Overview of Methodology

A cash flow projection model is used to calculate BEL. This projects cash inflows and outflows required to meet the Company's obligations to policyholders over the lifetime of the policy, taking into account the undertaking's regulatory duty to treat its customers fairly.

The projection of future cash flows is performed using realistic assumptions regarding future experience. The relevant assumptions include, expected future trends in mortality and lapse rates. An allowance is also made for future expenses.

The model takes account of the time value of money through discounting at an appropriate risk-free rate (see section D.2.3.3 below).

In certain specific circumstances, the best estimate may be negative (where the value of future charges exceeds the value of future expenses). A negative BEL is permitted under the regulations.

### D.2.3.3 Discount Rates

The valuation of future policyholder liabilities requires best estimate economic assumptions, and in particular a future interest rate assumption (i.e. yield curve). A risk free yield curve is the base curve used to value liabilities but with an allowance for credit risk. The risk free yield curves are based on swap rates, and specified by EIOPA. A different yield curve is used depending on the currency of the liabilities, which for the Company are Sterling and Euro. The Company has not used a matching adjustment to the risk free yield curves. During 2021 the Company received approval from the CBI to apply the Volatility Adjustment in the calculation of its Technical Provisions and this is applied to the risk-free yield curve for Euro denominated business.

An adjustment (also specified by EIOPA) is made to the swap curve for credit risk. At 31 December 2021, the Sterling credit risk adjustment was minus 10bps, and for Euros minus 10bps at each duration. The Volatility Adjustment at 31 December 2021 was 3bps.

### D.2 Technical provisions continued

### D.2.3.4 Tax Assumptions

The mainstream tax rate is 12.5% for profits arising in Ireland and 32% for profits arising in Germany.

### D.2.3.5 Contract Boundaries

The boundary of an insurance contract (or reinsurance contract) defines the cash flows which must be taken into account when calculating the technical provision in respect of that contract. Only cash flows that relate to premiums payable up to and including the contract boundary should be taken into account. These cash flows include not only those premiums, but also benefit payouts, charges, expenses and other cash flows related to the premiums within the contract boundary. For the avoidance of doubt, all premiums which have been paid up to and including the reporting date are included in the boundary of the contract. That means that all the related cash flows in respect of premiums paid up to and including the reporting date are included in the calculation of technical provisions.

In general, future premiums on products with insurance cover and premiums invested into with-profits funds or into unit-linked funds with a contractual cap on annual management fees are included within the contract boundary. Future premiums into funds with no guarantees and no cap on charges are not included within the contract boundary, even where the policyholder has the right to invest future premiums into with-profits or a fund with a charge cap. In this case, the contract boundary is at the reporting date.

Contracts currently investing in a combination of with-profits funds, funds with a charge cap and funds with no guarantee or charge cap are unbundled to allow for different contract boundaries on the different parts of the contract.

### D.2.3.6 Grouping of Liability Data

For stochastic modelling of options and guarantees on with-profits business, policies are grouped into model points to improve computational efficiency. This is performed in an automated process in MG-Alfa and is known as clustering. Groups are selected so that the model points appropriately allow for the risk characteristics of the individual policies and do not distort the valuation of BEL. Judgement is required when determining how policies are split, the level to which seriatim policies are reduced model points and what the clustering algorithm targets e.g. BEL

### D.2.4 Calculation

The following sub-sections outline how each component of BEL is calculated.

### D.2.4.1 Insurance with-profit participation

The Company has written a number of contract variations on a with-profits basis in Germany, Austria and Ireland. While these contracts may differ in certain aspects of the product features, they share the common feature in that they offer a form of investment guarantee:

- Ireland Conventional With Profits ('CWP') generally, a guaranteed benefit is set at the time the policy is issued to be paid on a date or events specified. Regular bonuses may be added to the guaranteed benefit over the term of the policy. In addition, a final bonus may be paid.
- Ireland Unitised With Profits ('UWP') under this type of with-profits policy contractual benefits are determined by reference to the number of units allocated under the relevant UWP policy. The number of units allocated increases on payment of premiums. Typically, for this type of policy, unit prices grow at a guaranteed minimum growth rate (either O%, 3% or 4% a year) plus any (additional) bonus growth rate. The unit value of a policy is normally guaranteed as a minimum payout in specific circumstances. In addition a final bonus may be payable when benefits are taken.
- German/Austrian UWP contracts a nominal value of units, which can grow with declared bonuses, is guaranteed on death, maturity and in some cases surrender. There are also guaranteed amounts (based on specified growth rates applied to all past and future premiums; depending on the contract, the rate is 1.2%, 2.375%, 2.875% or 4.875% a year) payable at maturity and, in some cases, surrender and selected other dates; in some cases these guaranteed amounts may be payable as an annuity.

There is also a small amount of German Conventional With Profits business written as part of a joint venture with Hannoversche Leben. This is similar to the Irish Conventional business described above. Some German and Austrian unit-linked contracts also offer guaranteed annuity factors applicable to the accrued fund at maturity.

The 'asset share' is a measure of the with-profits policy value at the valuation date. In addition to the asset share, BEL includes an allowance for the following cash flows:

- Future cost of guarantees: The cost of investment guarantees (which can apply on maturity, death or surrender depending on the contract) is assessed relative to the asset share.
- Guaranteed annuity rates and values: Costs can arise when the guaranteed annuity (available on some Ireland and Germany contracts) is greater than the expected future market annuity rate.
- Future guarantee deductions: Deductions are made from the asset share in respect of the expected future cost of guarantees, and are charged for by a percentage deduction applied to asset shares. The deductions vary between policy groups and over time.
- Future profits: PVIF in respect of UWP and CWP contracts, calculated in a manner consistent with unit-linked contracts.

Additional liabilities arise in respect of the Company's treatment of smoothing on with-profits claims and with-profits payout practice in respect of unitised pension business ('vintage unit' approach).

### D.2 Technical provisions continued

In practice, these requirements are interpreted as being equivalent to a current value of the policy at the valuation date (asset share) plus a valuation of future guarantee (and other) costs calculated on a stochastic basis. Therefore, depending on the contract type, the BEL for withprofits contracts is made up of the following components:

• Asset share.

Less present value of:

- Deduction for guarantees.
- Future profits.

Plus present value of:

- Cost of guarantees.
- Guarantee annuity costs.
- Smoothing cost.
- Mortgage Endowment Promise.
- Vintage unit cost, and other non-contractual commitments.

Asset shares are derived from a policy by policy retrospective roll-up of premiums allowing for investment returns on with-profits assets backing this business, guarantee deductions, mortality charges, expenses and charges and tax. The Company adopts a range of methods to determine the asset share, as appropriate to the different types of contracts and the materiality, in a manner consistent with the approach used to determine asset shares for with-profits payout purposes. A projection of the future value of the asset share is used in the valuation of future modelled cash flows (for example in the valuation of future cost of guarantees and future profits). For this class of business, the policyholder payout is a function of investment performance and is subject to a financial guarantee.

The effect of the guarantee is to render the possible future outcomes 'asymmetrical', and so the approach adopted considers deviations of future events from their expected values. The stochastic method adopted is consistent with generally accepted actuarial practice and will most appropriately allow for the possibility of an asymmetrical outcome uncertainty of cash flows. The Company uses a simulation technique to place a value on cash flows that are subject to financial guarantees. This considers a wide range of investment performance scenarios (produced by an economic scenario generator or 'ESG') and calculates the cash flow amounts payable in each scenario, having regard to the guarantees.

The nature of the approach is summarised below:

- Takes into account all cash flows, notably any guarantees and options on the contracts and the likelihood that policyholders may exercise these options.
- Costs calculated stochastically are: investment guarantees offered on contracts; annuity conversion offered on guaranteed terms; inability to recycle smoothing cost due to guarantees biting; minimum payouts in respect of endowments backing house purchase. These costs are offset by the value of: future deductions taken to cover investment guarantee costs; future contributions to capital (profits) accruing to the with-profits funds.
- A large number of simulated future investment returns are generated by the ESG, cash flows projected, guarantee (and other) costs emerging on the contracts calculated and costs discounted to the balance sheet. The final cost is taken as the average value across these simulations.
- Provided the scenarios produced by the ESG satisfy certain conditions, the average across the scenarios of the discounted value of the cash flows gives the value of the liabilities allowing for the guarantee.
- Policy data applied in the cash flow projection is derived from core policy systems. Similar policies are grouped together for practical modelling reasons.

The key assumptions used in the projection are the simulated investment returns, charges, expenses, best estimate persistency and mortality rates. The approach to determining the simulated future investment returns and the best estimate persistency and mortality/longevity rates are covered in sections D.2.6.1 and D.2.5.1 respectively.

### D.2.4.2 Other life insurance - annuities

This category of business covers the following contract classes:

- Pensions Annuities typically providing an income for life, with various policyholder options selected at outset (single/joint life, guaranteed period, escalation rate).
- Purchased Life Annuities tax efficient lump sum investment contracts providing an income for life or over a selected period, again with policyholder options (guaranteed period, escalation rate).
- Deferred Annuities pension savings products where the premiums paid purchase an annuity from a specified retirement date in the future.

### D.2 Technical provisions continued

### Valuation approach

The BEL is derived using a deterministic discounted cash flow approach. The valuation approach projects the cash flows for each annuity contract and their underlying features, and the BEL is equal to the annuity payments and expenses discounted using the Solvency II sterling or euro yield curve. The projection is carried out using best estimate assumptions, allowing for the relevant survival probabilities. The best estimate assumptions and Solvency II yield curve are described within sections D.2.5 and D.2.3.3 respectively.

Annuity payments are calculated based on the specifics of each contract. The benefit payments projected reflect any guarantee period, whether the payment can step up or step down, the level of payment, payment frequency and dependant's benefits. Expenses include renewal, termination and investment expenses, allowing for expense inflation as appropriate.

BEL are calculated excluding any reinsurance cash flows, with a separate valuation of the reinsurance recoveries receivable performed on a consistent basis.

### D.2.4.3 Other life insurance - protection and other business (including health)

This category of business covers conventional non-participating savings, protection and health contracts. The protection products include term assurance, critical illness and protection riders on other policies such as pension policies. Savings products include endowment assurances, pension endowments and pure endowments. Health products include permanent health insurance and income protection.

The non-investment component of with-profits business is included within this line of business and is valued in the same way as unit-linked PVIF (covered in section D.2.4.4).

### Valuation Approach

A cash flow approach is used to determine the best estimate liabilities as the expected present value of a contract, allowing for the following cash flows:

- Inflows (premiums, tax relief), less
- · Outflows (claims, expenses, commission, investment expenses, tax payable)

BEL are calculated excluding any reinsurance cash flows, with a separate valuation of the reinsurance asset allowing for reinsurance recoveries receivable and reinsurance premiums payable. These cash flows are discounted using the relevant Solvency II yield curve.

### D.2.4.4 Index-linked and unit-linked business

The unitised contracts include the following policy types: UK Offshore Bond, Ireland unitised life, Ireland unitised pensions and Germany unit-linked.

The UK and Ireland life product types include bonds and endowments, and pension product types including group pensions, individual pensions, and stakeholder pensions. Policies that have units in both unit-linked and UWP funds are referred to as 'hybrid' policies. The valuation of the UWP related cash flows are described in section D.2.4.1. The unit-linked product in Germany is a deferred annuity contract with an option to take the benefits in cash at retirement. A loyalty bonus may be payable.

### Valuation Approach

The non-profit unit-linked fund values meet the requirements to be a replicating portfolio. Under Solvency II, unit-linked contracts are unbundled and the unit liabilities are technically defined as "technical provisions calculated as a whole" as per the examples provided for Guideline 65 Reliable Replication (Calculation of Technical Provisions as a whole) in the "Guidelines on Valuation of Technical Provisions" as described below.

Insurance and reinsurance undertakings should not consider future cash-flows associated with insurance or reinsurance obligations to be reliably replicated if:

- (a) One or several features of the future cash-flow, inter alia its expected value, its volatility or any other feature, depend on risks whose specific pattern in the undertaking cannot be found in instruments actively traded in financial markets;
- (b) Current trade and price information are not normally readily available to the public, due to the fact that one or several features of the future cash-flow depend to any extent on the development of factors specific to the undertakings, such as expenses or acquisition costs; or,
- (c) One or more features of the future cash-flow depend on the development of factors external to the undertaking for which there are no financial instruments for which reliable market values are observable.

Therefore the gross unit fund value with no associated risk margin, is treated as 'technical provisions as a whole'.

The overall technical provision for a unit-linked contract then comprises the following components:

- Technical provisions as a whole (unit fund).
- BEL component (PVIF) plus risk margin on PVIF.

### D.2 Technical provisions continued

The best estimate is required to be a probability weighted average of future cash flows. The PVIF is calculated deterministically. To calculate the PVIF, best estimate charges, income and expense cash flows are projected, with the unit fund rolled up at the same risk-free interest rate term structure that is used for discounting the net cash flows. The projection is carried out using best estimate assumptions. The Solvency II yield curve and other best estimate assumptions are described in Sections D.2.3.3 and D.2.5.

Depending on the nature of the contract, the unit-linked PVIF valuation allows for the following cash flows:

- Inflows: fund management charge (net of large fund discounts), unallocated premiums, surrender penalties, policy fees, tax relief (on expenses and commission).
- Outflows: commission, initial expenses, renewal expenses, termination expenses, investment expenses, adviser payments, member fees, external fund manager charges, loyalty bonus.

### D.2.5 Demographic and expense assumptions

Non-economic assumptions are determined from annual experience investigations, are subject to detailed internal review and approved by the Board. Best estimate assumptions are made in respect of future levels of longevity, mortality, morbidity, surrenders, withdrawals, premium indexation, annuity take up rates and expenses. The assumptions vary depending on whether the business is written in the UK, Germany or Ireland. These assumptions reflect the Company's best estimates of likely future experience, based on recent experience, relevant industry data and expert judgement as appropriate.

Mortality/longevity assumptions are a combination of base mortality rates, which are set by reference to recent experience and for annuities, expected future changes in mortality. The latter for Irish annuities uses internal Group experience, along with data from external sources such as the Continuous Mortality Investigation Bureau ('CMI') in the UK, which produces standard mortality tables and projection bases for mortality improvements. This is an industry standard model and is a convenient 'currency' to allow direct comparison of assumptions to other companies through the use of benchmarking. Specific adjustments are made to the parameterisation of the CMI model to allow for socio-demographic differences between population and annuitant experience. German mortality and morbidity assumptions are supported by data from external reinsurers.

Assumptions regarding surrender and withdrawal reflect recent experience, with expert judgement applied to set long term rates where there is little experience.

Best estimate expense assumptions on a product basis are derived from an analysis of management expenses. This allows for all expenses incurred in servicing policies, including overheads, assuming that the Company continues to write new business. The investment management expense assumptions are derived as the best estimate of the future charges expected to be paid to abrdn reflecting current investment management agreements ('IMA'), varying by the nature of assets backing technical provisions. The overall expense is the sum of a weighted average basis point fee (based on the IMA rate card and assets under management), plus additional fees in relation to such items as performance, ancillary services, real estate support etc. Custody fees paid to the custodian are also included.

The main non-economic assumptions for each of the material lines of business are described below, with an indication of the factors that affect the assumption adopted. Expert judgement is applied where there is limited data or to remove one-off events and allow for future known changes.

### D.2 Technical provisions continued

D.2.5.1 Mortality

| Mortality<br>Insurance with-profit participation                          | Varies by: age, gender, product and territory   |
|---|---|
| Unit-linked   | Varies by: age, gender, product and territory<br>Varies by: age, gender, product and territory  |
| Health  | Varies by: age, gender, product and territory<br>Varies by: age, gender, product and territory  |
| Other life insurance  | Varies by: age, gender, product and territory<br>Varies by: age, gender, product and territory  |
|   | valles by: age, gender, product and territory   |
| Insurance with-profit participation                                       | This assumption is used to value guaranteed annuity terms, and varies by: age, gender, territory.   |
| Unit-linked   | n/a   |
| Health  | n/a   |
| Other life insurance  | Varies by: age, gender, compulsory purchase or purchased life annuity, individual or group business, immediate or deferred annuity and territory.   |
| Proportions Married   |   |
| Insurance with-profit participation                                       | n/a   |
| Unit-linked   | n/a   |
| Health  | n/a   |
| Other life insurance  | Varies by: individual or group business, immediate or deferred annuity, territory   |
| Insurance with-profit participation                                       | on the assumption, they vary by: product type, duration of business, policyholder age and territory.  |
| D.2.5.2 Persistency<br>Persistency<br>Insurance with-profit participation | These assumptions cover lapse, early retirement, withdrawal and paid-up rates. Depending  |
| Unit-linked   | These assumptions cover lapse, early retirement, withdrawal and paid-up rates. Depending<br>on the assumption, they vary by: product type, duration of business, policyholder age and   |
|   | territory.  |
| Health  | n/a   |
| Other life insurance  | n/a   |
| Premium Indexation  |   |
| Insurance with-profit participation                                       | With profits contracts in Germany give the policyholder the option of increasing their premium each year, subject to limits. Assumptions are required for both the future eligibility to premium increases, and the take-up rate. The assumption varies by: product, policy term, and maximum indexation level selected at policy outset. |
| Unit-linked   | n/a   |
| Health  | n/a   |
| Other life insurance  | n/a   |
| D.2.5.3 Option take-up rates  |   |
| Option Take-Up Rates  |   |
| Insurance with-profit participation                                       | The valuation of guaranteed annuities requires assumptions about the future guaranteed annuity and tax free cash take-up rates. The assumption varies depending on territory,   |

|                      | annuity and tax free cash take-up rates. The assumption varies depending on territory,<br>product and the age at which the guarantee applies. |
|----------------------|---|
| Unit-linked          | Take-up rates are also required for the valuation of guaranteed annuity factors applicable to   |
|                      | the accrued fund at maturity.   |
| Health               | n/a   |
| Other life insurance | n/a   |

### D.2 Technical provisions continued

D.2.5.4 Expense assumptions

| Expense Assumptions                 |   |
|-------------------------------------|---|
| Insurance with-profit participation | Maintenance Expenses<br>Some with-profits contracts are written on an 'expense basis', where the asset share<br>is determined with reference to incurred initial, renewal and termination expenses.<br>Assumptions vary by: product, territory and premium paying status. |
|                                     | <b>Investment Expenses</b><br>Varies by territory, long-term business fund and asset class.   |
| Unit-linked                         | <b>Maintenance Expenses</b><br>These include an allowance for both renewal and termination expenses, and vary by: product<br>and territory  |
|                                     | <b>Investment Expenses</b><br>Varies by: product grouping; territory, long-term business fund   |
| Health                              | These products are rolled up with other lines of business when setting expense assumptions.   |
| Other life insurance                | Maintenance Expenses<br>These include an allowance for both renewal and termination expenses.   |
|                                     | <b>Investment Expenses</b><br>Varies by territory and long-term business fund.  |

The only additional provisions held are an expense overrun in respect of German and Irish business. This is to reflect diseconomies of scale with the run off of the closed with-profits books of business.

### D.2.6 Stochastic model

### D.2.6.1 Economic Scenario Generators

An ESG has been used to support the stochastic valuation of all material options and guarantees in the with-profit funds. A stochastic methodology is required for options and guarantees due to their potential volatility and asymmetric behaviour under different sets of future economic scenarios. The stochastic methodology involves valuing the options and guarantees under 1,000 different future economic scenarios and then averaging over all scenarios. The central scenario in the ESG is equal to the single deterministic scenario used to value all non-profit and unit-linked business.

The ESG generates projected asset returns consistent with asset prices observed in financial markets and assumes no arbitrage opportunities exist. The calibration of the parameters and scenarios is consistent with the relevant risk-free interest rate term structure used to calculate the BEL provided by EIOPA. Where possible the ESG has been calibrated to assets from deep, liquid and transparent markets which are appropriate to the nature of the funds' options and guarantees.

### D.2.6.2 Management actions

For with-profits liabilities, the projections simulate the management actions that are applied in the respective with profits funds. This includes the regular review of deductions for guarantees, the application of smoothing on payouts, management of with profits assets and determination of regular bonus rates.

### D.2 Technical provisions continued

### D.2.7 Solvency II long term guarantee and transitional measures

D.2.7.1 Matching Adjustment and Volatility Adjustment

The Company does not currently use a matching adjustment. The Company has approval from the CBI to apply the Volatility Adjustment in the calculation of its Technical Provisions. The impact of the Volatility adjustment is quantified in the following table.

| mpact of Volatility Adjustment (VA)                          | With Volatility<br>Adjustment<br>€'000 | Zero Volatility<br>Adjustment<br>€'000 | Quantification<br>of the impact<br>of a change to zero VA<br>€'000 |
|--|--|--|--|
| Solvency II Best Estimate Liabilities – net                  | 17,706,321                             | 17,707,683                             | 1,362  |
| Risk Margin  | 208,460                                | 208,460                                | -  |
| Solvency II technical provisions – net                       | 17,914,781                             | 17,916,143                             | 1,362  |
| Solvency II reinsurance                                      | 17,133,641                             | 17,146,704                             | 13,063   |
| Solvency II technical provisions – gross                     | 35,048,422                             | 35,062,847                             | 14,425   |
| Solvency Capital Requirement                                 | 409,927                                | 410,095                                | 168  |
| Minimum Capital Requirement                                  | 129,773                                | 129,801                                | 29   |
| Basic own funds  | 653,393                                | 652,030                                | (1,362)  |
| Own funds eligible to cover the Minimum Capital Requirement  | 653,393                                | 652,030                                | (1,362)  |
| Own funds eligible to cover the Solvency Capital Requirement | 708,393                                | 707,030                                | (1,362)  |
|  |  |  |  |

D.2.7.2 Transitional Measures for Technical Provisions

The Company does not apply the transitional measure on technical provisions as described in the Solvency II Directive.

### D.2.8 Recoverables on reinsurance contracts

Under Solvency II, reinsurance is defined as business where there is a transfer of risk.

As part of the transfer of Irish, German and Austrian business in March 2019, the Company entered into a number of internal reinsurance arrangements with SLAL set up by treaty, covering Irish and German business. It also entered into a number of external reinsurance arrangements with GenRe and Partner Re at this time.

Reinsurance recoverables are calculated using the same models and assumptions as the corresponding BELs. The value of reinsurance recoverables is shown in QRT S.12.01.01 Life and Health SLT Technical Provisions, a copy of which is included in Appendix 1.

The Company does not have any insurance special purpose vehicles arrangements.

The amounts recoverable on the reinsurance contracts are recognised as a reinsurance asset on the Solvency II balance sheet.

D.2.8.1 Assessment of Reinsurers' Default Risk (Counterparty Default Adjustment) The valuation of reinsurance recoverables allows for the possibility of counterparty default.

For each reinsurance counterparty, an adjustment is made to reinsurance recoverables for the best estimate of the expected losses due to default of the reinsurance counterparty over the lifetime of the liabilities. The adjustment is calculated for each counterparty exposure as:

• the cumulative expected probability of default over the lifetime of the reinsurance exposure; multiplied by

• an assumption for losses given default.

The probability of default assumption is determined based on the credit rating of each counterparty using Article 199 of the Solvency II Delegated Acts. Loss given default assumptions are specific to the nature of the exposure.

### D.2 Technical provisions continued

### **D.2.9 Simplifications**

Where it is proportionate, the Company may adopt simplifications in the calculation of technical provisions. These simplifications may exist within the calculation methodology, or within the valuation models themselves.

Substantially all of the Company's BEL is calculated using probability weighted averages of future cash flows. However, simplified valuation techniques have been used in certain circumstances. These simplifications are typically used where material uncertainty exists around the size, incidence or timing of liability cash flows or, where further model development is required for a more robust assessment.

The Company uses the skills, knowledge and experience of actuaries, accountants and other subject matter experts to perform these assessments, which are carried out in accordance with the Company's internal framework on application of expert judgement.

Where modelling simplifications or limitations exist, judgement is applied as to whether these are accepted limitations or whether manual adjustments to the technical provisions are required, generally with reference to SLIDAC's materiality thresholds. These are reviewed regularly on an Approximations & Limitations log. While MG-Alfa resulted in some modelling enhancements and removal of prior simplifications in RAFM, the migration also identified a number of new modelling limitations that have subsequently been corrected for via manual adjustments.

### D.2.10 Uncertainty associated with the value of technical provisions

The valuation techniques adopted are in line with generally accepted actuarial principles and Solvency II requirements. The level of uncertainty associated with the amount of technical provisions primarily relates to assumed future experience.

The valuation of liabilities requires assumptions about the future (e.g. longevity/mortality, persistency, option take-up, expenses, economic conditions, management actions), which are inevitably the source of some uncertainty. While the approach adopted by the Company leads to its best estimate of future expected experience, there can be a number of alternative similarly justifiable assumptions. For example, a range of assumptions regarding the rate of future improvements in longevity could be considered reasonable.

Consideration has been given to the uncertainty in relation to COVID-19, currently no adjustment has been made for the following reasons:

- There is as yet no clear evidence of the longer term effects on mortality/morbidity, and it is judged prudent not to take credit for higher levels of mortality at higher ages. The exposure to mortality and morbidity is limited for retained business.
- While the economic effects (risk free rates, inflation) are also uncertain, the assumptions used in the calculation of Technical Provisions are prescribed by regulation (for the risk free rates, also assumed to apply to investment returns on all asset classes) or are set relative to market indicators (for price inflation).
- While heightened persistency experience was observed in 2020, this is not expected to have a long term impact on future persistency experience as this is an exceptional event which would not be expected to recur over the medium to long term.

The modelling of management actions (notably guarantee deductions) requires that at future time steps the model makes an assessment of the present value of future costs and guarantee deductions. It is not practical to perform a full stochastic calculation at every time step for this purpose and instead mathematical formulae are used to estimate the required present values. A calibration process derives scaling factors to apply to the formulaic results to best match an equivalent stochastic approach.

Overall, the vast majority of the Company's business is explicitly modelled in the way summarised in previous sections.

### D.2.11 Risk margin

The value of technical provisions is equal to the sum of a best estimate and a risk margin (plus technical provisions as a whole).

The risk margin is held in respect of non-hedgeable risks and is required to ensure that the value of the technical provisions is equivalent to the amount that insurance undertakings would be expected to require in order to take over and meet the insurance obligations.

When calculated separately, the risk margin is calculated by determining the cost of providing an amount of Eligible Own Funds equal to the SCR in respect of non-hedgeable risks necessary to support the insurance obligations over their lifetime. The cost of capital in this calculation is prescribed.

In theory, the calculation of the risk margin involves a projection of future SCRs. A simplified approach to determining these SCRs is permitted by the regulations and this has been implemented using a risk driver-based approach. For each risk and product group, a risk driver is chosen that approximates the expected run-off pattern of the capital relating to that risk. For example, the present value of future expenses at each future date will drive the expense risk capital at that date so this is selected as the risk driver for expense risk. The appropriate risk drivers are regularly reviewed. This ensures that they accurately reflect the size of the risk exposure and that the run-off of the risk driver is consistent with, and materially captures the run-off of the underlying risk.

The risk margin is currently calculated in an Excel based model outside of MG-Alfa. This is a short term tactical solution until further development has been carried out in MG-Alfa.

### **D.3 Other liabilities**

The valuation of other liabilities on the Solvency II balance sheet is covered in section D.1. The valuation of technical provisions is covered in section D.2. Some of the Company's liabilities (mainly financial instruments) are determined using alternative valuation methods which use non-observable market inputs. Further details are included in section D.4.1.

Further details regarding deferred tax liabilities are set out in section D.1.3.

### D.4 Alternative methods for valuation

This section provides details on the methods and assumptions used to determine the fair values of assets and other liabilities (other than technical provisions). More information about the valuation methods used for accounting purposes, including a fair value hierarchy, is provided in Note 18 of the Company's Annual Financial Statements 2021.

Investments carried at fair value in the Solvency II balance sheet have been valued based upon a three-level hierarchy ("the fair value hierarchy") depending on the valuation techniques used and whether the inputs to those valuation techniques are observable in the market, as follows:

Level 1: Fair values measured using quoted prices (unadjusted) in active markets for identical assets or liabilities. An active market exists where transactions take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2: Fair values measured using inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: Fair values measured using inputs that are not based on observable market data (unobservable inputs).

### D.4.1 Alternative valuation methods - assets

Some of the Company's financial instruments are valued using alternative valuation methods, which utilise a combination of observable and non-observable market inputs. All of the alternative valuation methods described below follow accepted market practice. The methods are consistent with the permitted alternative valuation methods under SII as set out in Article 10(5) – 10(7) of the Solvency II Delegated Regulation.

|  | Solvency II<br>Value |   |
|--|----------------------|---|
| Asset  | €′000                | Alternative Valuation Method  |
| Property, plant and equipment held for own use | 664                  | Property is valued using Royal Institution of Chartered Surveyors ('RICS') Appraisal and valuation methodology.   |
|  |                      | Equipment is stated at historical cost less depreciation. Cost includes the original purchase price of the assets and the costs attributable to bring the asset to its working condition for its intended use. Depreciation on equipment is charged to the income statement on a straight-line basis over their estimated useful. The residual values and useful lives of the assets are reviewed at each reporting date and adjusted if appropriate. |
| Loans and mortgages                            | 41,191               | Loans are initially measured at fair value plus directly attributable transaction costs.<br>Subsequently, other than those loans designated at FVTPL, they are measured at amortised<br>cost, using the effective interest rate method ('EIR'), less any impairment losses. Revenue<br>from financial assets classified as loans is recognised in the income statement on an EIR<br>basis.  |

For index-linked and unit-linked contracts, any change in the valuation of assets is offset by a corresponding change in the value of policyholder liabilities, with no material impact on Own Funds. Changing unobservable inputs in the measurement of the fair value of assets and liabilities to reasonably possible alternative assumptions would not have a significant impact on total Own Funds.

### D.4.2 Alternative valuation techniques - liabilities

The Company does not use alternative valuation techniques for any of its financial liabilities.

### D.5 Any other information

There is no further material information to be disclosed regarding the valuation of assets and liabilities for solvency purposes.

# **Section E**

# Capital management

| In tr | his section  |    |
|-------|--|----|
| E.1   | Own funds  | 66 |
| E.2   | Solvency capital requirement                           |    |
|       | & minimum capital requirement                          | 70 |
| E.3   | Use of the duration-based equity risk sub-module       |    |
|       | in the calculation of the solvency capital requirement | 72 |
| E.4   | Differences between the standard formula               |    |
|       | and any Internal Model used                            | 72 |
| E.5   | Non-compliance with the minimum capital                |    |
|       | requirement and non-compliance with the                |    |
|       | solvency capital requirement                           | 72 |
| E.6   | Any other information                                  | 72 |

### E.1 Own Funds

### E.1.1 Introduction

This section provides information on the Company's Own Funds and SCR, including changes over the reporting period, together with an explanation of the material differences between net assets under IFRS and the Solvency II excess of assets over liabilities.

A Solvency II capital assessment involves valuation of Own Funds in line with Solvency II regulations and a risk-based assessment of the SCR. Solvency II surplus is the excess of Eligible Own Funds over the SCR. The Company holds an amount of Eligible Own Funds that is greater than the SCR to allow for adverse events in the future that may reduce Own Funds and might otherwise cause failure to maintain the minimum level of regulatory capital, the MCR.

### **Key Solvency Metrics**

At 31 December 2021, the capital position for the Company is presented in the table below:

|                                    | 31December<br>2021<br>€'000 | 31December<br>2020<br>€′000 |
|------------------------------------|-----------------------------|-----------------------------|
| Eligible Own Funds                 | 708,393                     | 589,650                     |
| SCR                                | 409,927                     | 446,634                     |
| Solvency II surplus                | 298,466                     | 143,015                     |
| Ratio of Eligible Own Funds to SCR | 173%                        | 132%                        |

As at 31 December 2021, the Company's Solvency II surplus over the Company SCR is €298,466k, with a ratio of Eligible Own Funds to SCR of 173%. 92% of the Company's Eligible Own Funds are unrestricted Tier 1, and are principally comprised of ordinary share capital, share premium account related to ordinary share capital and the reconciliation reserve. The remaining 8% (€55,000k) are Tier 2 Ancillary Own Funds which will become Tier 1 if called upon. The Company has sufficient Tier 1 Own Funds to cover the SCR.

All the required SCR quantitative limits have been complied with by the Company, and result in no restrictions nor are any Own Funds required to be relegated to lower tiers. Further details regarding the capital position of the Company are set out in this section.

### E.1.2 Management of Own Funds

Harmonisation with the PGH Group capital management framework is ongoing and SLIDAC continues to improve consistency with the Group framework. There remains differences between the framework for SLIDAC and the PGH Group framework reflecting the different size and risk profile of SLIDAC relative to the other group entities. It also reflects differences arising from SLIDAC's Standard Formula capital calculation compared to the Group's Internal Model. In March 2022, SLIDAC received approval to use a PIM and the harmonisation of the framework will be further considered as this model is implemented. Details of the Company's current liquidity and management policy are provided below.

The Company closely monitors its current and projected solvency position and risk exposures, and has a series of triggers for further action. The Company's capital position is also tested under a series of stressed scenarios. The Company's capital needs and stresses are considered over a five-year planning horizon on a rolling basis.

The Company actively seeks to ensure that its capital position can be maintained at a viable level to continue to operate the business under stress, in order to protect policyholders, customers and other key stakeholders. Within this overriding framework, the Company seeks to optimise its use of capital to maximise returns for shareholders and policyholders at an appropriate level of rewarded risk, and to manage its operations effectively to minimise or eliminate unrewarded risk.

The Company primarily manages its capital position by reference to its Capital Targets Framework ('CTF'). A revised CTF was approved by the SLIDAC Board in September 2021. The new framework involves an all risk approach, whereby the Company will hold capital against a scenario which encompasses all the material risks to which SLIDAC is exposed. The risks to which SLIDAC is most sensitive (based on univariate analysis) have higher weightings in the all risk scenario. The All Risk scenario is calibrated and fully modelled annually. Sensitivity analysis will be performed regularly to ensure that the risk profile has not changed significantly and that the All Risk scenario remains valid. The CTF will be recalibrated upon implementation of the PIM to reflect the change in the Company's risk exposures. The Framework is used to inform all key Board decisions with capital implications, in particular dividend proposals, investment strategy, capital planning and other management actions.

In addition to this, the Company defines limits for those risks which it actively seeks to manage. The risk limits are set with the overriding aim of supporting an overall suitable capital position under stress, with individual limits then set subject to this constraint in order to support the delivery of the business plan.

The solvency position, risk exposures versus limits, and CTF status are monitored on an ongoing basis with regular reports produced for the Board. The report sets out a number of triggers for further action which are monitored and reported upon, many of which relate to capital coverage.

### E.1 Own Funds continued

### E.1.3 Structure and quality of $\mathsf{Own}\,\mathsf{Funds}$

Own Funds are split into Tiers in line with the regulations. There are three 'Tiers' based on both 'permanence' and 'loss absorbency' (Tier 1 being the highest quality). Tier 1 is further divided into 'unrestricted' and 'restricted' Tier 1. Own Funds which are classified as 'unrestricted' Tier 1 include share capital, surplus funds and the reconciliation reserve. The Ancillary Own Funds included at 31 December 2021 are Tier 2 funds, which will become restricted Tier 1 if called upon.

The regulations impose limits on the amount of each Tier that can be held to cover capital requirements with the aim of ensuring that the items will be available if needed to absorb any losses that may arise. Own Funds items need to be sufficient in amount, quality and liquidity to be available when the liabilities they are to cover arise. Items with a fixed duration or a right to redeem early may not be available when needed. Similarly, obligations to pay distributions or interest will reduce the amount available.

The Company has ample Tier 1 funds to cover its capital requirements, with the Tier 2 Ancillary Own Funds providing an additional layer of security.

### E.1.4 Analysis of solvency position

The table below summarises the SLIDAC solvency position at 31 December 2021. The Own Funds QRT S.23.01.01 can also be found in Appendix 1.

|  |           |              |        |        | 31 December | 31 December |
|--|-----------|--------------|--------|--------|-------------|-------------|
|  | Section   | Unrestricted |        |        | 2021        | 2020        |
| Description                              | Reference | Tier1        | Tier 2 | Tier 3 | Total       | Total       |
|  |           | €′000        | €′000  | €'000  | €'000       | €′000       |
| Ordinary Share Capital                   | E.1.4.1   | 50,020       | -      | -      | 50,020      | 50,020      |
| Share Premium account related to         |           |              |        |        |             |             |
| Ordinary Share Capital                   | E.1.4.1   | 382,358      | -      | -      | 382,358     | 382,358     |
| Reconciliation reserve (pre-availability |           |              |        |        |             |             |
| restrictions)                            | E.1.4.1   | 221,014      | -      | -      | 221,014     | 102,271     |
| Net Deferred Tax Assets                  | E.1.4.1   | -            | -      | -      | -           | -           |
| Excess of Assets over Liabilities        |           | 653,393      | _      | -      | 653,393     | 534,650     |
| Subordinated Liabilities                 | E.1.4.1   | _            | -      | _      | _           | -           |
| Total Basic and Available Own Funds      |           | 653,393      | -      | -      | 653,393     | 534,650     |
| Ancillary Own Funds                      | E.1.4.1   | _            | 55,000 | -      | 55,000      | 55,000      |
| Eligible Own Funds to meet SCR           |           | 653,393      | 55,000 | -      | 708,393     | 589,650     |
| SCR                                      | E.2.1     |              |        |        | (409,927)   | (446,634)   |
| Solvency II surplus                      |           |              |        |        | 298,466     | 143,015     |
| Ratio of Eligible own funds to SCR       | E.1.1     |              |        |        | 173%        | 132%        |
| Eligible Own Funds to meet MCR           |           |              |        |        | 653,393     | 534,650     |
| MCR                                      |           |              |        |        | (129,773)   | (111,659)   |
| Excess over MCR                          |           |              |        |        | 523,620     | 422,991     |
| Ratio of Eligible own funds to MCR       |           |              |        |        | 503%        | 479%        |

### E.1 Own Funds continued

### E.1.4.1 Eligible Own Funds

The Company's Eligible Own Funds total €708,393k (2020: €589,650k) and comprise of ordinary share capital, share premium account related to ordinary share capital, ancillary own funds and a reconciliation reserve. Further details regarding each Basic Own Funds item are set out below.

### **Ordinary Share Capital**

The Company's issued and fully paid ordinary share capital is €50,020k and is treated as Tier 1 unrestricted Own Funds. The Company's Articles of Association allow cancellation of the payment of dividends (or other distributions) on ordinary shares prior to payment in certain circumstances, where it may be necessary or appropriate to do so because of legal, regulatory, capital or solvency requirements.

### Share Premium Account Related to Ordinary Share Capital

The share premium account of €382,358k relates to the ordinary share capital and is treated as Tier 1 unrestricted Own Funds.

### **Reconciliation Reserve**

The reconciliation reserve is the amount of excess assets over liabilities (valued in accordance with the Solvency II regulations and guidance) that remain once all the other identified elements of basic own funds have been deducted. As such, it serves to ensure that the total of all the individual basic own funds items are equal to the total excess of assets over liabilities and subordinated liabilities. The reconciliation reserve is treated as Tier 1 unrestricted Own Funds. Further details regarding the impact of various sensitivities on the excess of assets over liabilities which forms part of the Own Funds calculation are set out in section C.7. The reconciliation reserve is calculated as follows:

| Reconciliation Reserve                                   | 31December 2021<br>€′000 | 31 December 2020<br>€′000 |
|--|--------------------------|---------------------------|
| Excess of Assets over Liabilities                        | 653,393                  | 534,650                   |
| Deduct other Basic Own Fund Items                        |                          |                           |
| Ordinary Share Capital                                   | (50,020)                 | (50,020)                  |
| Share Premium Account related to ordinary share capital  | (382,358)                | (382,358)                 |
| Net deferred tax asset – Tier 3                          | _                        | -                         |
| Reconciliation Reserve pre-availability restrictions     | 221,014                  | 102,271                   |
| Ring Fenced Fund Restriction                             | _                        | -                         |
| Reconciliation Reserve Total (as shown on Own Funds QRT) | 221,014                  | 102,271                   |

### **Deferred Tax Assets**

Under Solvency II regulations and guidance, the value of any net shareholder deferred tax assets must be deducted from Tier 1 Own Funds and recognised as Tier 3. Deferred tax assets and liabilities are netted where legal offset is permitted. At 31 December 2021, there was no recognition of net deferred tax asset as Tier 3 Capital.

### Ancillary Own Funds

During December 2020 €55,000k of ancillary own funds were made available to the Company from PGH for a term of 5 years. These funds are classified as Tier 2 amounts until they are called upon, at which point they will become restricted Tier 1 funds. Prior to 2020, the Company had no Tier 2 funds.

### E.1 Own Funds continued

E.1.4.2 Analysis of Movement in Capital Position

The table below provides an analysis of significant changes in the capital position during the year, including Own funds, SCR and Solvency II surplus.

| Analysis of Movement in Solvency Position   | Note | Own Funds<br>€'000 | SCR<br>€′000 | Solvency II Surplus<br>€'000 |
|---|------|--------------------|--------------|------------------------------|
| Opening position at 1 January 2021          |      | 589,650            | 446,635      | 143,015                      |
| Management Actions                          | 1    | 79,577             | (67,666)     | 147,243                      |
| Expected Run-Off                            | 2    | _                  | (30,508)     | 30,508                       |
| New Business                                | 3    | 8,804              | 27,940       | (19,136)                     |
| Demographic Experience Variances (including |      |                    |              |                              |
| changes to assumptions)                     | 4    | (25,430)           | (424)        | (25,006)                     |
| Economic Variances on Long-Term Business    | 5    | 32,042             | 36,347       | (4,305)                      |
| Model and Methodology Changes               | 6    | (5,026)            | (2,397)      | (2,629)                      |
| Movement in Risk Margin                     | 7    | 28,776             | -            | 28,776                       |
| Closing position at 31 December 2021        |      | 708,393            | 409,927      | 298,466                      |

| Note | ltem   | Information  |
|------|--|--|
| 1    | Management Actions                           | This relates to the upgrade to the SLAL rating (a decrease in risk margin and counterparty default adjustment as well as counterparty default SCR), the revision to the investment mandate for annuity assets and the introduction of VA during 2021.  |
| 2    | Expected Run-Off                             | Policy run-off over the year resulted in the release of the related SCR requirements and increased the Solvency II surplus.  |
| 3    | New Business                                 | Increase in the value of future charges less future expenses as a result of writing new business, offset by the acquisition costs and increase in capital requirements. Note the value of expected future premiums is not included on the Solvency II balance sheet, and the movement in the risk margin due to new business is not included in this item. |
| 4    | Demographic Experience<br>Variances          | This item covers variances in experience versus plan and also the impact of assumption changes to more accurately reflect recent and expected persistency, mortality and expense experience.   |
| 5    | Economic Variances on Long-<br>Term Business | The movement in Own Funds was a result of market movements throughout 2021. These movements had a corresponding impact on the SCR.   |
| 6    | Model and Methodology<br>Changes             | This item covers a number of model adjustments. This includes model migration impacts as well as updates to model parameters.  |
| 7    | Movement in Risk Margin                      | Changes in risk margin as a result of SCR impacts, along with interest rate movements throughout the year, increased the overall Solvency II surplus (this excludes impacts of the SLAL rating upgrade as already shown under Management Actions).   |

### E.1 Own Funds continued

E.1.4.3 Reconciliation of IFRS Equity to Excess of Assets over Liabilities

The table below provides an analysis of the key differences between the Company's net assets under IFRS and the excess of assets over liabilities under Solvency II.

|  |         | 31 December 2021 | 31 December 2020 |
|--|---------|------------------|------------------|
|  | Section | €′000            | €′000            |
| Total Equity per IFRS                        |         | 605,850          | 570,052          |
| Valuation differences:                       |         |                  |                  |
| Assets increase/(decrease):                  |         |                  |                  |
| Intangible Assets/Deferred Acquisition Costs | D.1.2   | (225,604)        | (222,577)        |
| Reinsurance Recoverables                     | D.1.2   | (1,549,366)      | (1,428,663)      |
| Deferred Tax Assets                          | D.1.2   | (2,466)          | (3,339)          |
| Receivables (trade, not insurance)           | D.1.2   | (3,114)          | (2,888)          |
| Liabilities increase/(decrease):             |         |                  |                  |
| Technical Provisions                         | D.2.2   | 1,687,345        | 1,471,511        |
| Deferred Tax Liabilities                     | D.1.2   | (898)            | _                |
| Reinsurance Payables                         | D.1.2   | 88,028           | 98,470           |
| Any other liabilities not elsewhere shown    | D.1.2   | 53,618           | 52,083           |
| Excess of assets over liabilities            | D.1.2   | 653,393          | 534,650          |

### E.2 Solvency capital requirement and minimum capital requirement

### E.2.1 Solvency capital requirement

The Company's capital position is governed by the Solvency II regulatory regime. Under Solvency II, every insurer is required to identify its key risks – e.g. that equity markets fall – and hold sufficient capital to withstand adverse outcomes from those risks. The capital required to withstand these outcomes is the SCR. The SCR is calibrated so that the likelihood of a loss being greater than the SCR in one year is less than 1 in 200.

The Company's SCR at 31 December 2021 is presented below.

|   |      | SLIDAC           |
|---|------|------------------|
|   |      | Standard Formula |
| Analysis of SCR – 31 December 2021      | Note | €′000            |
| Underwriting Risk (i.e. insurance risk) | 1    | 232,212          |
| Market and credit risk                  | 2    | 304,207          |
| Liquidity risk                          | 3    |                  |
| Operational risk                        | 4    | 81,894           |
| Other risks                             | 5    |                  |
| Total undiversified SCR                 |      | 618,314          |
| Diversification benefits                | 6    | 208,387          |
| Total SCR                               |      | 409,927          |
|   |      |                  |

The Company's SCR does not include a capital add-on, and does not include any impact from the use of undertaking-specific parameters. In addition, no simplified calculations have been used. The final SCR is not subject to supervisory assessment.

The definitions of each of the risks are included in the table below. The components and sources of each of the risks and, of the methods used to assess, measure and monitor each of the risks are included in section C.

### E.2 Solvency capital requirement and minimum capital requirement continued

| Note | Risk module                 | Information  |
|------|-----------------------------|--|
| 1    | Underwriting risk           | Underwriting risk (i.e. insurance risk) is the risk that the frequency and severity of insured events may be worse than expected. The main sources of insurance risk are lapse risk, longevity risk and expense risk. More details on these risks are included in section C.1.   |
| 2    | Market and credit risk      | Market risk is the risk that the fair value of future cash flows of a financial instrument fluctuates because of changes in market influences. More details on these risks are included in section C.2.  |
|      |                             | Credit risk is the risk that a party to a financial instrument will cause financial loss for the other party by<br>failing to discharge an obligation. These obligations can relate to both on and off balance sheet assets<br>and liabilities. More details on these risks are provided in section C.3.               |
| 3    | Liquidity risk              | Liquidity risk is defined as the failure of the Company to maintain adequate levels of financial resources to enable it to meet its obligations as they fall due. More details on these risks are provided in section C.4.   |
| 4    | Operational risk            | Operational risk is the risk of reduction in earnings and/or value, through financial or reputational loss, from inadequate or failed internal processes and systems, or from people related or external events. Details of the sources of operational risk are provided in section C.5.                               |
| 5    | Other risks                 | There are no other material risks to which SLIDAC is exposed.  |
| 6    | Diversification<br>benefits | Diversification arises when the adverse outcome from one risk can be offset by a more favourable outcome from another risk, where those risks are not perfectly correlated. Diversification benefits are determined using a full risk distribution approach. The impact of deferred tax is also included in this item. |

### E.2.2 Changes in SCR

The material changes in the SCR and reasons thereof are set out in section E.1.4.2.

### E.2.3 Minimum capital requirement

The MCR applies to EEA-based insurance undertakings. The MCR represents an absolute floor to the level of eligible own funds that the insurance undertaking is required to hold under Solvency II. If the level of own funds falls below the MCR, the CBI would intervene. The MCR should correspond to the amount of capital needed to ensure that the insurance undertakings will be able to meet their obligations over the next 12 months with a probability of at least 85%. It is bound between 25% (or €3.7m, whichever is higher) and 45% of the insurance undertaking's SCR.

As set out in section E.1.4, SLIDAC's MCR at 31 December 2021 is €129,773k (2020: €111,659k). The components of the overall calculation of the MCR as at 31 December 2021 are:

### Calculation of MCR – 31 December 2021

| Calculation of MCR – 31 December 2021        | €′000   |
|--|---------|
| MCR before the application of floors of caps | 129,773 |
| MCR cap (45% of SCR)                         | 184,467 |
| MCR floor (higher of 25% of SCR or €3.7m)    | 102,482 |
| MCR (post application of floors of caps)     | 129,773 |

The changes in MCR during the reporting period are set out below:

| Analysis of change in MCR  | 31 December 2021<br>€'000 | 31 December 2020<br>€'000 |
|--|---------------------------|---------------------------|
| Technical Provisions for Index-linked and unit-linked insurance business | 17,375,812                | 14,447,536                |
| Technical Provisions for Other business                                  | 330,504                   | 383,206                   |
| Capital at Risk  | 1,716,044                 | 1,427,436                 |
| Linear MCR   | 129,773                   | 110,179                   |
| 25% of SCR   | 102,482                   | 111,659                   |
| Linear MCR   | 129,773                   | 110,179                   |
| 45% of SCR   | 184,467                   | 200,985                   |
| Combined MCR   | 129,773                   | 111,659                   |

The increase in MCR is a result of the increase in technical provisions and capital at risk.

**E.3 Use of the duration-based equity risk sub-module in the calculation of the solvency capital requirement** The Company is not using the duration-based equity risk sub-module for the calculation of its SCR.

### E.4 Differences between the standard formula and any Internal Model used

The Company is not using any Internal Model for the calculation of its SCR. The Company has received approval from the CBI for use of a Partial Internal Model (PIM) in calculating its capital requirements and will use this model in the next Solvency and Financial Condition Report.

### E.5 Non-compliance with the minimum capital requirement and non-compliance with the solvency capital requirement

Throughout 2021 Own Funds have at all times exceeded both the MCR and the SCR and therefore the Company fully complied with capital requirements.

### E.6 Any other information

There is no further material information to be disclosed regarding the Company's Own Funds and SCR.

# Appendices and additional information

Appendix 1 – Quantitative reporting templates

| er 2021)                             |   |
|--------------------------------------|---|
| Balance sheet                        | 74  |
| Premiums, claims and expenses        |   |
| by line of business                  | 76  |
| Premiums, claims and                 |   |
| expenses by country                  | 77  |
| Life and health technical provisions | 78  |
| Impact of long term guarantees       |   |
| and transitional measures            | 80  |
| Own funds                            | 81  |
| Solvency capital requirement –       |   |
| using the standard formula           | 82  |
| Minimum capital requirement          |   |
| for life or non-life insurance       | 83  |
| - Glossary                           | 84  |
|                                      | Balance sheet<br>Premiums, claims and expenses<br>by line of business<br>Premiums, claims and<br>expenses by country<br>Life and health technical provisions<br>Impact of long term guarantees<br>and transitional measures<br>Own funds<br>Solvency capital requirement –<br>using the standard formula<br>Minimum capital requirement<br>for life or non-life insurance |

## Appendix 1 - Quantitative reporting templates (31 December 2021)

Appendix 1.1 – SE.02.01.16 Balance sheet

| Appendix 1.1 – SE.02.01.16 Balance sheet<br>Assets                                     |       | Solvency II value<br>C0010<br>€′000 |
|--|-------|-------------------------------------|
| Intangible assets  | R0030 |                                     |
| Deferred tax assets  | R0040 | _                                   |
| Pension benefit surplus  | R0050 |                                     |
| Property, plant & equipment held for own use   | R0060 | 664                                 |
| Investments (other than assets held for index-linked and unit-linked contracts)        | R0070 | 908,885                             |
| Property (other than for own use)  | R0080 | _                                   |
| Holdings in related undertakings, including participations                             | R0090 | _                                   |
| Equities   | R0100 | _                                   |
| Equities – listed  | R0110 | -                                   |
| Equities – unlisted  | R0120 | _                                   |
| Bonds  | R0130 | 367,817                             |
| Government Bonds   | R0140 | 253,510                             |
| Corporate Bonds  | R0150 | 114,307                             |
| Structured notes   | R0160 |                                     |
| Collateralised securities  | R0170 | _                                   |
| Collective Investments Undertakings  | R0180 | 540,001                             |
| Derivatives  | R0190 | 1,067                               |
| Deposits other than cash equivalents   | R0200 |                                     |
| Other investments  | R0210 |                                     |
| Assets held for index-linked and unit-linked contracts                                 | R0220 | 17,748,013                          |
| Loans and mortgages  | R0230 | 41,191                              |
| Loans on policies  | R0240 | 136                                 |
| Loans and mortgages to individuals   | R0250 | _                                   |
| Other loans and mortgages  | R0260 | 41,055                              |
| Reinsurance recoverables from:   | R0270 | 17,133,667                          |
| Non-life and health similar to non-life  | R0280 |                                     |
| Non-life excluding health  | R0290 | _                                   |
| Health similar to non-life   | R0300 | -                                   |
| Life and health similar to life, excluding health and index-linked and unit-linked     | R0310 | 16,244,869                          |
| Health similar to life   | R0320 | 173,768                             |
| Life excluding health and index-linked and unit-linked                                 | R0330 | 16,071,101                          |
| Life index-linked and unit-linked  | R0340 | 888,798                             |
| Deposits to cedants  | R0350 | -                                   |
| Insurance and intermediaries receivables   | R0360 | 5,228                               |
| Reinsurance receivables  | R0370 | 91,926                              |
| Receivables (trade, not insurance)   | R0380 | 60,887                              |
| Own shares (held directly)   | R0390 | -                                   |
| Amounts due in respect of own fund items or initial fund called up but not yet paid in | R0400 | _                                   |
| Cash and cash equivalents  | R0410 | 34,148                              |
| Any other assets, not elsewhere shown  | R0420 |                                     |
| Total assets   | R0500 | 36,024,609                          |

#### Appendix 1 - Quantitative reporting templates (31 December 2021) continued

| Appendix 1 – Quantitative reporting templates (31 December 2021) continued      |       | Solvency II value<br>C0010<br>€'000 |
|---|-------|-------------------------------------|
| Technical provisions – non-life   | R0510 |                                     |
| Technical provisions – non-life (excluding health)                              | R0520 | _                                   |
| TP calculated as a whole  | R0530 | -                                   |
| Best Estimate   | R0540 | _                                   |
| Risk margin   | R0550 | -                                   |
| Technical provisions – health (similar to non-life)                             | R0560 | _                                   |
| TP calculated as a whole  | R0570 | _                                   |
| Best Estimate   | R0580 | _                                   |
| Risk margin   | R0590 | _                                   |
| Technical provisions – life (excluding index-linked and unit-linked)            | R0600 | 16,725,671                          |
| Technical provisions – health (similar to life)                                 | R0610 | 176,234                             |
| TP calculated as a whole  | R0620 | _                                   |
| Best Estimate   | R0630 | 174,797                             |
| Risk margin   | R0640 | 1,436                               |
| Technical provisions – life (excluding health and index-linked and unit-linked) | R0650 | 16,549,438                          |
| TP calculated as a whole  | R0660 | _                                   |
| Best Estimate   | R0670 | 16,400,550                          |
| Risk margin   | R0680 | 148,888                             |
| Technical provisions – index-linked and unit-linked                             | R0690 | 18,322,751                          |
| TP calculated as a whole  | R0700 | 18,649,145                          |
| Best Estimate   | R0710 | (384,530)                           |
| Risk margin   | R0720 | 58,136                              |
| Contingent liabilities  | R0740 | -                                   |
| Provisions other than technical provisions                                      | R0750 | 3,670                               |
| Pension benefit obligations   | R0760 | -                                   |
| Deposits from reinsurers  | R0770 | _                                   |
| Deferred tax liabilities  | R0780 | 1,678                               |
| Derivatives   | R0790 | 13,580                              |
| Debts owed to credit institutions   | R0800 | 2,343                               |
| Financial liabilities other than debts owed to credit institutions              | R0810 | -                                   |
| Insurance & intermediaries payables   | R0820 | 159,990                             |
| Reinsurance payables  | R0830 | 8                                   |
| Payables (trade, not insurance)   | R0840 | 141,526                             |
| Subordinated liabilities  | R0850 |                                     |
| Subordinated liabilities not in BOF   | R0860 |                                     |
| Subordinated liabilities in BOF   | R0870 | _                                   |
| Any other liabilities, not elsewhere shown                                      | R0880 |                                     |
| Total liabilities   | R0900 | 35,371,216                          |
| Excess of assets over liabilities   | R1000 | 653,393                             |

#### Appendix 1 – Quantitative reporting templates (31 December 2021) continued Appendix 1.2– S.05.01.01 Premiums, claims and expenses by line of business

|                                       |       |                              | Line of  | Business for: life  | insurance obl                    | igations   |  | Life reinsurance obligations   |                              |                |
|---------------------------------------|-------|------------------------------|--|---|----------------------------------|--|--|--------------------------------|------------------------------|----------------|
|                                       |       | Health<br>insurance<br>C0210 | Insurance<br>with profit<br>participation<br>C0220 | Index-<br>linked and<br>unit-linked<br>insurance<br>C0230 | Other life<br>insurance<br>C0240 | Annuities<br>stemming<br>from non-life<br>insurance<br>contracts<br>and relating<br>to health<br>insurance<br>obligations<br>C0250 | Annuities<br>stemming<br>from non-life<br>insurance<br>contracts<br>and relating<br>to insurance<br>obligations<br>other than<br>health<br>insurance<br>obligations<br>CO260 | Health<br>reinsurance<br>C0270 | Life<br>reinsurance<br>C0280 | Total<br>C0300 |
| Premiums written                      |       | 00110                        | 00110  |   |                                  |  | 00100  |                                |                              |                |
| Gross                                 | R1410 | 82                           | 782,351  | 2,220,148   | 38,409                           | _  | _  | _                              | 17,770                       | 3,058,759      |
| Reinsurers' share                     | R1420 | 82                           | 775,988  | 19,864  | 295                              | _  | _  | _                              | -                            | 796,230        |
| Net                                   | R1500 | _                            | 6,362  | 2,200,283   | 38,114                           | _  | _  | _                              | 17,770                       | 2,262,529      |
| Premiums earned                       |       | _                            | _  | _   | _                                | _  | _  | _                              | -                            | -              |
| Gross                                 | R1510 | 82                           | 782,351  | 2,220,148   | 38,409                           | -  | _  | -                              | 17,770                       | 3,058,759      |
| Reinsurers' share                     | R1520 | 82                           | 775,988  | 19,864  | 295                              | -  | -  | -                              | -                            | 796,230        |
| Net                                   | R1600 | -                            | 6,362  | 2,200,283   | 38,114                           | -  | -  | -                              | 17,770                       | 2,262,529      |
| <b>Claims incurred</b>                |       | -                            | -  | -   | -                                | -  | -  | -                              | -                            | -              |
| Gross                                 | R1610 | 2,414                        | 811,972  | 1,280,009   | 44,565                           | -  | -  | -                              | 80,257                       | 2,219,216      |
| Reinsurers' share                     | R1620 | 2,414                        | 793,332  | 83,211  | 26,594                           | -  | -  | -                              | 0                            | 905,551        |
| Net                                   | R1700 | _                            | 18,640   | 1,196,798   | 17,971                           | _  | -  | -                              | 80,257                       | 1,313,665      |
| Changes in other technical provisions |       | -                            | -  | -   | -                                | -  | _  | -                              | -                            | -              |
| Gross                                 | R1710 | (53)                         | 195,012  | (2,423,883)   | 29,534                           | -  | -  | -                              | 56,671                       | (2,142,720)    |
| Reinsurers' share                     | R1720 | (30)                         | 236,367  | (56,417)  | 28,243                           | _  | -  | _                              | -                            | 208,164        |
| Net                                   | R1800 | (23)                         | (41,356)   | (2,367,467)   | 1,291                            | _  | -  | _                              | 56,671                       | (2,350,884)    |
| Expenses incurred                     | R1900 | 0                            | 59,846   | 149,371   | 4,111                            | _  | -  | _                              | _                            | 213,327        |
| Other expenses                        | R2500 | -                            | -  | -   | -                                |  | -  | _                              | _                            | -              |
| Total expenses                        | R2600 | -                            | -  |   | -                                |  | -  | -                              | -                            | 213,327        |

#### Appendix 1 – Quantitative reporting templates (31 December 2021) continued Appendix 1.2 – S.05.02.01 Premiums, claims and expenses by country

| Appendix 1.2- 5.05.02.01 Premiums, ciali |       | ises by cou  | iici y      | 1                | Top 5 countries |                    |       | Total Top 5<br>and home |
|--|-------|--------------|-------------|------------------|-----------------|--------------------|-------|-------------------------|
|  |       | Home country | y (by an    | nount of gross p | premiums writte | n) – life obligati | ons   | country                 |
|  |       | C0150        | C0160       | C0170            | C0180           | C0190              | C0200 | C0210                   |
|  | R1400 | IE           | DE          | GB               | AT              |                    |       |                         |
|  |       | C0220        | C0230       | C0240            | C0250           | C0260              | C0270 | C0280                   |
| Premiums written                         |       |              |             |                  |                 |                    |       |                         |
| Gross                                    | R1410 | 872,054      | 1,163,530   | 927,620          | 95,555          | -                  | -     | 3,058,759               |
| Reinsurers' share                        | R1420 | 28,060       | _           | 698,701          | 69,469          | _                  | -     | 796,230                 |
| Net                                      | R1500 | 843,993      | 1,163,530   | 228,919          | 26,087          | -                  | -     | 2,262,529               |
| Premiums earned                          |       | -            | _           | -                | -               | _                  | -     | -                       |
| Gross                                    | R1510 | 872,054      | 1,163,530   | 927,620          | 95,555          | _                  | -     | 3,058,759               |
| Reinsurers' share                        | R1520 | 28,060       | _           | 698,701          | 69,469          | _                  | -     | 796,230                 |
| Net                                      | R1600 | 843,993      | 1,163,530   | 228,919          | 26,087          | -                  | -     | 2,262,529               |
| Claims incurred                          |       | _            | _           | _                | -               | _                  | -     | -                       |
| Gross                                    | R1610 | 951,982      | 477,274     | 657,376          | 132,584         | _                  | -     | 2,219,216               |
| Reinsurers' share                        | R1620 | 174,068      | -           | 605,633          | 125,851         | -                  | -     | 905,551                 |
| Net                                      | R1700 | 777,914      | 477,274     | 51,744           | 6,733           | _                  | -     | 1,313,665               |
| Changes in other technical provisions    |       | -            | -           | -                | -               | _                  | -     | _                       |
| Gross                                    | R1710 | (665,028)    | (1,448,364) | (29,328)         | _               | -                  | _     | (2,142,720)             |
| Reinsurers' share                        | R1720 | (714)        | -           | 208,878          | -               | -                  | -     | 208,164                 |
| Net                                      | R1800 | (664,314)    | (1,448,364) | (238,206)        | _               | _                  | _     | (2,350,884)             |
| Expenses incurred                        | R1900 | 89,616       | 30,674      | 91,951           | 1,087           | -                  | -     | 213,327                 |
| Other expenses                           | R2500 | _            | _           | _                | _               | _                  | _     | _                       |
| Total expenses                           | R2600 | -            | -           | _                | -               | _                  | -     | 213,327                 |

## Appendix 1 - Quantitative reporting templates (31 December 2021) continued Appendix 1.3 - S.12.01.01 Life and health SLT technical provisions

|  |       |   | Index-linked and unit-linked insurance Other life insurance |   | nce   | Annuities<br>stemming<br>from |   | Total (life                                   |  |                         |  |
|--|-------|---|---|---|---|-------------------------------|---|---|--|-------------------------|--|
|  |       | Insurance<br>with profit<br>participation |   | Contracts<br>without<br>options and<br>guarantees | Contracts<br>with<br>options or<br>guarantees |                               | Contracts<br>without<br>options and<br>guarantees | Contracts<br>with<br>options or<br>guarantees | non-life<br>insurance<br>contracts<br>other than | Accepted<br>reinsurance | other than<br>health<br>insurance,<br>incl. unit-<br>linked) |
|  |       | C0020                                     | C0030   | C0040   | C0050   | C0060                         | C0070   | C0080   | C0090  | C0100                   | C0150  |
| Technical provisions<br>calculated as a whole                                      | R0010 | -   | 17,748,013  | -   | -   | -                             | -   | -   | -  | 901,128                 | 18,649,140   |
| Total Recoverables from<br>reinsurance/SPV and<br>Finite Re after adjustment       | R0020 | _   | 901,128   | _   | _   | -                             | _   | _   | _  | _                       | 901,128  |
| Technical provisions<br>calculated as a sum<br>of BE and RM                        |       | _   |   | _   | _   | _                             |   | _   | _  | _                       |  |
| Best Estimate  |       | -   | -   | _   | _   | -                             | -   | -   | -  | -                       |  |
| Gross Best Estimate  | R0030 | 15,641,347                                | -   | -   | -384,530                                      | -                             | -   | 759,202                                       | -  | -                       | 16,016,019   |
| Total Recoverables<br>from reinsurance/SPV<br>and Finite Re before<br>adjustment   | R0040 | 15,641,347                                | _   | _   | -12,330                                       | _                             | _   | 432,883                                       | _  | _                       | 16,061,901   |
| Total Recoverables from<br>reinsurance/SPV and<br>Finite Re after adjustment       | R0080 | 15,641,347                                | _   | _   | -12,330                                       | _                             | _   | 429,753                                       | _  | _                       | 16,058,771   |
| Best estimate minus<br>recoverables from<br>reinsurance/SPV and<br>Finite Re-total | R0090 | 0   | _   | _   | -372,201                                      | _                             | _   | 329,449                                       | _  | _                       | -42,752  |
| Risk Margin  | R0100 | 134,179                                   | 58,136  | -   | -   | 14,709                        | -   | -   | -  | -                       | 207,024  |
| Amount of the<br>transitional on<br>Technical Provisions                           |       | -   | -   | _   | _   | -                             | -   | -   | _  | _                       |  |
| Technical provisions calculated as a whole   | R0110 | _   | _   | _   | _   | _                             | _   | _   | _  | _                       | _  |
| Best estimate  | R0120 | -   | -   | -   | -   | -                             | -   | -   | -  | -                       | -  |
| Risk margin  | R0130 | -   | -   | _   | _   | -                             | -   | -   | -  | _                       | -  |
| Technical provisions<br>– total  | R0200 | 15,775,526                                | 17,421,618  | -   | _   | 773,912                       | -   | _   | -  | 901,128                 | 34,872,184   |

## Appendix 1 - Quantitative reporting templates (31 December 2021) continued

|   |       | Health  | insurance (direct bu                           | siness)                                    | Annuities  |  |                                   |
|---|-------|---------|--|--|--|--|-----------------------------------|
|   |       |         | Contracts<br>without options<br>and guarantees | Contracts<br>with options or<br>guarantees | stemming from<br>non-life<br>insurance<br>contracts related<br>to health | Health<br>reinsurance<br>(reinsurance<br>accepted) | Total Health<br>(similar to Life) |
|   |       | C0160   | <br>C0170                                      | <br>C0180                                  | C0190  | C0200  | C0210                             |
| Technical provisions calculated as a whole                                    | R0010 | _       | _  | _  | _  | _  | -                                 |
| Total Recoverables from<br>reinsurance/SPV and Finite<br>Re after adjustment  | R0020 | _       | _  | _  | _  | _  | _                                 |
| Technical provisions<br>calculated as a sum of BE<br>and RM                   |       | _       | _  | _  | _  | _  | _                                 |
| Best Estimate   |       | _       |  | _  | _  |  | _                                 |
| Gross Best Estimate   | R0030 | _       | _  | 174,797                                    | _  | _  | 174,797                           |
| Total Recoverables from<br>reinsurance/SPV and Finite<br>Re before adjustment | R0040 | _       | _  | 173,768                                    | _  | _  | 173,768                           |
| Total Recoverables from<br>reinsurance/SPV and Finite<br>Re after adjustment  | R0080 | _       | _  | 173,768                                    | _  | _  | 173,768                           |
| Best estimate minus<br>recoverables from<br>reinsurance/SPV and Finite        |       |         |  |  |  |  |                                   |
| Re- total   | R0090 | -       | _  | 1,029                                      | -  |  | 1,029                             |
| Risk Margin   | R0100 | 1,436   | -  | _  | -  | -  | 1,436                             |
| Amount of the transitional<br>on Technical Provisions                         |       | _       | _  | -  | -  | _  | -                                 |
| Technical provisions calculated as a whole                                    | R0110 | _       | _  | _  | _  | _  | -                                 |
| Best estimate   | R0120 | -       | _  | -  | -  |  | -                                 |
| Risk margin   | R0130 | -       | -  | -  | _  | -  | -                                 |
| Technical provisions – total  | R0200 | 176,234 | _  | -  | -  | _  | 176,234                           |

## Appendix 1 - Quantitative reporting templates (31 December 2021) continued

Appendix 1.4 – S.22.01.01 Impact of long term guarantees and transitional measures

|  |       | Amount<br>with Long<br>Term<br>Guarantee<br>measures<br>and<br>transitionals | Without<br>transitional<br>on<br>technical<br>provisions | on<br>technical | Without<br>transitional t<br>on interest |       | Without<br>volatility<br>adjustment<br>and without<br>other<br>transitional<br>measures | Impact of<br>volatility<br>adjustment<br>set to zero |            | matching<br>adjustment | Impact<br>of all LTG<br>measures<br>and<br>transitionals |
|--|-------|--|--|-----------------|--|-------|---|--|------------|------------------------|--|
|  |       | C0010  | C0020  | C0030           | C0040                                    | C0050 | C0060   | C0070  | C0080      | C0090                  | C0100  |
| Technical provisions   | R0010 | 35,048,422   | 35,048,422   | _               | 35,048,422                               | -     | 35,062,847  | 14,425   | 35,062,847 | -                      | 14,425   |
| Basic own funds  | R0020 | 653,393  | 653,393  | -               | 653,393                                  | -     | 652,030   | 1,362  | 652,030    | -                      | 1,362  |
| Excess of assets<br>over liabilities                                     | R0030 | 653,393  | 653,393  | _               | 653,393                                  | _     | 652,030   | 1,362  | 652,030    | _                      | 1,362  |
| Restricted own funds<br>due to ring-fencing<br>and matching<br>portfolio | R0040 | 0  | 0  | _               | 0  | _     | 0   | _  | 0          | _                      | _  |
| Eligible own funds<br>to meet Solvency                                   |       |  |  |                 |  |       |   |  |            |                        |  |
| Capital Requirement  | R0050 | 708,393  | 708,393  | -               | 708,393                                  | -     | 707,030   | 1,362  | 707,030    | -                      | 1,362  |
| Tier I   | R0060 | 653,393  | 653,393  | -               | 653,393                                  | -     | 652,030   | 1,362  | 652,030    | -                      | 1,362  |
| Tier II  | R0070 | 55,000   | 55,000   | _               | 55,000                                   | -     | 55,000  | -  | 55,000     | -                      | _  |
| Tier III   | R0080 | -  | -  | -               | -  | -     | -   | -  | -          | -                      | -  |
| Solvency Capital<br>Requirement  | R0090 | 409,927  | 409,927  | _               | 409,927                                  | _     | 410,095   | 168  | 410,095    | _                      | 168  |
| Eligible own funds<br>to meet Minimum<br>Capital Requirement             | R0100 | 653,393  | 653,393  | _               | 653,393                                  | _     | 652,030   | 1,362  | 652,030    | _                      | 1,362  |
| Minimum Capital<br>Requirement   | R0110 | 129,773  | 129,773  | _               | 129,773                                  | _     | 129,801   | 29   | 129,801    | _                      | 29   |

## Appendix 1 - Quantitative reporting templates (31 December 2021) continued

Appendix 1.5- S.23.01.01 Own funds

| Appendix 1.5– S.23.01.01 Own funds  |        |         |                         |                       |        |        |
|---|--------|---------|-------------------------|-----------------------|--------|--------|
|   |        | Total   | Tier 1–<br>unrestricted | Tier 1–<br>restricted | Tier 2 | Tier 3 |
|   | _      | C0010   | C0020                   | C0030                 | C0040  | C0050  |
|   |        | €000s   | €000s                   | €000s                 | €000s  | €000s  |
| Basic own funds before deduction for<br>participations in other financial sector<br>as foreseen in article 68 of Delegated<br>Regulation (EU) 2015/35 |        |         |                         |                       |        |        |
| Ordinary share capital (gross of own shares)  | R0010  | 50,020  | 50,020                  | _                     | _      | -      |
| Share premium account related to ordinary   |        |         |                         |                       |        |        |
| share capital   | R0030  | 382,358 | 382,358                 | _                     |        |        |
| Initial funds, members' contributions or the<br>equivalent basic own – fund item for mutual<br>and mutual-type undertakings                           | R0040  | _       | _                       | _                     | _      | _      |
| Subordinated mutual member accounts   | R0050  | _       | _                       | _                     | _      |        |
| Surplus funds   | R0070  | _       | _                       | _                     | _      |        |
| Preference shares   | R0090  | _       | _                       | _                     | _      |        |
| Share premium account related to preference   |        |         |                         |                       |        |        |
| shares  | R0110  | _       | _                       | _                     | _      | _      |
| Reconciliation reserve  | R0130  | 221,014 | 221,014                 | _                     | _      |        |
| Subordinated liabilities  | R0140  | _       | _                       | _                     | _      |        |
| An amount equal to the value of net deferred  |        |         |                         |                       |        |        |
| tax assets  | R0160  | _       | _                       | _                     | _      | _      |
| Other items approved by supervisory authority   |        |         |                         |                       |        |        |
| as basic own funds not specified above  | R0180  | _       |                         | _                     | _      |        |
| Own funds not represented by the reconciliation reserve   | R0220  | -       | -                       | -                     | _      | _      |
| Deductions  |        | _       | -                       | _                     | -      | -      |
| Deductions for participations in financial and  |        |         |                         |                       |        |        |
| credit institutions   | R0230  | _       | _                       | _                     | _      | _      |
| Total basic own funds after adjustments   | R0290  | 653,393 | 653,393                 | —                     | —      |        |
| Ancillary own funds   |        |         |                         |                       |        |        |
| Unpaid and uncalled ordinary share capital  | R0300  | _       | -                       | _                     | _      | -      |
| Unpaid and uncalled initial funds   | R0310  | —       | -                       | -                     | -      |        |
| Unpaid and uncalled preference share capital  | R0320  | —       | -                       | -                     | -      |        |
| Commitment to subscribe and pay for   | R0330  | 55,000  |                         |                       | 55,000 |        |
| subordinated liabilities  | R0330  | 55,000  |                         |                       | 55,000 |        |
| Letters of credit and guarantees under Article<br>96(2)   | R0340  | _       | _                       | _                     | _      | _      |
| Letters of credit and guarantees other than   |        |         |                         |                       |        |        |
| under Article 96(2)   | R0350  | _       | _                       | _                     | _      | _      |
| Supplementary members calls under Article<br>96(3)  | R0360  | _       | _                       | _                     | _      | -      |
| Supplementary members calls other than  |        |         |                         |                       |        |        |
| under Article 96(3)   | R0370  | —       | -                       | —                     | —      |        |
| Other ancillary own funds   | R0390  | —       | -                       | —                     | —      |        |
| Total ancillary own funds   | R0400  | 55,000  | -                       | -                     | 55,000 |        |
| Available and eligible own funds  |        |         |                         |                       |        |        |
| Total available own funds to meet the SCR   | R0500  | 708,393 | 653,393                 | _                     | 55,000 |        |
| Total available own funds to meet the MCR   | R0510  | 653,393 | 653,393                 | -                     | -      |        |
| Total eligible own funds to meet the SCR  | R0540  | 708,393 | 653,393                 | -                     | 55,000 |        |
| Total eligible own funds to meet the MCR  | R0550  | 653,393 | 653,393                 | _                     | _      | _      |
| SCR   | R0580  | 409,927 |                         |                       |        |        |
| MCR   | R0600  | 129,773 |                         |                       |        |        |
| Ratio of eligible own funds to SCR  | R0620  | 173%    |                         |                       |        |        |
|   | 110020 |         |                         |                       |        |        |

#### Appendix 1 - Quantitative reporting templates (31 December 2021) continued

|       | C0060  |
|-------|--|
|       |  |
| R0700 | 653,393  |
| R0710 | -  |
| R0720 | -  |
| R0730 | 432,379  |
| R0740 | 0  |
| R0760 | 221,014  |
|       |  |
| R0770 | 492,726  |
| R0780 | -  |
| R0790 | 492,726  |
|       | R0710<br>R0720<br>R0730<br>R0740<br>R0760<br>R0770<br>R0770<br>R0780 |

## ${\small Appendix 1.6-S.25.01.01 \, Solvency \, capital \, requirement-using \, the \, standard \, formula}$

|                                    |       | Net solvency<br>capital | Gross solvency      | Allocation from<br>adjustments due<br>to RFF and Matching |
|------------------------------------|-------|-------------------------|---------------------|---|
|                                    |       | requirement             | capital requirement | adjustments portfolios                                    |
|                                    |       | C0030<br>€′000          | C0040<br>€′000      | C0050<br>€′000  |
| Market risk                        | R0010 | 182,217                 | 182,217             |   |
| Counterparty default risk          | R0020 | 80,111                  | 80,111              | _   |
| Life underwriting risk             | R0030 | 191,499                 | 191,499             | -   |
| Health underwriting risk           | R0040 | -                       | -                   | -   |
| Non-life underwriting risk         | R0050 | -                       | -                   | -   |
| Diversification                    | R0060 | (124,116)               | (124,116)           | -   |
| Intangible asset risk              | R0070 | -                       | -                   | -   |
| Basic Solvency Capital Requirement | R0100 | 329,710                 | 329,710             | -   |

| Calculation of Solvency Capital Requirement   |       | C0100<br>€'000 |
|---|-------|----------------|
| Operational risk  | R0130 | 81,894         |
| Loss-absorbing capacity of technical provisions   | R0140 | -              |
| Loss absorbing capacity of deferred taxes   | R0150 | (1,678)        |
| Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC | R0160 |                |
| Solvency capital requirement excluding capital add-on                                       | R0200 | 409,927        |
| Capital add-on already set  | R0210 |                |
| Solvency capital requirement  | R0220 | 409,927        |
| Other information on SCR  |       |                |
| Capital requirement for duration-based equity risk sub-module                               | R0400 |                |
| Total amount of Notional Solvency Capital Requirement for remaining part                    | R0410 |                |
| Total amount of Notional Solvency Capital Requirements for ring fenced funds                | R0420 | -              |
| Total amount of Notional Solvency Capital Requirement for matching adjustment portfolios    | R0430 | -              |
| Diversification effects due to RFF nSCR aggregation for article 304                         | R0440 | -              |
| Method used to calculate the adjustment due to RFF/MAP nSCR aggregation                     | R0450 | 4–Noadjustment |

## Appendix 1 - Quantitative reporting templates (31 December 2021) continued

## Appendix 1.7- S.28.01.01 - Minimum capital requirement only life or non-life insurance or reinsurance activity (life)

| MCRL Result  | R0200 |                       | 129,773               |
|--|-------|-----------------------|-----------------------|
|  |       | Net (of               |                       |
|  |       | reinsurance/SPV)      | Net (of               |
|  |       | best estimate and TP  | reinsurance/SPV)      |
|  |       | calculated as a whole | total capital at risk |
|  |       | C0050                 | C0060                 |
| Obligation with profit participation – guaranteed benefits           | R0210 | -                     | -                     |
| Obligation with profit participation – future discretionary benefits | R0220 | -                     | -                     |
| Index-linked and unit-linked insurance obligations                   | R0230 | 17,375,812            | -                     |
| Other life (re)insurance and health (re)insurance obligations        | R0240 | 330,504               | -                     |
| Total capital at risk for all life (re)insurance obligation          | R0250 | _                     | 1,716,044             |

| Overall MCR calculation     |       |         |
|-----------------------------|-------|---------|
|                             |       | C0070   |
| Linear MCR                  | R0300 | 129,773 |
| SCR                         | R0310 | 409,927 |
| MCR cap                     | R0320 | 184,467 |
| MCR floor                   | R0330 | 102,482 |
| Combined MCR                | R0340 | 129,773 |
| Absolute floor of the MCR   | R0350 | 3,700   |
| Minimum Capital Requirement | R0400 | 129,773 |

#### **Minimum Capital Requirement**

Note: The non-life fields are not shown as the Company does not have any non-life insurance.

#### Appendix 2 – Glossary

#### Ancillary own funds

Ancillary own funds shall consist of items other than basic own funds which can be called up to absorb losses.

Ancillary own funds may comprise the following items to the extent that they are not basic own-fund items:

(a) unpaid share capital or initial fund that has not been called up;

(b) letters of credit and guarantees;

(c) any other legally binding commitments received by insurance and reinsurance undertakings.

Where an ancillary own-fund item has been paid in or called up, it shall be treated as an asset and cease to form part of ancillary own-fund items.

#### Assumptions

Variables, which can be economic or non-economic in nature, used in actuarial models to project expected policy cash flows.

#### **Best estimate liability**

The part of technical provisions representing a probability weighted average of future cash flows, taking account of the time value of money, using an appropriate risk-free interest rate term structure. The calculation is based upon realistic assumptions, using appropriate actuarial and statistical methods and taking account of all future cash inflows and outflows required to settle the insurance obligations.

#### Board

The board of Directors of Standard Life International Designated Activity Company.

#### Capital resources (CR)

Capital resources include the assets in excess of liabilities, valued on a regulatory basis, and certain other components of capital.

#### CBI

The Central Bank of Ireland.

#### Company

Standard Life International Designated Activity Company.

#### **Contract boundary**

The boundary of an insurance contract (or reinsurance contract) defines the cash flows which must be taken into account when calculating the technical provision in respect of that contract.

#### **Delegated regulation**

Commission Delegated Regulation supplementing the Solvency II Directive.

#### Director

A director of Standard Life International Designated Activity Company.

#### Discounting

This is the process of reducing a future cash flow back to present value terms, by way of an assumed future interest (discount) rate.

#### **Economic assumptions**

Assumptions in relation to future interest rates, investment returns, inflation and tax.

#### EIOPA

European Insurance and Occupational Pensions Authority.

#### External fund links (EFL)

These are unit linked fund options on Standard Life products, where the funds are not managed by Standard Life.

#### FCA

Financial Conduct Authority.

#### Appendix 2 - Glossary continued

#### Large fund discounts

The practice of reducing the effective annual management charge applied to a policy depending on the size of the unit fund.

#### Maintenance expenses

Expenses relating to the ongoing maintenance of business. This would include customer service costs, for example.

#### Market consistency

A market consistent value is the market value if the instrument is readily traded. In the context of liabilities, a market consistent value is a valuation that is consistent with the prices of assets with similar characteristics to those liabilities. For liability cash flows with option-like features e.g. guarantees, these values should be consistent with market option prices.

#### Matching adjustment

An adjustment to the risk free yield used to calculate the best estimate to reflect where long-term liabilities are backed by assets which closely match the cash flows, where these assets have yields in excess of risk free and the extent that the assets are expected to be held long term.

#### Non-economic assumptions

Assumptions in relation to future expenses and future lapse, withdrawal, and mortality rates.

#### Own funds

Own funds are the regulatory capital resources of an insurance undertaking or group under Solvency II.

#### **Option (insurance policy feature)**

A benefit feature of an insurance contract that may be selected at the discretion of the policyholder e.g. right to convert a maturity value into an income for life at guaranteed terms.

#### PGH

Phoenix Group Holdings plc.

#### ΡΙΜ

Partial Internal Model.

#### PRA

Prudential Regulation Authority.

#### Present value of in-force business (PVIF)

The expected future profits (usually excess of charges over expenses) on existing business.

#### Reinsurance

Process whereby one entity takes on all or part of the risk covered under a policy issued by an insurance company in return for a premium payment.

#### **Risk margin**

The part of technical provisions in addition to the best estimate liability required to ensure that the value of the technical provisions is equivalent to the amount that insurance undertakings would be expected to require in order to take over and meet the insurance obligations.

#### Appendix 2 - Glossary continued

#### SLAL

Standard Life Assurance Limited.

#### SLIDAC

Standard Life International Designated Activity Company.

#### **Solvency II Directive**

Directive 2009/138/EC of the European Parliament and of the Council of 25 November 2009 on the taking-up and pursuit of the business of Insurance and Reinsurance (Solvency II).

#### Solvency capital requirement (SCR)

The economic capital to be held by an insurer in order to ensure that it will still be in a position to meet its obligations to policyholders over the following 12 months, with a probability of at least 99.5% (i.e. limit probability of failure to less than 1 in 200 years).

#### Stochastic model

An actuarial projection model in which the input variables (e.g. future investment returns) are defined in terms of a range of values in the form of probability distributions, reflecting the volatility of those variables. This leads to a range of modelled outcomes. This approach is useful when a policy provides a guarantee e.g. a minimum rate of investment return. A deterministic model would not allow for the volatility of future investment returns and hence is a less appropriate way of estimating the cost of providing the guarantee.

#### **Technical provisions**

The value attributed to future insurance obligations determined in line with Solvency II regulations, comprising a best estimate liability plus risk margin.

#### Technical provisions as a whole

The best estimate and the risk margin are typically calculated separately. Where the future cash flows can be replicated reliably using financial instruments for which a reliable market value is observable (such as unit linked fund values) then the value of technical provisions equals the market value of those financial instruments ('technical provisions as a whole').

#### **Unit linked**

Unit linked refers to a proposition or fund where the customer will buy 'units' of the fund. The value of a unit changes based on the performance of underlying assets, and the number of units in the fund will change depending on the size of the fund.

#### Unit linked policy

A policy where the benefits are determined by reference to the investment performance of a specified pool of assets.

#### Volatility adjustment

An adjustment made to the liquid part of the risk free interest rate in order to reduce the impact of short term market volatility on the balance sheet.

## **Registered** address

Standard Life International 90 St. Stephen's Green Dublin 2 D02 F653

**Registered Number** 408507

thephoenixgroup.com